Selective degradation-inducing compounds for PLK1
A bifunctional compound targeting PLK1 through CRBN or VHL E3 ubiquitin ligase binding sites addresses the limitations of conventional PLK1 inhibitors by inducing selective PLK1 degradation, enhancing therapeutic efficacy with reduced side effects.
Patent Information
- Application Number
- JP2023177565
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-03-27
- Filing Date
- 2023-10-13
- Publication Date
- 2026-11-09
- Estimated Expiration
- 2041-03-27
AI Technical Summary
Conventional PLK1 inhibitors fail to sufficiently inhibit PLK1 activity at clinically safe concentrations, leading to incomplete cell cycle arrest in cancer cells and potential drug resistance, while existing PROTAC compounds exhibit off-target effects and side effects due to non-selective degradation of proteins like BRD4.
A bifunctional compound linking a PLK1 binding moiety and an E3 ubiquitin ligase binding moiety through a chemical linker, specifically designed to induce selective degradation of PLK1, minimizing off-target effects by using CRBN or VHL E3 ubiquitin ligase binding sites.
The compound effectively induces selective PLK1 degradation, reducing side effects and achieving superior PLK1 inhibitory effects compared to conventional inhibitors, with minimal off-target degradation, thus providing a promising therapeutic approach for PLK1-related diseases.
Smart Images

Figure 0007946328000343 
Figure 0007946328000344 
Figure 0007946328000001
Abstract
Description
[Technical Field]
[0001] The present invention relates to a selective degradation-inducing compound for PLK1, a method for producing the same, and its uses. [Background technology]
[0002] PLK1 (Polo-like kinase 1) is a serine / threonine kinase known to be involved in the transition to the G2 / M phase during cell growth and division. PLK1 is expressed and activated in a pulsed manner from the S phase to the G2 / M phase, and is rapidly degraded once mitosis is complete.
[0003] PLK1 is overexpressed in various cancers, including colorectal cancer, lung cancer, bladder cancer, and malignant melanoma, and cancer cells that overexpress PLK1 tend to show resistance to various types of anticancer drugs. Thus, since PLK1 dependence has been revealed in numerous cancers, attempts have been made to develop PLK1 inhibitor compounds such as volasertib (also known as BI6727).
[0004] However, conventional PLK1 inhibitors have the problem that they cannot sufficiently inhibit PLK1 activity at clinically safe concentrations, and even if the cell cycle of cancer cells is temporarily delayed, some cancer cells will eventually resume their cell cycle, potentially resulting in insufficient clinical efficacy (see references [Gheghiani et al. Cell Reports, 2017], etc.). In fact, numerous pharmaceutical companies such as Boehringer Ingelheim and GSK (GlaxoSmithKline) have attempted to develop small molecule-based PLK1 inhibitors, but most have failed or been discontinued at the clinical trial stage, and to this day, no PLK1 inhibitors have been commercialized. This indicates that the pharmacological mechanism of small molecule inhibitors, which bind to the active site of PLK1 and inhibit enzyme activity, is not sufficiently effective in the development of new drugs aimed at eliciting anticancer effects by suppressing the PLK1 activity of cancer cells.
[0005] Recently, PROTAC (Proteolysis Targeting Chimera) has been proposed as a small molecule-based platform technology capable of inducing proteolysis of target proteins in the body. PROTAC is a bifunctional compound in which a ligand molecule that binds to disease-related target proteins and an E3 ubiquitin ligase binding portion are linked by a chemical linker. Theoretically, PROTAC compounds can induce the degradation of target proteins by positioning them closer to the E3 ubiquitin ligase.
[0006] In the case of PROTAC compounds targeting PLK1 as a protein, Chinese Patent Application Publication No. 106543185 A partially discloses a bifunctional compound in which a borasertib derivative compound and an E3 ubiquitin ligase CRBN binding site are linked by a chemical linker. However, the aforementioned prior art only describes a limited number of synthetic examples of PROTAC compounds, and generally, the targeted degradation activity and selectivity of the PROTAC can vary significantly depending on the selection of the target protein site, the E3 ubiquitin ligase binding site, etc. (e.g., [Burslem and Crews, 2017]).
[0007] Furthermore, the PROTAC compound described in the aforementioned document is characterized by its ability to simultaneously degrade PLK1 and BRD4, and similarly degrade other PLK family proteins other than PLK1, as well as various other proteins such as BRD4. This is a key feature of the invention, and it is useful during drug development for off-targeting There is a possibility of side effects due to off-target effects. In particular, given that it is already widely known that potent inhibition of BRD4 activity inevitably leads to on-target toxicity such as hematological toxicity and gastrointestinal toxicity along with pharmacological effects, it is expected that the more effectively the PROTAC compounds described in the above literature degrade BRD4, the greater the clinical side effects will be (reference [Bolden et al. Cell Reports, 2014], etc.).
[0008] Furthermore, according to a document published by the inventors of the aforementioned document [Mu et al. BBRC, 2019], it can be confirmed that the PROTAC compound that simultaneously degrades PLK1 and BRD4 has a much stronger BRD4 degrading ability at the cellular level than its PLK1 degrading ability, and the cell cycle is almost stopped in the G1 phase. This confirms that, independently of how conventional PLK1 inhibitors exert their pharmacological effects, it actually acts solely as a BRD4 inhibitor.
[0009] Therefore, there is an unmet need for selective PLK1 degradation-inducing compounds that effectively induce PLK1 degradation while possessing selective degradation activity against PLK1 and minimizing side effects. [Overview of the Initiative] [Problems that the invention aims to solve]
[0010] The object of the present invention is to provide a compound that selectively induces the degradation of PLK1.
[0011] Another object of the present invention is to provide a method for producing a selective degradation-inducing compound of PLK1.
[0012] Another object of the present invention is to provide applications for selective degradation-inducing compounds of PLK1. [Means for solving the problem]
[0013] Selective degradation-inducing compounds for PLK1 The present invention provides a novel compound that induces selective degradation of PLK1 (Polo-like kinase 1). Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase binding moiety are linked by a chemical linker.
[0014] In one aspect of the present invention, there is provided a compound represented by the following Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
[0015] [Formula I] [Chemical Formula]
[0016] In the aforementioned Formula I, ULM is a CRBN or VHL E3 ubiquitin ligase binding moiety, PTM is a PLK1 binding moiety represented by the following Formula II, [Formula II] [Chemical Formula] {In the aforementioned Formula II, R1 is hydrogen, C 1-5 alkyl or C 3-6 cycloalkyl, R 1A is hydrogen or C 1-3 alkyl, R2 is hydrogen, halogen, C 1-6 alkyl or -OR 2A , R 2A is C which may be substituted with one or more halogen or hydroxy groups 1-4 alkyl or C 3-6 cycloalkyl, R3 is hydrogen, halogen, -NO2, -CN, -OH, C 1-4 alkyl or -OC 1-4 alkyl, R4 is a single bond,
Chemical formula
[0017] The linker is a group that chemically connects ULM and PTM.
[0018] In Formula II,
Chemical formula
[0019] (1) E3 ubiquitin ligase binding moiety (ULM) According to one embodiment of the present invention, ULM is a CRBN E3 ubiquitin ligase binding moiety.
[0020] In the present invention, CRBN means Cereblon E3 ubiquitin ligase. CRBN, together with DDB1, Cul4A and ROC1, constitutes the E3 ubiquitin ligase complex, wherein CRBN is the substrate recognition subunit of the aforementioned complex. Some compounds capable of binding to CRBN E3 ubiquitin ligase are partially known in the art. For example, thalidomide targets CRBN Since the fact that it binds to E3 ubiquitin ligase was known (Reference [Ito et al., 2010]), a large number of immunomodulatory imide drugs (IMiDs) including lenalidomide and pomalidomide have been reported to possess CRBN binding capacity (Reference [Chamberlain and Brian. 2 019], Reference [Akuffo et al. 2018]), Reference [Burslem et al. 2018], etc.).
[0021] In one embodiment, the CRBN E3 ubiquitin ligase binding portion of the present invention is a compound represented by the following formula A-1.
[0022] [Formula A-1] [ka] Here, [ka] teeth, [ka] It is a ring selected from the group consisting of; X1 is a single bond, -CH2-, -NH-, -O-, -CH2CH2-, -CC-, -CO-, -COO-, -NHCO-, or -CONH-; X2 is -CH2-, -CH(C 1-4 Alkyl)-, -NH-, -N(C 1-4 Alkyl)-, -O-, -CO-, -CH2-CH 2- -NH-CH2-, -NH-CH(C 1-4 Alkyl)-, -N=CH-, -N=C(C 1-4 Alkyl)- or -N=N-; X3 is hydrogen or C 1-4 It is alkyl; The X4 uses hydrogen, halogen, and C 1-6 These are alkyl, CN, NH2, NO2, OH, COH, COOH, or CF3.
[0023] In one embodiment, formula A-1 is represented by the following formula A-2. [Formula A-2] [ka] Here, X2 is -CH2-, -CH(C 1- 4 It is alkyl)-, -CO-, or -N=N-; X3 is hydrogen or C1 -3 is alkyl.
[0024] In one embodiment, X3 is hydrogen.
[0025] In one embodiment of the present invention, the aforementioned formula A-2 may be selected from the group consisting of the following moieties.
Chemical Formula
[0026] An example of the CRBN E3 ubiquitin ligase ligand according to the present invention is as follows (Reference [Chamberlain and Brian. 2019] and Reference [Akuffo et al. 2018]).
Chemical Formula
[0027] Another example of the CRBN E3 ubiquitin ligase binding moiety according to the present invention is as follows (Reference [Burslem et al. 2018]).
Chemical Formula
Chemical Formula
[0028] In a specific embodiment, the CRBN E3 ubiquitin ligase binding moiety of the present invention is as follows.
Chemical Formula
[0029] According to one embodiment of the present invention, ULM is a VHL E3 ubiquitin ligase binding moiety.
[0030] In the present invention, VHL stands for von Hippel-Lindau tumor suppressor. VHL, together with Elongin B, Elongin C, CUL2, and Rbx1, constitutes the VCB E3 ubiquitin ligase complex, where VHL is the substrate-recognizing subunit of the complex. Compounds capable of binding to VHL E3 ubiquitin ligase are partially known in the art. For example, since peptides such as Ala-Leu-Ala-(Hy)Pro-Tyr-Ile-Pro heptapeptide (Reference [Schneekloth et al., 2004]) and Leu-Ala-(Hy)Pro-Tyr-Ile pentapeptide (Reference [Rodriguez-Gonzalez et al., 2008]) became known, improved low-molecular-weight VHL E3 ubiquitin ligase-binding compounds have been reported (References [Buckley et al. J. Am. Chem. Soc. 2012], [Buckley et al. Ang. Chem. Int. Ed. 2012], [Galdeano et al., 2014], [Soares et al. 2017], etc.).
[0031] In one example, the VHL E3 ubiquitin ligase binding site is a compound represented by the following formula B-1.
[0032] [Formula B-1] [ka] Here, n is an integer between 1 and 3; [ka] This is a five-membered to six-membered cycloalkyl, phenyl, a five-membered to six-membered heterocycloalkyl, or a five-membered to six-membered heteroaryl, where the heterocycloalkyl or heteroaryl contains 1 to 3 N, O, or S atoms; Y1 is hydrogen or C 1-4It is alkyl; Y2 is C 1-4 Alkyl, hydroxy(C) 1-4 Alkyl), -(C 0-2 Alkyl)-COH, C 3-8 It is cycloalkyl or phenyl; Y3 is hydrogen, [ka] or [ka] And, Y4 is hydrogen, halogen, C 1-4 Alkyl, -O(C 1-4 Alkyl), C 3-6 A cycloalkyl or a four-membered to six-membered heterocycloalkyl [where optionally substituted with halogens, -OH, -CN, -NHCOH, -NHCOCH3, -COH, or -COCH3]; Y5 is hydrogen or C 1-4 It is alkyl.
[0033] In one embodiment of the present invention, the VHL E3 ubiquitin ligase binding portion is a compound selected from the group consisting of the following formulas B-2-1 and B-2-2.
[0034] [Formula B-2-1] [ka]
[0035] [Formula B-2-2] [ka]
[0036] Here, [ka] This is a five-membered heteroaryl ring selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, oxadiazole, pyrrole, pyrrolidine, furan, dihydrofuran, and tetrahydrofuran; Y1 is hydrogen or C 1-3 It is alkyl; Y4 can be substituted with hydrogen or halogen. 1-4 Alkyl or C 3-5 It is a cycloalkyl group. In one embodiment, the VHL E3 ubiquitin ligase represented by formula B-2-1 is selected from the following group. [ka]
[0037] In one embodiment, the VHL E3 ubiquitin ligase represented by formula B-2-2 is Select from the following group. [ka]
[0038] Another example of a VHL E3 ubiquitin ligase ligand relating to the present invention is as follows (Reference [Galdeano et al. (2014)]). [ka] [ka]
[0039] Another example of a VHL E3 ubiquitin ligase ligand relating to the present invention is as follows (Reference [Soares et al. 2017]). [ka]
[0040] In the present invention, the ULM has linkers coupled at positions necessary to exhibit the dual functionality of PROTAC. In the present invention, represented by formulas A-1, A-2, B-1, B-2-1 and B-2-2 [ka] Linkers can be joined by covalent bonds via this mechanism. [ka] If not specified, one hydrogen atom in the moiety of the E3 ubiquitin ligase ligand-binding compound may be substituted with a single bond and linked to the linker.
[0041] (2) Target protein ligand (PTM) In the compound represented by formula I of the present invention, the PTM, which is the part that performs the target protein ligand function, is the PLK1 (Polo-like kinase 1) binding site represented by formula II described above.
[0042] Formula II, which constitutes the compound portion of Formula I of the present invention, is a pyrimidodiazepinone derivative on its own and can bind to the active site of PLK1 (see references [Nie, Zhe, et al. Bioorganic & medicinal chemistry letters 23.12(2013):3662-3666.] and International Patent Publication WO2009 / 042711, etc.).
[0043] In one example, formula II is the compound represented by the following formula III. [Formula III] [ka] Here, R1 is C 1-5 Alkyl or C 3-7 It is a cycloalkyl, R2 is hydrogen or -OR2A And, R 2A C 1-6 Alkyl, C 3-7 Cycloalkyl, CF3 or (C 1-3 It is alkylene)-OH. R3 is either hydrogen or a halogen. In one embodiment, the PTM portion is the PTM portion contained in compounds 1 to 175.
[0044] (3) Linker According to one embodiment of the present invention, the linker defined by formula I is represented by the following formula L. [Formula L] [ka] Here, [ka] Each is independent, and the other is a combination. [ka] L ULM , L PTM and L INT These are, independently, null, single bond, and -CH. 2- , -NH-, -O-, -S-, -SO-, -SO2-, -CO-, -CH2CH2-, -CHCH-, -CC-, -CH2CH2O-, -OCH2CH2-, -CH2CH2S-, -SCH2CH2-, -COO-, -CONH-, -NHCO- and [ka] Selected from the group consisting of, 1 or more C 1-6 Alkyl, C 3-8 It can be optionally substituted with cycloalkyl, halogen, hydroxy, amine, nitro, cyano, or haloalkyl, {where, [ka] These are cycloalkyl, heterocycloalkyl, aryl, or heteroaryl compounds. p is an integer between 1 and 30.
[0045] In one embodiment, p is an integer greater than or equal to 1, 5, 10, 15, 20, or 25, and less than or equal to 25, 20, 15, 10, or 5.
[0046] In the present invention, L ULM teeth, [ka] That's fine. {Here, L U1 This is a single bond, -CH 2- Selected from the group consisting of -CH2CH2-, -CH=CH-, -CC-, -NH-, -NCH3-, -CO-, -NHCO- and -O-, L U2 It is selected from the group consisting of single bonds, -CH2-, -NH-, -O-, -CO-, and -CONH-, [ka] This is selected from the group consisting of null, three-membered to ten-membered cycloalkyl rings, four-membered to ten-membered heterocycloalkyl rings, six-membered to ten-membered aryl rings, or five-membered to ten-membered heteroaryl rings.
[0047] In specific examples, [ka] -CH2-, -CC-, -NH-, -NHCO-, -NHCO-CH2-O-, -NH-CH2-CONH-, -O-, -OCH2-CONH-, [ka] That is the case.
[0048] In the present invention, L PTM teeth [ka] That's fine. {Here, L P1 These are single bonds, -O-, -S-, -NH-, -N(C) 1-4 Alkyl)-, -CH2-, -CH(C 1-4 Selected from the group consisting of alkyl)-, -CH2NH-, and -CH2CH2-, L P2 The group is selected from the group consisting of single bonds, -CO-, -COCH2-, -NHCO-, -NHCOCH2-, -HET-, and -HET-CH2-, where HET is a five-membered to six-membered heterocyclyl or heteroaryl having one or more N, S, or O atoms. [ka] This is a null C substituted with an amine group. 1-8 Alkyl; or a ring selected from the group consisting of three-membered to ten-membered cycloalkyl groups, four-membered to ten-membered heterocycloalkyl groups, six-membered to ten-membered aryl groups, and five-membered to ten-membered heteroaryl groups.
[0049] In specific examples, [ka] teeth, [ka] Selected from the group consisting of, for example, [ka] That is the case.
[0050] In another example, [ka] teeth [ka] That is {Here, X1 is CH or N, and X2 and X3 are independently hydrogen, CH3, or CH2CH3, respectively}.
[0051] In another example, [ka] teeth, [ka] Selected from the group consisting of, for example, [ka] That is the case.
[0052] In the present invention, [ka] teeth, [ka] That's fine. {Here, [ka] This is a null ring, or a ring selected from the group consisting of three-membered to ten-membered cycloalkyl rings, four-membered to ten-membered heterocycloalkyl rings, six-membered to ten-membered aryl rings, and five-membered to ten-membered heteroaryl rings. L INT1 and L INT2 are each independently selected from the group consisting of -CH2-, -NH-, -NCH3-, -O-, -S-, -SO-, -SO2-, -CO-, -CH2CH2O-, -OCH2CH2-, -CH2CH2S-, -SCH2CH2-, -COO-, -CONH- and -NHCO-, q and r are each independently an integer of 1 to 10.}
[0053] In one embodiment, the linker is a linker contained in a compound selected from the group consisting of Compounds 1 to 175.
[0054] According to specific embodiments of the present invention, the compound represented by Formula I is one or more compounds selected from the group consisting of the following Compounds 1 to 175, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
[0055] As used in the present invention, the pharmaceutically acceptable salt refers to any organic or inorganic acid addition salt that is relatively non-toxic, harmless, has a beneficial effect on patients, and at a concentration where side effects caused by the salt do not reduce the beneficial effects of the compound represented by Formula I. For example, the pharmaceutically acceptable salt can be, but is not limited to, inorganic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, or nitric acid, and organic acids such as methanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid or hydroiodic acid.
[0056] <Method for producing selective degradation-inducing compound of PLK1> In the present invention, the compound represented by formula I described above, its stereoisomer, or a pharmaceutically acceptable salt thereof can be produced by synthetic methods known in the art of organic chemistry or by modifications and modifications obvious to the ordinary skill, through reactions such as those shown in the following reaction formulas 1 to 3.
[0057] [Reaction Equation 1] [ka]
[0058] [Reaction Equation 2] [ka]
[0059] [Reaction Equation 3] [ka]
[0060] In the above reaction formulas 1 to 3, PTM, linker, and ULM are the groups defined above or their reaction derivatives, and RG 1 RG 2 RG 2a RG 2b RG 3 RG 3a RG 3b and RG 4 This is a molar containing a suitable reactive group that can be bonded together with an intermediate of the PROTAC compound represented by formula I by forming a covalent bond in the field of organic synthesis. The formation of the covalent bond can be, but is not limited to, amide formation, ester formation, carbamate formation, urea formation, ether formation, amine formation, and various synthetic reactions such as carbon-carbon single bond formation, double bond formation, and click chemistry, by specific reactive groups.
[0061] Variations of each step in the above reaction equation may include one or more synthetic steps. Separation and purification of the product can be achieved by standard procedures known to the ordinary technicians in the field of organic chemistry.
[0062] In one embodiment, the compound of the present invention can be prepared, for example, via reaction formula 1 of one or more synthesis steps.
[0063] As an example of reaction formula 1, if ULM is formula A-1, the compound of the present invention can be prepared via the following reaction formula 1-A (see, for example, Example 40).
[0064] [Reaction Equation 1-A] [ka]
[0065] As an example of reaction formula 1, if ULM is formula B-1, the compound of the present invention can be prepared via the following reaction formula 1-B.
[0066] [Reaction Equation 1-B] [ka]
[0067] In another embodiment, the compound of the present invention can be prepared, for example, via reaction formula 2 of one or more synthesis steps.
[0068] As an example of reaction formula 2, when ULM is formula A-1, the compound of the present invention can be prepared via the following reaction formula 2-A (see Examples 1-39, 41-60, 63-79, 90-122, 124-158, 162-175).
[0069] [Reaction Equation 2-A] [ka]
[0070] As an example of reaction formula 2, when ULM is formula B-1, the compound of the present invention can be prepared via the following reaction formula 2-B (see, for example, Examples 80-89).
[0071] [Reaction Equation 2-B] [ka]
[0072] In another embodiment, the compound of the present invention can be prepared, for example, via reaction 3 of one or more synthesis steps.
[0073] As an example of reaction formula 3, when ULM is formula A-1, the compound of the present invention can be prepared via the following reaction formula 3-A (see, for example, Examples 61, 62, 123, 159, 160, 161).
[0074] [Reaction Equation 3-A] [ka]
[0075] As an example of reaction formula 3, if ULM is formula B-1, the compound of the present invention can be prepared via the following reaction formula 3-B.
[0076] [Reaction formula 3B] [ka]
[0077] In the above reaction equation, RG 1 RG 2 , and RG 2a Each is independently L PTM or its reaction precursor, RG 3 RG 4 and RG 3a Each is independently L ULMor a reaction precursor thereof, and the aforementioned moieties can be appropriately selected depending on the structure of the target compound and the position of the linker.
[0078] In the aforementioned reaction formula, the reactants presented as PTM and ULM can be easily synthesized by a person of ordinary skill in the field with reference to known documents in the field of organic chemistry and the descriptions of the examples of the present invention.
[0079] The present invention relates to PTM-Linker-RG which is a reaction intermediate represented by Formula I 3 or PTM-Linker1-RG 2b It includes compounds of the form.
[0080] <Use of selective degradation-inducing compound for PLK1> One example of the present invention is a composition for inducing degradation of PLK1, comprising a compound represented by Formula I or a pharmaceutically acceptable salt thereof. Formula I is as defined above.
[0081] In the examples of the present invention, it was confirmed that the compounds of the present invention effectively induce the degradation of PLK1 (Table 2). Specifically, it was confirmed that the compounds of the present invention have significantly superior PLK1 degradation activity compared to the compound disclosed in prior art Chinese Patent Application Publication No. 106543185 A (Figure 1 and Figure 2). Furthermore, the compounds of the present invention, for PL Since it has no degradation capacity for BRD4, which is a target protein other than K1, side effects due to off-target degradation represented by the compound disclosed in Chinese Patent Application Publication No. 106543185 A were also confirmed to be minimized (Figure 2).
[0082] The PLK1 degradation-inducing PROTAC compound of the present invention, based on its mechanism of action, can fundamentally degrade PLK1 which is the target protein, thus achieving an excellent PLK1 inhibitory effect even compared to conventional PLK1 small molecule inhibitors that merely inhibit the simple activity of PLK1.
[0083] Therefore, compositions containing the compound represented by formula I of the present invention or a pharmaceutically acceptable salt thereof can be usefully used for the selective decomposition of PLK1.
[0084] One embodiment of the present invention is a pharmaceutical composition for the prevention or treatment of PLK1-related disease comprising a compound represented by formula I or a pharmaceutically acceptable salt thereof. Formula I is as defined above.
[0085] In the present invention, PLK1-related disease means any disease or condition that can be treated, mitigated, delayed, inhibited, or prevented from the induction of PLK1 degradation or inhibition of its activity. In one embodiment, PLK1-related disease may be cancer (malignant tumor), benign tumor, neurological disorder, or any other genetic or non-genetic disease caused by excessive cell division.
[0086] The cancers mentioned above include all cancers that can be prevented or treated by inhibiting PLK1 activity, and may be solid tumors or hematological cancers. For example, the cancers may be one or more selected from the group consisting of squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous cell carcinoma of the lung, peritoneal cancer, skin cancer, melanoma of the skin or eye, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatocellular carcinoma, gastrointestinal cancer, stomach cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumors, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancer, brain cancer, osteosarcoma, etc., but are not limited to these. The cancers mentioned above include not only primary cancers but also metastatic cancers.
[0087] The aforementioned benign tumors include all benign tumors that can exhibit a preventive or therapeutic effect by inhibiting PLK1 activity, so-called precancerous benign tumors, and may be solid tumors or hematological malignancies. For example, the tumors may be one or more selected from the group consisting of Barrett's esophagus, colon adenomas and polyps, mammary fibroadenomas and cysts, monoclonal immunoglobulinemia of unknown significance (MGUS), monoclonal lymphocytosis, etc., but are not limited to these.
[0088] The aforementioned neurological diseases include all neurological diseases for which prevention or therapeutic effects can be exerted by inhibiting the activity of PLK1, and may be, but are not limited to, one or more selected from central nervous system diseases, degenerative neurological diseases, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntint's disease, senile dementia, epilepsy, Lou Gehrig's disease, stroke, and nerve damage and axonal degeneration-related diseases due to brain or spinal cord injury.
[0089] The pharmaceutical composition of the present invention may further contain, in addition to the compound represented by formula I or a pharmaceutically acceptable salt thereof, one or more active ingredients exhibiting the same or similar pharmacological effects.
[0090] One embodiment of the present invention involves administering a compound represented by formula I or a pharmaceutically acceptable salt thereof to humans. This method involves administering it to mammals containing the substance to degrade the PLK1 protein.
[0091] Another embodiment of the present invention is a method for degrading the PLK1 protein by administering a compound represented by formula I or a pharmaceutically acceptable salt thereof to a sample in vitro. The sample may, but is not limited to, cells, cell cultures, bodily fluids, or tissues of a mammal, including humans. [Effects of the Invention]
[0092] The compound of the present invention exhibits the effect of inducing PLK1 degradation. Therefore, the compound of the present invention can be effectively used for the prevention or treatment of PLK1-related diseases. [Brief explanation of the drawing]
[0093] [Figure 1] The results of Western blotting measuring the PLK1 protein resolution using the bifunctional compound according to the present invention are shown. [Figure 2] The results of Western blotting showing the selective PLK1 protein degradation and off-target degradation of the bifunctional compound according to the present invention are shown. [Modes for carrying out the invention]
[0094] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as those generally understood by an ordinary person skilled in the art to which this disclosure pertains. Terms used in the description are for illustrative purposes of specific embodiments and are not intended to limit this disclosure.
[0095] The present invention provides a method for synthesizing compounds 1 to 175 shown in the following table. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] Table 1-6 Table 1-7 Table 1-8 Table 1-9 Table 1-10 Table 1-11 Table 1-12 Table 1-13 Table 1-14 Table 1-15 Table 1-16 Table 1-17 Table 1-18 Table 1-19 Table 1-20 Table 1-21 Table 1-22 Table 1-23 Table 1-24 Table 1-25 Table 1-26 Table 1-27 Table 1-28 Table 1-29 Table 1-30 Table 1-31 Table 1-32 Table 1-33 [Table 1-34] [Table 1-35] [Table 1-36] [Table 1-37] [Table 1-38] [Table 1-39] [Table 1-40] [Table 1-41] [Table 1-42] [Table 1-43]
[0096] Compounds 1-175 were purified using the following method, and their structures were analyzed.
[0097] analytical equipment LCMS: Shimadzu LCMS-2020 NMR: BRUKER AVANCE III / 400MHz HPLC: Shimadzu LC-20AB and Shimadzu LC-20AD, Agilent 1100 LC, Agilent 1200 LC, Agilent 1290 LC
[0098] LCMS analysis method LCMS data were recorded using a Shimadzu LCMS-2020 equipped with an electrospray ionization system. 0.0375% TFA in water (solvent A) and 0.01875% TFA in acetonitrile (solvent B) were used as mobile phases. A Kinetex EVO C18 (2.1*30) mm, 5 μm column was used.
[0099] HPLC analysis method HPLC analysis was performed using Shimadzu LC-20AB, Shimadzu LC-20AD, Agilent 1100 LC, Agilent 1200 LC, or Agilent 1290 LC, with 0.0375% TFA in water (solvent A) and 0.01875% TFA in acetonitrile (solvent B) or 0.025% NH3·H2O in water (solvent A) and acetonitrile (solvent B) as the mobile phase. The columns used were XBridge C18 (2.1*50) mm, 5 μm, Kinetex C18 LC column (4.6*50) mm, 5 μm, Eclipse plus C18 (4.6*150) mm, 3.5 μm, or Waters Xbridge® C18 (4.6*150) mm, 3.5 μm.
[0100] Methods of NMR analysis 1 The 1H NMR spectrum was obtained using a Bruker AVANCEIII 400MHz / 5mm Recorded using Probe (BBO).
[0101] Example 1: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0102] Step 1: Synthesis of 2-(2,6-dioxopiperidine-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino)isoindoline-1,3-dione(3)
[0103] TEA (4.40 g, 43.44 mmol, 6.05 mL) was added to a solution of 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione (4 g, 14.48 mmol) and 2-(2-aminoethoxy)ethanol (2.10 g, 19.97 mmol, 2 mL) in DMSO (60 mL). The reaction mixture was stirred at 90 °C for 16 hours. LC-MS showed a main peak with the desired mass. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (150 mL x 3). The combined organic layers were dried over sodium sulfate and filtered. The filtrate was concentrated under vacuum to obtain the title compound (3.5 g, 9.69 mmol, 66.89% yield) as a green oil, which was used directly in the next step.
[0104] MS(M+H) + =362.1.
[0105] Step 2: Synthesis of 2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonic acid (4)
[0106] To a solution of 2-(2,6-dioxopiperidine-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino)isoindoline-1,3-dione (3.5 g, 9.69 mmol) and TosCl (2.22 g, 11.62 mmol) in DCM (100 mL), TEA (2.94 g, 29.06 mmol, 4.04 mL) was added. The mixture was stirred at 20 °C for 16 hours. One peak (55%) with the desired mass was confirmed by LC-MS. The reaction product was concentrated under vacuum. The residue was purified by reverse-phase MPLC (FA, MeCN / water), and the eluent was lyophilized to obtain the title compound (1 g, 1.94 mmol, 20.03% yield) as a yellow solid.
[0107] MS(M+H) + =516.1.
[0108] Step 3: Synthesis of tert-butyl(1-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)piperidine-4-yl)carbamate (6)
[0109] To a solution of 2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonic acid (1 g, 1.94 mmol) and tert-butylpiperidine-4-yl carbamate (582.73 mg, 2.91 mmol) in dioxane (15 mL), DIPEA (752.09 mg, 5.82 mmol, 1.01 mL) and NaI (29.08 mg, 193.97 μmol) were added, and the reaction mixture was stirred at 65°C for 3 hours. LC-MS confirmed that 50% of the substance remained, and the reaction mixture was stirred at 65°C for 16 hours. LC-MS confirmed a single major peak with the desired mass. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (60 mL x 2). The combined organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, EA / methanol = 100%~8%), and the eluent was concentrated under vacuum to obtain the title compound (600 mg, 1.09 mmol, 56.33% yield, 99% purity) as a yellow solid.
[0110] MS(M+H) + =544.2.
[0111] Step 4: Synthesis of 4-((2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (7)
[0112] To a solution of tert-butyl(1-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)piperidine-4-yl)carbamate (600 mg, 1.10 mmol) in dioxane (5 mL), HCl / dioxane (4 M, 16.22 mL) was added, and the mixture was stirred at 20°C for 3 hours. LC-MS confirmed complete consumption of the starting material and identified a single major peak (74%) with the desired mass. The reaction mixture was concentrated under vacuum to obtain the title compound (810 mg, crude, HCl salt) as a yellow solid.
[0113] MS(M+H) + =444.2.
[0114] Step 5: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 1)
[0115] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (174.55 mg, 375.03 μmol) in DMF (7 mL), HATU (356.50 mg, 937.59 μmol) and DIEA (403.92 mg, 3.13 mmol, 544.37 μL) were added, and the mixture was stirred at 20°C for 2 hours. Next, 4-((2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (300 mg, crude, HCl salt) was added to the mixture, and the resulting mixture was stirred at 20°C for 12 hours. LC-MS confirmed that the reactants were completely consumed and that there was one major peak (85%) with the desired mass. The reaction mixture was filtered, and the filtrate was separated by HPLC (column: Phenomenex Luna C). 18 The sample was purified using a 150*40mm*15um mobile phase (water (0.1% TFA)-ACN); B%: 22%-52%, 10 min). The eluent was freeze-dried to obtain the title compound (237.5 mg, 224.52 μmol, 35.92% yield, 95% purity, TFA salt) as a yellow solid.
[0116] MS(M+H) + =891.6.
[0117] 1 HNMR (400MHz, DMSO-d6)δ=11.09-11.08(m, 1H), 9.53-9.36(m, 1H), 8.34-8.22(m, 2H), 8.22-8.08(m, 2H), 7.61(dd, J1=8 .4Hz, J2=7.2Hz, 1H), 7.25-7.13(m, 2H), 7.10-7.01(m, 1H), 6.63(s, 1H), 5.08(dd, J1=12.8Hz, J2=5.4Hz, 1H), 4.84(t, J =8.1Hz, 1H), 4.15-4.05(m, 3H), 3.95-3.92(m, 3H), 3.80(s, 2H), 3.71-3.66(m, 2H), 3.57-3.48(m, 4H), 3.33(s, 3H) , 3.32-3.27(m, 2H), 3.20-3.08(m, 1H), 2.94-2.80(m, 1H), 2.58-2.51(m, 1H), 2.16-1.83(m, 6H), 1.82-1.47(m, 8H).
[0118] Example 2: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0119] The title compound (126.5 mg, 133.95 umol, 31.17% yield, 99% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0120] MS(M+H) + =935.5
[0121] 1H NMR (400MHz, CDCl3)δ=9.15(brs, 1H), 8.38(d, J =14.6Hz, 1H), 8.07(s, 1H), 7.86(s, 1H), 7.56-7.43(m, 2H), 7.09(d, J=7.0Hz, 1H), 6.94(d, J=8. 8Hz, 1H), 6.88-6.79(m, 1H), 6.48-6.45(m, 1H), 5.01-4.98(m, 1H), 4.87(t, J=8.6Hz, 1H), 4.25(b rs, 1H), 4.04-3.87(m, 7H), 3.77-3.69(m, 6H), 3.49-3.46(m, 2H), 3.42(s, 3H), 3.40-325(m, 2H) , 3.09-3.06(m, 2H), 2.93-2.71(m, 3H), 2.30-2.02(m, 6H), 1.85-1.77(m, 3H), 1.70-1.56(m, 6H).
[0122] Example 3: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide
[0123] The title compound (112.5 mg, 113.76 umol, 26.47% yield, 99% purity) was synthesized as a yellow solid using the same method as described in the examples above.
[0124] MS(M+H) + =979.4
[0125] 11H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.87 (dd, J=7.6, 3.2 Hz, 1H), 7.61-7.55 (m, 1H), 7.17 (dd, J=21.8, 7.6 Hz, 2H), 7.04 (d, J=7.0 Hz, 1H), 6.61 (t, J=5.8 Hz, 1H), 5.06 (dd, J=12.9, 5.5 Hz, 1H), 4.81 (q, J=8.5 Hz, 1H), 4.08 (t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.75-3.68 (m, 1H), 3.63 (t, J=5.5 Hz, 2H), 3.59-3.56 (m, 2H), 3.55-3.53 (m, 2H), 3.52-3.50 (m, 2H), 3.49-3.46 (m, 6H), 3.31-3.26 (m, 2H), 2.94-2.79 (m, 3H), 2.66-2.51 (m, 3H), 2.43 (t, J=6.1 Hz, 2H), 2.07-2.00 (m, 3H), 2.00-1.93 (m, 2H), 1.81-1.69 (m, 4H), 1.67-1.57 (m, 4H), 1.56-1.46 (m, 2H).
[0126] Example 4: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
[0127] The title compound (97.2 mg, 95.01 μmol, 27.64% yield, 100% purity) was synthesized as a yellow solid in the same manner as in the examples described above.
[0128] MS (M+H) + =1023.5
[0129] 1¹H NMR (400MHz, chloroform-d) δ 9.08 (s, 1H), 8.33 (d, J=14.9Hz, 1H), 8.05 (s, 1H), 7.84 (s, 1H), 7.55-7.37 (m, 2H), 7.06 (d, J=7.1Hz, 1H), 6.96-6.77 (m, 2H), 6.51-6.40 (m, 1H), 5.02-4.78 (m, 2H), 4.34-4.09 (m, 1H), 3.98-3.85 (m , 5H), 3.82(t, J=4.9Hz, 2H), 3.78-3.59(m, 17H), 3.53-3.42(m, 3H), 3.40(s, 3H), 3.37-3.17(m, 2H), 3.12-3.0 1(m, 1H), 2.90-2.65(m, 3H), 2.26(d, J=13.7Hz, 1H), 2.18-2.01(m, 5H), 1.79-1.69(m, 4H), 1.65-1.50(m, 2H).
[0130] Example 5: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(17-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0131] Based on the above reaction equation, the title compound (36.5 mg, 31.81 μmol (13.77% yield, 93% purity) was obtained as a yellow solid.
[0132] MS(M+H) + =1067.9
[0133] 1H NMR (400MHz, DMSO-d6) δ=11.07(brs, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.02(s, 1H) ), 7.90-7.81(m, 1H), 7.62-7.54(m, 1H), 7.23-7.11(m, 2H), 7.03(d, J=7.1Hz, 1H), 6.60(br t, J=5.5Hz, 1H), 5.10-4.99(m, 1H), 4.88-4.75(m, 1H), 4.07(br t, J=13.8Hz, 2H), 3.91(s, 3H), 3.75-3.69(m, 1H), 3.65-3.59(m, 2H), 3.56-3.48(m, 18H), 3.47-3.44(m, 2H), 3.33-3.21( m, 3H), 2.88-2.79(m, 2H), 2.62-2.54(m, 2H), 2.48-2.42(m, 2H), 2.10-1.92(m, 6H), 1.81-1.68(m, 5H), 1.67-1.47(m, 5H).
[0134] Example 6: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxy-N-(1-(2-(2-(2-((2-((1-methyl-2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)benzamide [ka]
[0135] Step 1: Synthesis of 4-fluoro-2-(1-methyl-2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (2)
[0136] A mixture of 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione (5g, 18.10 mmol) and MeI (3.08g, 21.72 mmol, 1.35 mL) in DMF (50 mL) to which potassium carbonate (2.75 g, 19. 91 mmol) was added, and the resulting mixture was stirred at 25°C for 14 hours. LC-MS confirmed the consumption of the starting material and identified one major peak with mass (89%). Ethyl acetate (100 mL) and water (100 mL) were added, and the layers were separated. The aqueous phase was extracted with ethyl acetate (100 mL x 2). The combined extract was washed with brine (100 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 2 / 1 to 1 / 1) to obtain the title compound (2.5 g, 8.53 mmol, 47.11% yield, 99% purity) as a white solid.
[0137] MS(M+H) + =291.1
[0138] Step 2: Synthesis of 4-((2-(2-(2-hydroxyethoxy)ethoxy)ethyl)amino)-2-(1-methyl-2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione(3)
[0139] To a solution of 4-fluoro-2-(1-methyl-2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (1 g, 3.42 mmol) in DMF (25 mL), 2-(2-(2-aminoethoxy)ethoxy)ethanol (510.46 mg, 3.42 mmol) and DIPEA (884.43 mg, 6.84 mmol, 1.19 mL) were added, and the resulting mixture was heated at 90°C for 16 hours. LC-MS confirmed that the reactants were completely consumed and that 37% of the desired mass was detected. The mixture was combined with another batch (1 g scale). The combined mixture was diluted with water (80 mL) and extracted with ethyl acetate (80 mL x 2). The combined organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was analyzed by column chromatography (silicon dioxide). The compound was purified using PE / ethyl acetate (50%-100%) to obtain the title compound (1.45 g, 3.34 mmol, 97.54% yield, 97% purity) as a yellow oily substance. MS(M+H) + =420.1
[0140] Step 3: Synthesis of 2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (4)
[0141] To a solution of 4-((2-(2-(2-hydroxyethoxy)ethoxy)ethyl)amino)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.45 g, 3.46 mmol) and TosCl (3.30 g, 17.29 mmol) in DCM (20 mL) was added Py (2.19 g, 27.66 mmol, 2.23 mL), and the resulting mixture was stirred at 15°C for 16 hours. One peak (30%) with the desired mass was confirmed by LCMS. The mixture was diluted with water (60 mL) and extracted with DCM (80 mL×2). The combined organic layers were dried over sodium sulfate and filtered. The filtrate was concentrated under vacuum. The residue was subjected to column chromatography (silicon dioxide , PE / ethyl acetate, 50%~100%) to afford the title compound (1.64 g, 2.77 mmol, 80.22% yield, 97% purity) as a green oil.
[0142] MS(M+H) + =574.1
[0143] Step 4: Synthesis of tert-butyl (1-(2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (6)
[0144] 2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)eth A solution of xy)ethoxy)ethyl 4-methylbenzenesulfonic acid (1.64 g, 2.86 mmol) and tert-butylpiperidine-4-ylcarbamate (1.15 g, 5.72 mmol) was mixed with DIPEA (1.11 g, 8.58 mmol, 1.49 mL) and NaI (42.86 mg, 285.91 μmol). The resulting mixture was stirred at 80°C for 16 hours. A single major peak with the desired mass was identified by LC-MS. The mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over sodium sulfate and filtered. The filtrate was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, ethyl acetate (100%) ~ DCM / methanol (10%)) to obtain the title compound (1.46 g, 2.38 mmol, 83.17% yield, 98% purity) as a green oil. MS(M+H) + =602.3
[0145] Step 5: Synthesis of 4-((2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(1-methyl-2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (7)
[0146] Tert-butyl(1-(2-(2-(2-((2-(1-methyl-2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (1.46 g, 2.43 mmol) was dissolved in dioxane (10 mL), and HCl / dioxane (4 M, 10 mL) was added. The mixture was stirred at 15°C for 16 hours. One major peak with the desired mass was confirmed by LC-MS. The mixture was concentrated under vacuum, and the title compound (1.4 g, crude, HCl salt) was obtained as a brown oily substance. Ms(M+H) + =502.1
[0147] Step 6: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxy-N-(1-(2-(2-(2-((2-((1-methyl-2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)benzamide (compound 6)
[0148] 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (300 mg, 644.57 μmol, in) in DMF (6 mL) To a solution of DMF (6 mL), HATU (367.63 mg, 966.86 μmol) and DIPEA (249.92 mg, 1.93 mmol, 336.82 μL) were added and stirred for 10 minutes. Then, 4-((2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(1-methyl-2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (416.16 mg, 773.49 μmol, HCl salt) was added. The resulting mixture was stirred at 15°C for 2 hours. One major peak with the desired mass was confirmed by LC-MS. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic layer was dried over sodium sulfate and filtered. The filtrate was concentrated under vacuum. The residue was diluted with MeCN and preparative HPLC (column: Phenomenex Luna C). 18 The sample was purified using a 150*25mm*10um mobile phase (water (0.225% FA)-ACN); B%: 25%~55%, 10 min) to produce two batches. The eluents were freeze-dried to obtain two batches of the title compound as a yellow solid (Batch 1: 108 mg, 110.16 μmol, 17.09% yield, 96.8% purity; Batch 2: 72 mg, 75.87 μmol, 11.77% yield, FA salt, 100% purity).
[0149] MS(M+H) + =949.2
[0150] 1 H NMR (400MHz, CDCl3) δ=8.51(s, 1H), 8.39(d, J=15.1Hz, 1H), 8.09(s, 1H), 7.84( s, 1H), 7.58-7.47(m, 2H), 7.12(d, J=6.9Hz, 1H), 6.95(d, J=8.5Hz, 1H), 6.73(br dd, J=7.7, 14.9Hz, 1H), 6.50(t, J=5.5Hz, 1H), 5.01-4.82(m, 2H), 4.15-4.05( m, 1H), 4.02-3.88(m, 5H), 3.78-3.73(m, 4H), 3.71-3.65(m, 4H), 3.50(q, J=5. 4Hz, 2H), 3.44(s, 3H), 3.25-3.15(m, 5H), 3.02-2.96(m, 1H), 2.88-2.76(m, 4H) ), 2.55-2.47(m, 2H), 2.19-2.05(m, 5H), 1.87-1.72(m, 6H), 1.69-1.56(m, 2H).
[0151] Example 7: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxy-N-(1-(14-((2-(1-methyl-2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidine-4-yl)benzamide [ka]
[0152] Based on the above reaction equation, batches of the two title compounds were obtained as yellow solids in the same manner as in the examples described above, and then freeze-dried (Batch 1: 103 mg, 92.36 μmol, 14.33% yield, 93% purity; Batch 2: 99 mg, 95.46 μmol, 14.81% yield, 100% purity).
[0153] MS(M+H) + =1037.4
[0154] 1 H NMR (400MHz, chloroform-d) δ8.37(d, J=15.0Hz, 1H), 8.05(s, 1H), 7.87-7.80(m, 1H), 7.51-7.44(m, 2H), 7.08(d, J=7.0Hz, 1H), 6.91(d, J=8.5Hz, 1H), 6.79(dd , J=14.7, 7.7Hz, 1H), 6.46(t, J=5.7Hz, 1H), 5.00-4.80(m, 2H), 4.29-4.16(m , 1H), 4.00-3.87(m, 7H), 3.71(t, J=5.4Hz, 2H), 3.67-3.53(m, 14H), 3.46(q, J =5.5Hz, 2H), 3.41(s, 3H), 3.19(s, 3H), 3.18-3.12(m, 2H), 3.00-2.8 8(m, 3H), 2.82-2.70(m, 2H), 2.28-2.16(m, 4H), 2.16-2.04(m, 3H), 1.84-1.71(m, 4H), 1.67-1.51(m, 2H).
[0155] Example 8: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)butyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0156] Based on the above reaction equation, the title compound (234.1 mg, 244.03 μmol, 37.74% yield, 96% purity, FA salt) was obtained as a yellow solid by the same method as in the examples described above.
[0157] MS(M+H) + =875.7.
[0158] 1 H NMR (400MHz, DMSO-d6)δ=11.10(s, 1H), 8.3 6-8.20(m, 2H), 8.14(s, 1H), 8.10-7.97(m, 2H), 7.60(dd, J 1= 8.3Hz, J 2= 7.4Hz, 1H), 7.23-7.08(m, 2H), 7.04(d, J=7.0Hz, 1H), 6.61(t, J=5.8Hz, 1H), 5.05(dd, J 1= 12.8Hz, J 2= 5.3Hz, 1H), 4.86-4.82(m, 1H), 4.08(t, J=13.9Hz, 2H), 3.96-3.87(m, 4H), 3.23- 3.02(m, 6H), 2.90-2.83(m, 1H), 2.78-2.70(m, 2H), 2.69-2.41(m, 4H), 2.06-1.88 (m, 5H), 1.86-1.39(m, 13H).
[0159] Example 9: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(5-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)pentyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0160] Based on the above reaction equation, the title compound (224.8 mg, 230.13 μmol, 42.84% yield, 91% purity, FA salt) was obtained as a yellow solid by the same method as in the examples described above.
[0161] MS(M+H) + =889.3
[0162] 1H NMR (400MHz, DMSO-d6)δ=11.09(s, 1H), 8.29(s, 1H), 8.26(s, 1H), 8.21(d, J=10.4Hz, 1H), 8 .03(s, 1H), 7.88(dd, J=3.2, 7.2Hz, 1H), 7.58(dd, J=7.2, 8.4Hz, 1H), 7.19(d, J=6.6Hz, 1H), 7.10(d, J =8.8Hz, 1H), 7.02(d, J=7.0Hz, 1H), 6.53(t, J=5.8Hz, 1H), 5.04(dd, J=5.4, 12.8Hz, 1H), 4.86-4.76(m , 1H), 4.12-4.02(m, 2H), 3.91(s, 3H), 3.81-3.67(m, 2H), 3.33(s, 3H), 2.93-2.82(m, 3H), 2.63-2.52( m, 3H), 2.34-2.27(m, 2H), 2.07-1.91(m, 5H), 1.83-1.68(m, 4H), 1.66-1.43(m, 10H), 1.40-1.29(m, 2H) .
[0163] Example 10: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(6-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)hexyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0164] Based on the above reaction equation, the title compound (23.2 mg, 23.89 μmol, 28.13% yield, 93% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0165] MS(M+H) + =903.7
[0166] 1H NMR (400MHz, CDCl3)δ=9.21-8.79(m, 1H), 8.38(d, J=15.2Hz, 1H), 8.07(s, 1H), 7 .86(s, 1H), 7.55-7.47(m, 2H), 7.11(d, J=7.1Hz, 1H), 6.94-6.81(m, 2H), 6.20(br t, J=5.5Hz, 1H), 4.97-4.90(m, 1H), 4.89-4.82(m, 1H), 4.40-4.18(m, 1H), 3.97(s, 3H), 3.92(m, 2H), 3.63-3.49(m, 2H), 3.42(s, 3H), 3.30(q, J=5.6Hz, 2H), 3.04-2.68(m, 8H), 2.16-2.11(m, 5H) ), 1.88-1.72(m, 7H), 1.71-1.64(m, 2H), 1.60(m, 2H), 1.51-1.40(m, 4H).
[0167] Example 11: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(7-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)heptyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0168] Stage 1: Compound of 2-(7-hydroxyheptyl)isoindoline-1,3-dione(2) Growth
[0169] A mixture of 7-bromoheptan-1-ol (5 g, 25.63 mmol) and potassium 1,3-dioxoisindorin-2-oid (7.12 g, 38.44 mmol) in DMF (20 mL) was stirred at 85°C for 16 hours. The reaction was confirmed to be free of reaction products by LC-MS, and the desired mass of 64% was detected. The reaction mixture was diluted with water (150 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (200 mL x 5), dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was subjected to silica gel chromatography (silicon dioxide chromatography). The compound was purified using petroleum ether / ethyl acetate (10 / 1 to 5 / 1) to obtain the title compound (6.4 g, 24.49 mmol, 95.56% yield) as a white solid. MS(M+H) + =262.0.
[0170] Step 2: Synthesis of 7-aminoheptan-1-ol (3)
[0171] To a solution of 2-(7-hydroxyheptyl)isoindoline-1,3-dione (6.4 g, 24.49 mmol) in EtOH (120 mL), hydrazine hydrate (14.42 g, 244.91 mmol, 14.00 mL, 85% purity in H2O) was added, and the mixture was stirred at 80°C for 4 hours. TLC (ethyl acetate:methanol = 10:1) showed that the starting material was completely consumed, and one major novel spot with most polarity was detected. The reaction mixture was concentrated under vacuum to remove most of the solvent, the residue was diluted in DCM (50 mL), filtered, and the filtrate was concentrated under vacuum. The residue was purified by flash silica gel chromatography (20 g SepaFlash® silica flash column, eluent 0-14% methanol / ethyl acetate gradient @ 100 mL / min) to obtain the title compound (1.3 g, 9.91 mmol, 40.45% yield) as a yellow oil.
[0172] 1 H NMR (400MHz, DMSO-d6) δ = 3.43-3.30 (m, 4H), 1.54-1.37 (m, 2H), 1.37-1.30 (m, 2H), 1.30-1.18 (m, 6H).
[0173] Step 3: Synthesis of 2-(2,6-dioxopiperidine-3-yl)-4-((7-hydroxyheptyl)amino)isoindoline-1,3-dione(4)
[0174] A mixture of 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione (2.3 g, 8.33 mmol), 7-aminoheptan-1-ol (1.20 g, 9.16 mmol), and TEA (2.53 g, 24.98 mmol, 3.48 mL) in DMSO (20 mL) was stirred at 85°C for 16 hours under an N2 atmosphere. Complete consumption of the reactants was confirmed by LC-MS, and the desired mass of 61% was detected. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layer was washed with brine (400 mL x 5), dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash silica gel chromatography (40g SepaFlash® silica flash column, eluent 50-65% ethyl acetate / petroleum ether gradient @ 80 mL / min) to obtain the title compound (1.74 g, 4.49 mmol, 53.94% yield) as a green oily substance.
[0175] MS(M+H) + =388.2.
[0176] Step 4: Synthesis of 7-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)heptyl 4-methylbenzenesulfonic acid (5)
[0177] To a solution of 2-(2,6-dioxopiperidine-3-yl)-4-((7-hydroxyheptyl)amino)isoindoline-1,3-dione (1.74 g, 4.49 mmol) in DCM (25 mL), TEA (1.82 g, 17.96 mmol, 2.50 mL) and TosCl (1.71 g, 8.98 mmol) were added, and the mixture was stirred at 20°C for 16 hours. The remaining starting material was confirmed by LC-MS, and the desired mass of 69% was detected. The reaction mixture was concentrated under vacuum. The residue was purified by flash silica gel chromatography (40 g SepaFlash® silica flash column, eluent 50-70% ethyl acetate / petroleum ether gradient @ 100 mL / min) to obtain the title compound (1.64 g, 3.03 mmol, 67.42% yield) as a yellow oil.
[0178] MS(M+H) + =542.2.
[0179] 1 H NMR (400MHz, DMSO-d6) δ=11.09(s, 1H), 7.77(d, J=8.3Hz, 2H), 7.58(dd, J=7.2Hz, J=8.5Hz, 1 H), 7.47(d, J=8.1Hz, 2H), 7.07(d, J=8.6Hz, 1H), 7.02(d, J=7.0Hz, 1H), 6.51(t, J=5.9Hz, 1H) , 5.05(dd, J=5.4Hz, J=12.8Hz, 1H), 4.02-3.96(m, 2H), 3.25(q, J=6.7Hz, 2H), 2.94-2.82(m, 1 H), 2.68-2.51(m, 2H), 2.40(s, 3H), 2.07-1.99(m, 1H), 1.60-1.44(m, 4H), 1.32-1.19(m, 6H).
[0180] Step 5: Synthesis of tert-butyl(1-(7-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)heptyl)piperidine-4-yl)carbamate (6)
[0181] A solution of 7-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)heptyl-4-methylbenzenesulfonic acid (1.64 g, 3.03 mmol), tert-butylpiperidine-4-yl carbamate (909.66 mg, 4.54 mmol), and DIEA (978.36 mg, 7.57 mmol, 1.32 mL) in dioxane (20 mL) was prepared by adding NaI (45.39 mg, 302.80 μmol), and the mixture was stirred at 60°C for 16 hours. LC-MS confirmed that the starting material was completely consumed, and 96% of the desired mass was detected. The reaction mixture was concentrated under vacuum. The residue was purified by flash silica gel chromatography (40g SepaFlash® silica flash column, eluent 60-100% ethyl acetate / petroleum ether gradient @ 100mL / min) to obtain the title compound (1.21g, 2.12 mmol, 70.14% yield) as a yellow solid. MS(M+H) + =570.6.
[0182] Step 6: Synthesis of 4-((7-(4-aminopiperidine-1-yl)heptyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (7)
[0183] To a solution of tert-butyl(1-(7-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)heptyl)piperidine-4-yl)carbamate (1.21 g, 2.12 mmol) in dioxane (10 mL), HCl / dioxane (4 M, 20 mL) was added, and the mixture was stirred at 20°C for 3 hours. Complete consumption of the starting material was confirmed by LC-MS. The reaction mixture was concentrated under vacuum to obtain the title compound (1.52 g, HCl salt, crude) as a yellow solid, which was used directly in the next step. MS(M+H) + =470.4.
[0184] Stage 7: 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo Synthesis of -6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(7-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)heptyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 11)
[0185] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (252.93 mg, 543.44 μmol) in DMF (8 mL), HATU (563.54 mg, 1.48 mmol) and DIEA (766.21 mg, 5.93 mmol, 1.03 mL) were added, and the mixture was stirred at 20°C for 15 minutes. To this mixture, 4-((7-(4-aminopiperidine-1-yl)heptyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (500 mg, 988.07 μmol, HCl salt) was added, and the resulting mixture was stirred at 20°C for 2 hours. Trace amounts of the reaction product were confirmed by LC-MS, and the desired mass of 68% was detected. The reaction mixture was filtered, and the filtrate was preparatively HPLC (column: Phenomenex luna C). 18 After purification by 150*40mm*15um; mobile phase: [water (0.1% TFA)-ACN]; B %: 26%-56%, 10 min), preparative HPLC (column: Phenomenex Luna C) was performed. 18 The sample was purified using a 150*40mm*15um mobile phase (water (0.1% TFA)-ACN); B%: 27%~57%, 10 min). The eluent was freeze-dried to obtain the title compound (181.6 mg, 169.09 μmol, 17.11% yield, 96% purity, TFA salt) as a yellow solid.
[0186] MS(M+H) + =917.2.
[0187] 1H NMR (400MHz, DMSO-d6) δ=11.11(s, 1H), 9.47-9.34(m, 1H), 8.43-8.08(m, 4H), 7.59(t, J=7.7Hz, 1H) , 7.19-7.17(m, 1H), 7.09(d, J=8.5Hz, 1H), 7.03(d, J=6.9Hz, 1H), 6.54(s, 1H), 5.05(dd, J=5.1Hz, J =12.6Hz, 1H), 4.86-4.79(m, 1H), 4.10(t, J=13.7Hz, 2H), 3.91(s, 3H), 3.52(d, J=10.3Hz, 2H), 3.40-3.27 (m, 5H), 3.12-2.97(m, 4H), 2.93-2.83(m, 1H), 2.62-2.56(m, 1H), 2.23-1.84(m, 6H), 1.84-1.48(m, 12H), 1 46-1.21(m, 6H).
[0188] Example 12: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(8-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)octyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0189] Based on the above reaction equation, the title compound (191.9 mg) was obtained in the same manner as in the above-described examples. 176.77 μmol, 22.98% yield, 90% purity (FA salt) was obtained as a yellow solid.
[0190] MS(M+H) + =931.8.
[0191] 1H NMR (400MHz, DMSO-d6)δ=11.09(br s, 1H), 8.28(s, 1H), 8.25(d, J=13.4Hz, 1H), 8.05(s, 1H), 8.09-8.01(m, 2H), 7.58(dd, J=7.2, 8.4Hz, 1H), 7.21-7.15(m, 1H), 7.09(d, J=8.5Hz, 1H), 7.02(d, J=6.9Hz, 1H), 6.51(t, J=5.8Hz, 1H), 5.04(dd, J=5.4, 12.7Hz, 1H), 4.86-4.77(m, 1H), 4.06(br t, J=13.9Hz, 3H), 3.96-3.83(m, 5H), 3.32(s, 3H), 3.15(br d, J=11.0Hz, 2H), 2.91-2.84(m, 1H), 2.71-2.55(m, 5H), 2.04-1.87(m, 5H), 1.80-1.45(m, 13H), 1.30(br d, J=12.1Hz, 8H).
[0192] Example 13: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(9-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)nonyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0193] Based on the above reaction equation, the title compound (312.6 mg, 283.36 μmol, 30.27% yield, 96% purity, TFA salt) was obtained as a yellow solid by the same method as in the examples described above.
[0194] MS(M+H) + =945.6.
[0195] 1H NMR (400MHz, DMSO-d6)δ=11.10(s, 1H), 9.56-9.24(m, 1H), 8.31(s, 1H), 8.19-8.27(m, 2H), 8.17(s, 1H) ), 7.66-7.55(m, 1H), 7.26-7.16(m, 1H), 7.13-7.07(m, 1H), 7.06-7.00(m, 1H), 6.53(s, 1H), 5.06(dd, J 1= 12.8Hz, J 2= 5.3Hz, 1H), 4.82-4.86(m, 1H), 4.21-4.02(m, 3H), 3.92(s, 3H), 3.52(d, J=10.8Hz, 2H), 3.37-3.27(m, 5H), 3.09 -2.99(m, 3H), 2.94-2.84(m, 1H), 2.63-2.57(m, 1H), 2.29-1.87(m, 6H), 1.86-1.50(m, 12H), 1.39-1.22(m, 10H).
[0196] Example 14: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(10-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)decyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0197] Based on the above reaction equation, the title compound (144.2 mg, 124.97 μmol, 19.57% yield, 93% purity, TFA salt) was obtained as a yellow solid by the same method as in the examples described above.
[0198] MS(M+H) + =959.7.
[0199] 1H NMR (400MHz, DMSO-d6)δ=11.09(s, 1H), 9.39-9.08(m, 1H), 8.30(s, 1H), 8.29-8.17(m, 2H), 8.13(s, 1H) ), 7.62-7.54(m, 1H), 7.25-7.15(m, 1H), 7.12-7.06(m, 1H), 7.05-7.00(m, 1H), 6.52(s, 1H), 5.05(dd, J 1= 12.7Hz, J 2= 5.4Hz, 1H), 4.8 3(t, J=8.3Hz, 1H), 4.13-4.06(m, 2H), 3.91(s, 3H), 3.52(d, J=10.9Hz, 2H), 3.33(s, 3H), 3.31-2.26(m, 2H), 3.13-2.95(m , 4H), 2.93-2.84(m, 1H), 2.62-2.56(m, 1H), 2.17-1.85(m, 6H), 1.84-1.68(m, 4H), 1.66-1.54(m, 8H), 1.36-1.25(m, 12H).
[0200] Example 15: 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-
[0201] Synthesis of 5H,6H,7H,8H,9H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(11-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindole-4-yl)amino)undecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0202] Based on the above reaction equation, the title compound (215.1 mg, 210.00 μmol, 39.35% yield, 95% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0203] MS(M+H) + =973.3.
[0204] 1 H NMR (400MHz, DMSO-d6) δ=11.09(s, 1H), 8.29(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.03 (s, 1H), 7.86(dd, J1=7.4Hz, J2=3.4Hz, 1H), 7.57(dd, J1=8.4Hz, J2=7.3Hz, 1H), 7.19(d, J=6.6Hz, 1H), 7.08(d, J=8.6Hz, 1H), 7.01 (d, J=7.0Hz, 1H), 6.52(t, J=5.6Hz, 1H), 5.04(dd, J1=12.5Hz, J2=5.4Hz, 1H), 4.88-4.76 (m, 1H), 4.07(t, J=13.9Hz, 2H), 3.91(s, 3H), 3.78-3.65(m, 1H), 3.30-3.24(m, 3H), 2.94 -2.85(m, 1H), 2.80(d, J=11.4Hz, 2H), 2.64 -2.55(m, 2H), 2.22(t, J=7.3Hz, 2H), 2.04- 1.90(m, 5H), 1.82-1.69(m, 4H), 1.66-1.50(m, 8H), 1.49-1.13(m, 18H).
[0205] Example 16: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(13-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)tridecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka] Based on the above reaction equation, the title compound (142.5 mg, 142.34 μmol, 17.87% yield) was obtained as a yellow solid by the same method as in the examples described above.
[0206] MS(M+H) + =1001.4.
[0207] 1H NMR (400MHz, DMSO-d6) δ=11.09(s, 1H), 8.34-8.20(m, 2H), 8.03(s, 1H), 7.87(dd, J 1= 7.7Hz, J 2= 3.5Hz, 1H), 7.57(dd, J 1= 8.4Hz, J 2= 7.2Hz, 1H), 7.18(d, J=6.7Hz, 1H), 7.08(d, J=8.5Hz, 1H), 7.01(d, J=6.9Hz, 1H), 6.52(t, J=5.8Hz, 1H), 5.04(dd, J 1= 12.9Hz, J 2= 5.4Hz, 1H), 4.89-4.73(m, 1H), 4.07(t, J=13.9Hz, 2H), 3.91(s, 3H), 3.76-3.67(m, 1H), 3.31-3.26(m, 3H), 2.94-2.85(m, 1H), 2.84- 2.76(m, 2H), 2.85-2.75(m, 2H), 2.23(t, J=7.3Hz, 2H), 2.05-1.90(m, 5H), 1.81-1.68(m, 4H), 1.66-1.49(m, 8H), 1.43-1.17(m, 22H).
[0208] Example 17: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)tetradecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0209] Based on the above reaction equation, the title compound (80.7 mg, 75.52 μmol, 22.82% yield, 95% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0210] MS(M+H) + =1015.5.
[0211] 1 H NMR (400MHz, CDCl3) δ=8.37(d, J=15.2Hz, 1H), 8.07(s, 1H), 7.83(s, 1H), 7.57(d, J=7.1Hz, 1H), 7.49(dd, J=7.3 , 8.4Hz, 1H), 7.09(d, J=7.1Hz, 1H), 6.89(d, J=8.6Hz, 1H), 6.70(dd, J=7.5, 15.2Hz, 1H), 6.23(t, J=5.4Hz, 1H), 4 .97-4.80(m, 2H), 4.13-4.00(m, 1H), 3.99-3.87(m, 5H), 3.42(s, 3H), 3.31-3.23(m, 2H), 3.00-2.68(m, 5H), 2.4 8-2.31(m, 2H), 2.26-2.04(m, 7H), 1.86-1.69(m, 6H), 1.53-1.49(m, 2H), 1.45-1.39(m, 2H), 1.36-1.22(m, 22H).
[0212] Example 18: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(3-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)propoxy)propyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0213] Based on the above reaction equation, the title compound (58.7 mg, 58.13 μmol (85.97% yield, 91% purity) was obtained as a yellow solid.
[0214] MS(M+H) + =919.7
[0215] 1H NMR (400MHz, CDCl3) δ=8.39(d, J=15.2Hz, 1H), 8.07(s, 1H), 7.85(s, 1H), 7.57-7.48(m, 2H), 7.11(d , J=6.8Hz, 1H), 6.94-6.82(m, 2H), 6.59(t, J=5.2Hz, 1H), 5.00-4.93(m, 1H), 4.90-4.82(m, 1H), 4.4 5-4.25(m, 1H), 3.97(s, 3H), 3.92(t, J=13.4Hz, 2H), 3.64-3.46(m, 6H), 3.42(s, 3H), 3.09-3.02(m, 2H), 2.92-2.72(m, 6H), 2.19-2.12(m, 8H), 2.01-1.92(m, 3H), 1.84-1.75(m, 5H), 1.67-1.54(m, 3H).
[0216] Example 19: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(3-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)propoxy)butyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0217] Based on the above reaction equation, the title compound (37.2 mg, 35.88 μmol (6.68% yield, 90% purity) was obtained as a yellow solid.
[0218] MS(M+H) + =933.4
[0219] 1H NMR (400MHz, CDCl3) δ=8.39(d, J=15.2Hz, 1H), 8.07(s, 1H), 7.84(s, 1H), 7.55-7.47(m, 2H), 7.1 0(d, J=7.1Hz, 1H), 6.91(d, J=8.6Hz, 1H), 6.82(dd, J=7.9, 14.7Hz, 1H), 6.72-6.65(m, 1H), 4.98 -4.90(m, 1H), 4.90-4.82(m, 1H), 4.33-4.12(m, 1H), 3.97(s, 3H), 3.96-3.88(m, 2H), 3.63-3.43 (m, 6H), 3.42(s, 3H), 3.03-2.56(m, 8H), 2.17-2.07(m, 6H), 1.97-1.86(m, 6H), 1.75-1.52(m, 8H)
[0220] Example 20: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)butoxy)propyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0221] Step 1: Synthesis of ethyl 3-(4-(benzyloxy)butoxy)propanoic acid (3)
[0222] A solution of 4-benzyloxybutan-1-ol (8.0 g, 44.38 mmol, 7.77 mL), Cs2CO3 (28.92 g, 88.77 mmol), and ethylprop-2-enoate (44.44 g, 443.85 mmol, 48.25 mL) in CH3CN (100 mL) was stirred at 25°C for 12 hours. The reaction was confirmed to be complete by LC-MS. The mixture was filtered, and the filtrate was concentrated under vacuum. The crude product was purified by reverse-phase HPLC (0.1% FA conditions, MeCN / water) to obtain the title compound (9.04 g, crude) as a colorless oil. MS(M+H)+ =281.0
[0223] Step 2: Synthesis of 3-(4-(benzyloxy)butoxy)propan-1-ol (4)
[0224] To a solution of ethyl 3-(4-benzyloxybutoxy)propanoic acid (9.04 g, 32.24 mmol) in THF (100 mL), LAH (1.47 g, 38.69 mmol) was added at 0°C, and the mixture was stirred at 25°C for 2 hours. The completion of the reaction was confirmed by TLC (petroleum ether / ethyl acetate = 3 / 1). The mixture was sequentially quenched with water (1.5 mL), 1.5 mL of 15% sodium hydroxide aqueous solution, and water (4.5 mL). The mixture was stirred at 25°C for 30 minutes, the mixture was filtered, and the filtrate was concentrated under vacuum to obtain the title compound (8.41 g, crude) as a colorless oil.
[0225] Step 3: Synthesis of 3-(4-(benzyloxy)butoxy)propyl 4-methylbenzenesulfonic acid (5)
[0226] To a solution of 3-(4-benzyloxybutoxy)propan-1-ol (8.41 g, 35.29 mmol) in DCM (100 mL), TEA (4.28 g, 42.35 mmol, 5.89 mL) was added, followed by TosCl (8.07 g, 42.35 mmol). The reaction mixture was stirred at 20°C for 3 hours. The desired mass was confirmed by LC-MS. The reaction mixture was diluted with water (250 mL) and extracted with DCM (200 mL x 3). The combined organic layers were washed with brine (50 mL x 1), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (20 g SepaFlash® silica flash column, eluent 10-30% ethyl acetate / petroleum ether gradient @ 60 mL / min) to obtain the title compound (6.8 g, 17.32 mmol, 49.09% yield) as a colorless oil. MS(M+H) + =393.0
[0227] Step 4: Synthesis of tert-butyl(1-(3-(4-(benzyloxy)butoxy)propyl)piperidine-4-yl)carbamate (6)
[0228] A solution of 3-(4-benzyloxybutoxy)propyl 4-methylbenzenesulfonic acid (3.4 g, 8.66 mmol) and tert-butylpiperidine-4-ylcarbamate (2.60 g, 12.99 mmol) in dioxane (20 mL) was prepared by adding NaI (129.84 mg, 866.22 μmol) and DIEA (2.24 g, 17.32 mmol, 3.02 mL). The mixture was heated at 60°C for 12 hours. The desired mass was confirmed by LC-MS. The mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 2 / 1 to ethyl acetate / methanol = 10 / 1) to obtain the title compound (3.05 g, 7.25 mmol, 83.72% yield) as a yellow oil. MS(M+H) + =421.2
[0229] Step 5: Synthesis of tert-butyl(1-(3-(4-hydroxybutoxy)propyl)piperidine-4-yl)carbamate (7)
[0230] tert-butyl(1-(3-(4-(benzyloxy) in ethyl acetate (20 mL) To a solution of butoxy)propyl)piperidine-4-yl)carbamate (2.4 g, 5.71 mmol), Pd / C (400 mg, 10% purity) and Pd(OH)2 / C (400 mg, 10% purity) were added under N2. The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 60°C for 24 hours under H2 (50 psi). TLC (ethyl acetate / methanol = 10 / 1) confirmed the presence of residual reaction products and the detection of the desired product. The mixture was filtered, and the filtrate was concentrated under vacuum to obtain the title compound (1.9 g, 4.52 mmol, 79.17% yield) as a colorless oil.
[0231] Step 6: Synthesis of 4-(3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)propoxy)butyl 4-methylbenzenesulfonic acid (8)
[0232] To a solution of tert-butyl(1-(3-(4-hydroxybutoxy)propyl)piperidine-4-yl)carbamate (1.69 g, 5.11 mmol) in DCM (20 mL), TEA (1.55 g, 15.34 mmol, 2.14 mL) and TosCl (1.46 g, 7.67 mmol) were added, and the mixture was stirred at 25°C for 12 hours. The desired mass was confirmed by LC-MS. The mixture was concentrated under vacuum. The residue was purified by flash silica gel chromatography (Biotage, 25 g SepaFlash® silica flash column, eluent 30-100% ethyl acetate / petroleum ether gradient @ 80 mL / min) to obtain the title compound (1.23 g, 2.09 mmol, 40.84% yield, 82.3% purity) as a yellow oil. MS(M+H) + =485.3.
[0233] Step 7: Synthesis of tert-butyl(1-(3-(4-(1,3-dioxoisoindorin-2-yl)butoxy)propyl)piperidine-4-yl)carbamate (9)
[0234] A solution of 4-(3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)propoxy)butyl4-methylbenzenesulfonic acid (1.23 g, 2.54 mmol) and (1,3-dioxoisoindorin-2-yl) potassium (940.15 mg, 5.08 mmol) in DMF (15 mL) was stirred at 80°C for 12 hours. The desired mass was confirmed by LC-MS. The reaction mixture was diluted with brine (10 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage, 25g SepaFlash® silica flash column, eluent 30-100% ethyl acetate / petroleum ether gradient @ 80 mL / min) to obtain the title compound (600 mg, 1.30 mmol, 51.34% yield, 99.8% purity) as a colorless oil. MS(M+H) + =460.2.
[0235] Step 8: Synthesis of tert-butyl(1-(3-(4-aminobutoxy)propyl)piperidine-4-yl)carbamate (10)
[0236] tert-butyl(1-(3-(4-(1,3-dioxoisoindolin-2-yl)butoxy)propyl)piperidine-4-yl)carbamate (0.78 g, 1.70 mmol) and NH2NH2·H2O (999.56 mg, 16.97 mmol, 970.45 μL, 85% purity) were placed in a 50 mL round-bottom flask, and EtOH (10 mL) was added. The mixture was stirred at 75 °C for 2 hours. The completion of the reaction was confirmed by TLC (ethyl acetate / methanol = 10 / 1). Heating was stopped, insoluble solids were removed by filtration, and the filtrate was concentrated to obtain the title compound (0.5 g, 1.52 mmol, 89.41% yield) as a yellow oil.
[0237] 1 H NMR (400MHz, MeOD) δ=3.51-3.41(m, 4H), 3.40-3.35(m, 1H), 2.92(d, J=11.6Hz, 2H), 2.73(t , J=7.0Hz, 2H), 2.51-2.38(m, 2H), 2.17-2.06(m, 2H), 1.90-1.81(m, 2H), 1.82-1.73(m, 2H), 1.65-1.55(m, 4H), 1.48-1.40(m, 11H).
[0238] Step 9: Synthesis of tert-butyl(1-(3-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)butoxy)propyl)piperidine-4-yl)carbamate (11)
[0239] To a solution of tert-butyl(1-(3-(4-aminobutoxy)propyl)piperidine-4-yl)carbamate (440 mg, 1.34 mmol) and 2-(2,6-dioxo-3-piperidyl)-4-fluoroisoindoline-1,3-dione (400 mg, 1.45 mmol) in DMSO (5 mL), TEA (439.60 mg, 4.34 mmol, 604.68 μL) was added, and the mixture was stirred at 60°C for 12 hours. The completion of the reaction was confirmed by TLC (ethyl acetate / methanol = 10 / 1). Water (30 mL) was added to the mixture, and it was extracted with ethyl acetate (20 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate / methanol = 10 / 1) to obtain the title compound (160 mg, 264.99 μmol, 18.30% yield, 97% purity) as a yellow oil. MS(M+H) + = 586.2
[0240] Step 10: Synthesis of 4-((4-(3-(4-aminopiperidine-1-yl)propoxy)butyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (12)
[0241] To a solution of tert-butyl(1-(3-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)butoxy)propyl)piperidine-4-yl)carbamate (160 mg, 273.18 μmol) in dioxane (5 mL), HCl / dioxane (4 M, 5 mL) was added, and the mixture was stirred at 20 °C for 1 hour. The completion of the reaction was confirmed by LC-MS. The mixture was concentrated to obtain the title compound (140 mg, 268.18 μmol, 98.17% yield, HCl) as a yellow oil. MS(M+H) + =486.5.
[0242] Step 11: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)butoxy)propyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 20)
[0243] To a solution of 4-((4-(3-(4-aminopiperidine-1-yl)propoxy)butyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (140 mg, 268.18 μmol, HCl) and 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino]-2-fluoro-5-methoxybenzoic acid (124.82 mg, 268.18 μmol) in DMF (3 mL), HATU (203.94 mg, 536.36 μmol) and DIPEA (103.98 mg, 804.54 μmol, 140.14 μL) were added, and the resulting mixture was stirred at 20°C for 1 hour. After confirming the completion of the reaction by LC-MS, water (20 mL) was added to the mixture and extracted with ethyl acetate (20 mL x 3). The combined organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Unisil 3-100 C1). The sample was purified using an 8μL tra 150*50mm*3um mobile phase (water (0.225% FA)-ACN); B%: 33%~53%, 10 min), and the eluent was freeze-dried to obtain the title compound (14.8 mg, 15.55 μmol, 5.80% yield, 98% purity, FA) as a yellow solid.
[0244] MS(M+H) + =933.3
[0245] 1 H NMR (400MHz, DMSO-d6) δ=11.10(s, 1H), 8.30(s, 1H), 8.26(d, J=13.2Hz, 1H), 8.14(s, 1H), 8.08-7.99(m, 2H), 7.6 5-7.54(m, 1H), 7.19(d, J=6.8Hz, 1H), 7.11(d, J=8.6Hz, 1H), 7.04(d, J=6.8Hz, 1H), 6.61-6.54(m, 1H), 5.12-5.0 0(m, 1H), 4.89-4.77(m, 1H), 4.08(t, J=13.6Hz, 2H), 3.95-4.83(m, 5H), 3.42-3.41(m, 8H), 3.18-3.07(m, 1H), 2. 95-2.82(m, 2H), 2.70-2.56(m, 5H), 1.97-1.95(m, 2H), 1.89-1.88(m, 2H), 1.76-1.72(m, 4H), 1.71-1.55(m, 12H).
[0246] Example 21: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(3-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)propoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0247] Based on the above reaction equation, the title compound (199.8 mg) was prepared in the same manner as in the above-described examples. 200.01 μmol (46.55% yield, 95% purity) was obtained as a yellow solid.
[0248] MS(M+H) + =949.2.
[0249] 1 H NMR (400MHz, DMSO-d6) δ=11.10(s, 1H), 8.30(s, 1H), 8.26(d, J=13.2Hz, 1H), 8.16-8.15(m, 1H), 8.06(s , 1H), 7.61-7.57(m, 1H), 7.25-7.14(m, 2H), 7.05(d, J=6.8Hz, 1H), 6.66-6.65(m, 1H), 5.13-5.05(m, 1H) , 4.81-4.73(m, 1H), 4.13-4.06(m, 2H), 4.12-3.95(m, 4H), 3.69-3.64(m, 2H), 3.60-3.56(m, 2H), 3.53- 3.46(m, 8H), 3.33(s, 3H), 3.27-3.18(m, 2H), 3.15-3.05(m, 2H), 2.78-2.69(m, 1H), 2.58-2.50(m, 2H), 2 05-1.94(m, 5H), 1.87-1.73(m, 6H), 1.67-1.56(m, 4H).
[0250] Example 22: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-((8-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)octyl)oxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0251] Based on the above reaction equation, the title compound (172.4 mg) was obtained in the same manner as in the above-described examples. A yellow solid was obtained (164.09 μmol, 55.14% yield, 97% purity).
[0252] MS(M+H) + =1019.3.
[0253] 1 H NMR (400MHz, CDCl3) δ=9.09(s, 1H), 8.36(d, J=15.2Hz, 1H), 8.06(s, 1H), 7.87(s, 1H) , 7.49-7.45(m, 2H), 7.07(d, J=6.8Hz, 1H), 6.92-6.87(m, 2H), 6.54-6.51(m, 1H), 4.97-4.94 (m, 1H), 4.89-4.83(m, 1H), 4.34-4.16(m, 1H), 3.94-3.91(m, 5H), 3.78-3.77(m, 3H), 3.70-3 .65(m, 2H), 3.49-3.41(m, 11H), 3.19-3.11(m, 2H), 2.81-2.78(m, 3H), 2.31-2.25(m, 2H), 2. 19-2.07(m, 5H), 1.78-1.71(m, 6H), 1.62-1.49(m, 6H), 1.42-4.33(m, 2H), 1.32-1.21(m, 6H).
[0254] Example 23: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(3-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)propoxy)butyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka] [ka]
[0255] Based on the above reaction equation, the title compound (6.3 mg, 5.80 μmol, 8.85% yield, 94% purity, FA salt) was obtained as a yellow solid by the same method as in the examples described above.
[0256] MS(M+H) + =1021.8.
[0257] 1 H NMR (400MHz, DMSO-d6) δ=11.10(br s, 1H), 8.31(s, 1H), 8.25(d, J=13.2Hz, 1H), 8.18(s, 1H), 8.04(s, 1H), 7.9 4-7.86(m, 1H), 7.62-7.55(m, 1H), 7.19(d, J=6.6Hz, 1H), 7.15(d, J=8.6Hz, 1H), 7.05(d, J=7.0Hz, 1H), 6.61(t, J=5, 6Hz, 1H), 5.11-5.02(m, 1H) ), 4.87-4.79(m, 1H), 4.08(t, J=14.0Hz, 2H), 3.92(s, 3H), 3.83-3.72(m , 2H), 3.63(t, J=5.3Hz, 2H), 3.59-3.55(m, 2H), 3.51-3.40(m, 13H), 2.9 5-2.82(m, 2H), 2.63-2.56(m, 4H), 2.53(s, 3H), 2.37-2.31(m, 2H), 2.12-1.96(m, 4H), 1.87-1.78(m, 2H), 1.75-1.68(m, 4H), 1.64-1.55(m, 4H), 1.50-1.42(m, 2H).
[0258] Example 24: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(3-(3-(2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)propoxy)propoxy)propyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka] [ka]
[0259] Based on the above reaction equation, the title compound (134.7 mg, 120.05 μmol, 35.21% yield, 91% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0260] MS(M+H) + =1021.7.
[0261] 1 H NMR (400MHz, CD3OD) δ=8.41(d, J=14.8Hz, 1H), 8.21(s, 1H), 7.56-7.52(m, 1H), 7.33(d, J=6.4Hz, 1H), 7.09-7.04(m, 2H), 5.08-5.06(m, 1H), 4.94-4.92(m, 1H) , 4.62-4.55(m, 2H), 4.24-4.12(m, 1H), 4.07-3.98(m, 5H), 3.70-3.66( m, 2H), 3.57-3.48(m, 14H), 3.04(s, 3H), 3.26-3.25(m, 2H), 3.15-3.10 (m, 1H), 2.76-2.72(m, 1H), 2.70-2.65(m, 2H), 2.21-2.28(m, 2H), 2.11 -2.18(m, 3H), 2.03-1.97(m, 2H), 1.80-1.75(m, 4H), 1.69-1.62(m, 4H).
[0262] Example 25: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-3,6,9,13-tetraoxapentadecane-15-yl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0263] Based on the above reaction equation, the title compound (21.3 mg, 17.21 μmol, 11.44% yield, 93% purity (TFA) was obtained as a yellow solid.
[0264] MS(M+H) + =1037.5
[0265] 1 H NMR (400MHz, CD3OD) δ=8.36-8.29(m, 1H), 8.21(s, 1H), 7.53(dd, J=7.2, 8.6Hz, 1H), 7.37-7.32(m, 1H), 7.08-7.03 (m, 2H), 5.06(dd, J=5.6, 12.6Hz, 1H), 4.99-4.94(m, 1H), 4.08(t, J=13.0Hz, 2H), 3.98(s, 3H), 3.77-3.70(m, 6H), 3.67-3.63(m, 6H), 3.60-3.56(m, 6H), 3.49(t, J=5.4Hz, 3H), 3.41(s, 3H), 3.37-3.30(m, 2H), 3.21-3.13(m, 2H), 2 .93-2.80(m, 1H), 2.78-2.67(m, 2H), 2.32-2.26(m, 2H), 2.15-2.07(m, 4H), 1.93-1.83(m, 5H), 1.77-1.70(m, 4H).
[0266] Example 26: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0267] Step 1: Synthesis of tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetic acid (3)
[0268] To a mixture of 2-(2-chloroethoxy)ethanol (10 g, 80.28 mmol, 8.47 mL) and tert-butyl 2-bromoacetate (31.32 g, 160.56 mmol, 23.73 mL) in THF (100 mL), TBAB (25.88 g, 80.28 mmol) and t-BuOK (9.01 g, 80.28 mmol) were added simultaneously at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 5:1) confirmed the presence of residual 2-(2-chloroethoxy)ethanol and the detection of three novel spots. The reaction mixture was concentrated under vacuum. It shrunk. The residue was subjected to column chromatography (silicon dioxide). The compound was purified using petroleum ether / ethyl acetate (10 / 1 to 5 / 1) to obtain the title compound (3 g, 12.57 mmol, 15.66% yield) as a yellow oily substance.
[0269] Step 2: Synthesis of tert-butyl 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)acetic acid (4)
[0270] To a mixture of tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetic acid (1.5 g, 6.28 mmol) and benzylpiperidine-4-ylcarbamate (1.77 g, 7.54 mmol) in ACN (20 mL), potassium carbonate (2.61 g, 18.85 mmol) was added all at once at 20 °C, and the resulting mixture was stirred at 60 °C for 16 hours. LC-MS confirmed that 64% of tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetic acid remained and a 14% peak with the desired mass was detected. NaI (188.38 mg, 1.26 mmol) was added to the reaction mixture at 20 °C, and the resulting mixture was stirred at 80 °C for 12 hours. LC-MS confirmed the presence of 51% tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetic acid and the detection of 36% of the desired mass. The reaction mixture was concentrated under vacuum. The residue was diluted with dioxane (20 mL) at 20°C, and the resulting mixture was stirred at 90°C for 16 hours. LC-MS confirmed the presence of 46% tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetic acid and the detection of 38% of the desired mass. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 3 / 1~0 / 1) to obtain the title compound (860 mg, 1.77 mmol, 28.22% yield, 90% purity) as a yellow oil. MS(M+H) + =437.2
[0271] Step 3: Synthesis of 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)acetic acid (5)
[0272] To tert-butyl 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)acetic acid (750 mg, 1.72 mmol) in dioxane (5 mL), HCl / dioxane (4 M, 10 mL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that the starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (680 mg, crude) as a yellow oil. MS(M+H) + =381.2
[0273] Step 4: Synthesis of benzyl(1-(2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (6)
[0274] To a mixture of 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)acetic acid (650 mg, 1.71 mmol) and 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (560.23 mg, 2.05 mmol) in DMF (4 mL), T3P (6.52 g, 10.25 mmol, 6.10 mL, 50% purity ethyl acetate solution) and Py (1.35 g, 17.09 mmol, 1.38 mL) were added all at once at 20°C, and the resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic layer was washed with brine (15 mL x 3), dried over sodium sulfate, filtered, and concentrated. The crude product was separated by preparative HPLC (color). Mu: Phenomenex luna C 18After purification by MS(M+H) (150*40mm*15um; mobile phase: [water (0.1% TFA)-ACN]; B%: 17%-47%, 10 min), the sample was freeze-dried to obtain the title compound (910 mg, 1.40 mmol, 82.11% yield, 98% purity) as a yellow solid. + =636.1
[0275] 1 H NMR (400MHz, CD3OD) δ=8.79(d, J=8.6Hz, 1H), 7.84-7.76(m, 1H), 7.61(d, J=7.4 Hz, 1H), 7.34-7.26(m, 5H), 5.15(dd, J=5.6, 12.8Hz, 1H), 5.04(s, 2H), 4.22(s, 2) H), 3.90(t, J=5.0Hz, 2H), 3.85-3.83(m, 3H), 3.75-3.54(m, 3H), 3.50-3.33(m, 2H), 3.29-3.05(m, 2H), 2.94-2.65(m, 3H), 2.24-1.91(m, 4H), 1.86-1.56(m, 2H)
[0276] Step 5: Synthesis of 2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)acetamide (7)
[0277] A solution of benzyl(1-(2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (810 mg, 1.27 mmol) in THF (10 mL) was mixed with Pd / C (0.1 g, 10% purity) under N2. The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 20°C for 16 hours under H2 (15 psi). LCMS confirmed that 72% of the starting material remained and 18% of the peaks with the desired mass were detected. Pd / C (0.4 g, 127.43 μmol, 10% purity) was added to the reaction mixture under N2. The reaction mixture was stirred at 20°C for 16 hours under H2 (15 psi). LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with THF (20 mL) and filtered. The filtrate was concentrated under vacuum to obtain the title compound (563 mg, 1.04 mmol, 81.93% yield, 93% purity) as a yellow solid. MS(M+H) + =502.1
[0278] Step 6: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 26)
[0279] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (120 mg, 257.83 μmol) in DMF (2 mL), HATU (98.03 mg, 257.83 μmol) and DIPEA (99.97 mg, 773.49 μmol, 134.73 μL) were added. The mixture was stirred at 20°C for 10 minutes, and a solution of 2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)acetamide (168.10 mg, crude) in DMF (2 mL) was added dropwise at 20°C. The resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (10 mL x 3) and extracted with ethyl acetate (10 mL x 3). The organic layer was dried over sodium sulfate and filtered. The residue was concentrated. The residue was separated by HPLC (column: 3_Phenomenex Luna C). 18 After purification to a 75*30mm*3um mobile phase (water (0.1% TFA)-ACN), the mixture was freeze-dried to obtain the title compound (105.3 mg, 95.10 μmol, 36.88% yield, 96% purity, TFA) as a white solid.
[0280] MS(M+H) + =949.0
[0281] 1H NMR (400MHz, CD3OD) δ=8.85-8.74(m, 1H), 8.38-8.29(m, 1H), 8.23-8.20(m, 1H), 7.83-7.76(m, 1H) , 7.62-7.53(m, 1H), 7.31(d, J=6.8Hz, 1H), 5.17(dd, J=5.4, 12.8Hz, 1H), 4.99-4.94(m, 1H), 4.26-4 .21(m, 2H), 4.08(t, J=13.2Hz, 2H), 3.99(s, 3H), 3.93(t, J=4.8Hz, 2H), 3.90-3.84(m, 4H), 3.73-3. 69(m, 1H), 3.50-3.44(m, 1H), 3.40(s, 3H), 3.39-3.35(m, 2H), 3.25-3.11(m, 2H), 2.96-2.69(m, 3H) , 2.26-2.03(m, 6H), 1.93-1.78(m, 4H), 1.76-1.66(m, 4H)
[0282] Example 27: Synthesis of 14-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)-N-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxatetradecaneamide [ka] [ka]
[0283] Based on the above reaction equation, the title compound (22.6 mg, 20.70 μmol, 9.64% yield, 95% purity) was obtained as a white solid by the same method as in the examples described above.
[0284] MS(M+H) + =1037.3
[0285] 1H NMR (400MHz, DMSO-d6)δ=11.20(br s, 1H), 10.36(s, 1H), 8.72(d, J=8.4Hz, 1H), 8.29(s, 1H), 8.23(d, J=13.4Hz, 1H), 8.04( s, 1H), 7.94-7.81(m, 2H), 7.62(d, J=7.6Hz, 1H), 7.17(d, J=6.8Hz, 1H), 5.16(dd, J=5.6 , 12.8Hz, 1H), 4.88-4.73(m, 1H), 4.20(s, 2H), 4.08(t, J=13.6Hz, 2H), 3.90(s, 3H), 3.80-3.73(m, 2H), 3.72-3.63(m, 3H), 3.58-3.35(m, 12 H), 2.95-2.79(m, 3H), 2.69-2.53(m, 2H), 2.43(t, J=5.9Hz, 2H), 2.14-1.99(m, 3H), 1.97-1.87(m, 2H), 1.79-1.69(m, 4H), 1.69-1.44(m, 7H) .
[0286] Example 28: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-((8-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethoxy)octyl)oxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0287] Based on the above reaction equation, the title compound (14.1 mg, 12.15 μmol (6.30% yield, 89% purity) was obtained as a white solid.
[0288] MS(M+H) + =1033.4
[0289] 1H NMR (400MHz, DMSO-d6) δ=11.17(s, 1H), 10.35(s, 1H), 8.74(d, J=8.4Hz, 1H), 8.30(s, 1H), 8.24(d, J=13.6Hz, 1H), 8.03 (s, 1H), 7.89-7.84(m, 2H), 7.63(d, J=7.2Hz, 1H), 7.18(d, J=6.4Hz, 1H), 5.18-5.14(m, 1H), 4.86-4.77(m, 1H), 4.14-4 .08(m, 5H), 3.91(s, 4H), 3.76-3.69(m, 1H), 3.61-3.57(m, 3H), 3.46-3.43(m, 1H), 2.88-2.86(m, 2H), 2.63-2.54(m, 2H) ), 2.15-2.10(m, 2H), 2.05-1.95(m, 2H), 1.76-1.73(m, 5H), 1.65-1.61(m, 10H), 1.47-1.39(m, 5H), 1.28-1.19(m, 9H).
[0290] Example 29: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamide)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0291] Step 1: Synthesis of tert-butyl 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)aminoacetic acid (3)
[0292] DIPEA (4.68 g, 36.20 mmol, 6.31 mL) was added to a solution of 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione (5 g, 18.10 mmol) and tert-butyl 2-aminoacetic acid (2.37 g, 18.10 mmol) in DMSO (50 mL). The reaction mixture was stirred at 90°C for 24 hours. LC-MS confirmed the detection of 51% of the desired mass. The mixture was poured into water (100 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phase was washed with brine (30 mL x 3), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1000 mesh silica gel, eluent petroleum ether:ethyl acetate = 10:1~1:1) to obtain the title compound (4.4 g, crude) as a green solid. MS(M-56+H) + =332.0
[0293] Step 2: Synthesis of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)aminoacetic acid (4)
[0294] To a solution of tert-butyl 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetic acid (4 g, 10.33 mmol) in dioxane (5 mL), HCl / dioxane (4 M, 40 mL) was added, and the resulting mixture was stirred at 25°C for 2 hours. One peak (7%) with the desired mass was confirmed by LC-MS. The mixture was concentrated under reduced pressure. The residue was solidified with petroleum ether / ethyl acetate (10:1, 40 mL) and stirred for 20 minutes. The suspension was then filtered. The filtered cake was collected and dried under vacuum to obtain the title compound (3.3 g, crude) as a yellow solid. MS(M+H) + =332.0
[0295] Step 3: Synthesis of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (5)
[0296] A mixture of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetic acid (3.15 g, 9.51 mmol) and 2-(2-aminoethoxy)ethanol (1.40 g, 13.31 mmol, 1.33 mL) in DCM (40 mL) was mixed with HOBt (1.54 g, 11.41 mmol), EDCI (2.19 g, 11.41 mmol), and TEA (2.89 g, 28.53 mmol, 3.97 mL). The resulting mixture was stirred at 25°C for 12 hours. One peak (83%) with the desired mass was confirmed by LC-MS. The mixture was concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (0.1% FA conditions) to obtain the title compound (1.79 g, 4.28 mmol, 44.99% yield, 100% purity) as a green solid. MS(M+H) + =419.2
[0297] Step 4: Synthesis of 2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamide)ethoxy)ethyl 4-methylbenzenesulfonic acid (6)
[0298] To a solution of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (1.69 g, 4.04 mmol) and TEA (1.63 g, 16.16 mmol, 2.25 mL) in DCM (20 mL), TosCl (3.08 g, 16.16 mmol) was added at 25 °C. The solution was stirred at 25 °C for 12 hours. LC-MS confirmed that the starting material had been completely consumed and that there was one peak (15%) with the desired mass. The mixture was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (1000 mesh). The compound was purified using silica gel and eluent (petroleum ether / ethyl acetate = 3:1 to 0:1) to obtain the title compound (1.7 g, 2.67 mmol, 66.15% yield, 90% purity) as a brown oily substance. MS(M+H) + =573.1
[0299] Step 5: Synthesis of tert-butyl(1-(2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamide)ethoxy)ethyl)piperidine-4-yl)carbamate (8)
[0300] A solution of 2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamide)ethoxy)ethyl 4-methylbenzenesulfonic acid (787.00 mg, 3.93 mmol) and tert-butyl N-(4-piperidyl)carbamate (787.00 mg, 3.93 mmol) in dioxane (20 mL) was mixed with DIPEA (1.02 g, 7.86 mmol, 1.37 mL) and NaI (196.34 mg, 1.31 mmol). The reaction mixture was stirred at 100 °C for 16 hours. One peak (72%) with the desired mass was confirmed by LC-MS. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1000 mesh silica gel, eluted with petroleum ether:ethyl acetate = 5:1 to 0:1; ethyl acetate:methanol = 10:1) to obtain the title compound (0.8 g, 1.31 mmol, 49.82% yield, 98% purity) as a green solid. MS(M+H) + =601.2
[0301] Step 6: Synthesis of N-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamide (9)
[0302] A solution of tert-butyl(1-(2-(2-(2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)aminoacetamide)ethoxyethyl)piperidine-4-yl)carbamate (1.2 g, 2.00 mmol) in HCl / dioxane (4 M, 40 mL) was stirred at 25°C for 2 hours. LC-MS confirmed one peak (41%) with the desired mass. The mixture was concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (0.1% HCl conditions) to obtain the title compound (500 mg, crude, HCl salt) as a yellow solid. MS(M+H) + =501.3
[0303] Step 7: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamide)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 29)
[0304] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (150 mg, 322.29 μmol) in DMF (2 mL), HATU (134.80 mg, 354.51 μmol) and DIPEA (83.31 mg, 644.57 μmol, 112.27 μL) were added. Stir the mixture at 25°C for 10 minutes, then add the solution of N-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamide (224.99 mg, 418.97 μmol, HCl salt) and DIPEA (83.31 mg, 644.57 μmol, 112.27 μL) in DMF (2 mL), and stir the resulting mixture for 25 minutes. The mixture was stirred at °C for 1 hour. LC-MS confirmed the presence of the starting material. HATU (110.29 mg, 290.06 μmol) was added, and the resulting mixture was stirred at 25°C for 12 hours. LC-MS confirmed the complete consumption of the starting material and a single major peak with the desired mass. The mixture was concentrated under reduced pressure. The crude product was preparatively HPLC (column: Phenomenex Luna C). 18 The sample was purified using a 150*40mm*15um mobile phase (water (0.1% TFA)-ACN); B%: 19%-49%, 10 min), and the eluent was freeze-dried to obtain the title compound (94.1 mg, 82.41 μmol, 25.57% yield, 95% purity, TFA salt) as a yellow solid.
[0305] MS(M+H) + =948.2.
[0306] 1 H NMR (400MHz, CD3OD) δ=8.36(d, J=13.9Hz, 1H), 8.21(s, 1H), 7.64-7.55(m, 1H), 7.40-7.31(m, 1H), 7.17-7.10(m, 1H), 6.97-6.90(m, 1H), 4.97(br dd, J=7.0, 11.6Hz, 2H), 4.11-4.03(m, 4H), 4.00(s, 3H), 3.84-3.75(m, 2H), 3.69-3.56(m, 4H), 3.54-3.42(m, 3H) ), 3.41(s, 3H), 3.31-3.41(m, 1H), 3.22-3.06(m, 2H), 2.65-2.83(m, 3H), 2.29-1.84(m, 8H), 1.84-1.64(m, 6H).
[0307] Example 30: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0308] Based on the above reaction equation, the title compound (99.4 mg, 83.84 μmol, 26.01% yield, 97% purity (TFA salt) was obtained as a yellow solid.
[0309] MS(M+H) + =1036.8
[0310] 1 H NMR (400MHz, CD3OD) δ=8.30(d, J=13.8Hz, 1H), 8.19(s, 1H), 7.51(dd, J=7.2, 8.4Hz, 1H), 7.32(d, J=6.8Hz, 1H ), 7.07(d, J=7.0Hz, 1H), 6.83(d, J=8.4Hz, 1H), 5.06(dd, J=5.4, 12.4Hz, 2H), 4.07(m, 2H), 3.99-3.95(m, 5H), 3.85-3.79(m, 2H), 3.72(m, 2H), 3.68-3.63(m, 4H), 3.60(s, 3H), 3.55(m, 2H), 3.50-3.42(m, 3H), 3.41(s, 3H) , 3.36(m, 2H), 3.25-3.10(m, 2H), 2.93-2.81(m, 1H), 2.79-2.67(m, 2H), 2.35-1.86(m, 8H), 1.84-1.63(m, 6H).
[0311] Example 31: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)acetyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0312] Based on the above reaction equation, the title compound (35.3 mg, 36.80 μmol (83.25% yield, 94.330% purity) was obtained as a yellow solid.
[0313] MS(M+H) + =905.4
[0314] 1 H NMR (400MHz, CDCl3)δ=9.91-9.22(m, 1H)
[0315] , 8.44-8.31(m, 1H), 8.08(s, 1H), 7.84(br d, J=7.5Hz, 1H), 7.72-7.48(m, 2H), 7.13(t, J=6.7Hz, 1H), 6.95-6.85(m, 1H), 6.81-6.66(m, 1H) ), 6.58-6.48(m, 1H), 4.98-4.78(m, 2H), 4.60-4.47(m, 1H), 4.45-4.21(m, 2H), 4.19-4.08(m, 1 H), 4.06-3.87(m, 6H), 3.82-3.70(m, 2H), 3.60-3.46(m, 2H), 3.42(s, 3H), 3.36-3.22(m, 1H), 2 .99-2.66(m, 4H), 2.26-2.03(m, 5H), 1.85-1.70(m, 4H), 1.61-1.55(m, 2H), 1.53-1.34(m, 2H).
[0316] Example 32: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)propanoyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0317] Based on the above reaction equation, the title compound (82.1 mg, 86.66 μmol, 33.61% yield, 97% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0318] MS(M+H) + =918.8
[0319] 1 H NMR (400MHz, DMSO-d6) δ=11.29-10.79(m, 1H), 8.32-8.22(m, 2H), 8.03(s, 1H), 7.94(dd, J=3. 1, 7.6Hz, 1H), 7.62-7.55(m, 1H), 7.20(d, J=6.7Hz, 1H), 7.14(d, J=8.7Hz, 1H), 7.04(d, J=7.1 Hz, 1H), 6.59(t, J=5.6Hz, 1H), 5.06(dd, J=5.3, 13.2Hz, 1H), 4.84-4.80(m, 1H), 4.29(d, J=12.1Hz, 1H), 4.0 7(t, J=13.9Hz, 2H), 4.03-3.96(m, 1H), 3.91(s, 3H), 3.89-3.86(m, 1H), 3.68(t, J=6.5Hz, 2H), 3.63-3.58(m, 2H), 3.47(q, J=5.2Hz, 2H), 3.33(s, 3H), 3.12(t, J=12.3Hz, 1H), 2.93-2.83(m, 1H), 2.77-2.69(m, 1H), 2.63 -2.55(m, 4H), 2.06-1.94(m, 3H), 1.87-1.78(m, 2H), 1.71-1.67(m, 2H), 1.67-1.57(m, 4H), 1.49-1.34(m, 2H)
[0320] Example 33: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)acetyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0321] Based on the above reaction equation, the title compound (20.5 mg, 21.39 μmol, 11.06% yield, 99% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0322] MS(M+H) + =949.4
[0323] 1H NMR (400MHz, DMSO-d6) δ=11.20-10.96(m, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.03(s, 1H), 7.95(dd, J=3.2, 7.7Hz, 1H ), 7.62-7.53(m, 1H), 7.23-7.11(m, 2H), 7.03(d, J=7.0Hz, 1H), 6.61(t, J=5.8Hz, 1H), 5.04(dd, J=5.2, 12.9Hz, 1H), 4.82(br t, J=7.8Hz, 1H), 4.30-4.20(m, 1H ), 4.19-4.14(m, 2H), 4.12-3.98(m, 3H), 3.91(s, 3H), 3.83-3.72(m, 1H), 3.66-3.55(m, 6H), 3.51-3.44(m, 2H), 3.17-3.00(m, 1H), 2 .93-2.81(m, 1H), 2.80-2.69(m, 1H), 2.64-2.51(m, 5H), 2.09-1.89(m, 3H), 1.88-1.77(m, 2H), 1.76-1.54(m, 6H), 1.54-1.29(m, 2H).
[0324] Example 34: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-3,6,9,12-tetraoxatetradecanoyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0325] Based on the above reaction equation, the title compound (75.6 mg, 69.98 μmol, 32.57% yield, 96% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0326] MS(M+H) + =1037.4.
[0327] 1 H NMR (400MHz, DMSO-d6) δ=11.09(s, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.06(s, 1H), 7.96(dd, J 1= 3.0, J 2= 7.5Hz, 1H), 7.57(dd, J 1= 7.2, J 2= 8.5Hz, 1H), 7.20(d, J=6.7Hz, 1H), 7.13(d, J=8.5Hz, 1H), 7.03(d, J=7.0Hz, 1H), 6.64-6.5 4 (m, 1H), 5.05 (dd, J 1= 5.3, J 2= 12.9Hz, 1H), 4.82(br t, J=7.5Hz, 1H), 4.24(br d, J=11.9Hz, 1H), 4.13(br d, J=12.5Hz, 2H), 4.10-3.95(m, 3H), 3.91(s, 3H), 3.79(br d, J=12.8Hz, 1H), 3.63-3.59(m, 2H), 3.58-3.50(m, 12H), 3.46(br d, J=6.0Hz, 2H), 3.33(s, 3H), 3.09(br t, J=11.9Hz, 1H), 2.93-2.83(m, 1H), 2.80-2.71(m, 1H), 2.62-2.55(m, 2H), 2.06-1.91(m, 3H), 1.89-1.78(m, 2H), 1.77-1.65(m, 2H), 1.68-1.56(m, 4H), 1.55-1.45(m, 1H), 1.44-1.33(m, 1H).
[0328] Example 35: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-((2-((2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)amino)-2-oxoethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0329] Based on the above reaction equation, the title compound (170.2 mg, 163.19 μmol, 49.11% yield, 91% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0330] MS(M+H) + =948.3
[0331] 1 H NMR (400MHz, DMSO-d6) δ11.10(s, 1H), 8.31(s, 1H), 8.25(d, J=13.4Hz, 1H), 8.04(s, 1H), 7.87(dd, J=3.4, 7.5Hz, 1H), 7.69(br t, J=5.9Hz, 1H), 7.62-7.54(m, 1H), 7.21-7.11(m, 2H), 7.04(d, J=7.0Hz, 1H), 6.61(t, J=5.6Hz, 1H), 5.09-5.03(m, 1H), 4.87-4.77(m, 1H), 4.08(br t, J=13.7Hz, 2H), 3.92(s, 3H), 3.80-3.68(m, 1H), 3.64-3.58(m, 2H), 3.53
[0332] -3.46(m, 4H), 3.31-3.28(m, 2H), 2.96-2.85(m, 3H), 2.81-2.75(m, 2H), 2.61 -2.53(m, 4H), 2.17(t, J=10.6Hz, 2H), 2.06-1.92(m, 3H), 1.83-1.50(m, 11H).
[0333] Example 36: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxo-6,9,12-trioxa-3-azatetradecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0334] Based on the above reaction equation, the title compound (53.8 mg, 50.89 μmol, 15.79% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0335] MS(M+H) + =1036.6
[0336] 1 H NMR (400MHz, DMSO-d6) δ11.08(br s, 1H), 8.30(s, 1H), 8.25(d, J=13.3Hz, 1H), 8.03(s, 1H), 7.88(dd, J=3.5, 7 .5Hz, 1H), 7.65(t, J=5.7Hz, 1H), 7.60-7.54(m, 1H), 7.19(d, J=6.7Hz, 1H), 7.13(d, J=8.7Hz, 1H), 7.03(d, J=7.0Hz, 1H), 6.59(t, J=5.6Hz, 1H), 5.10-5.02(m, 1H), 4.87-4.77 (m, 1H), 4.08(t, J=13.9Hz, 2H), 3.91(s, 3H), 3.80-3.69(m, 1H), 3.65-3.59(m, 2H), 3.58-3.53(m, 4H), 3.53-3.48(m, 4H), 3.47-3.40(m, 4H), 3.34(s, 3H), 3.28-3.22(m, 2H), 2.93-2.84(m, 3H), 2.8 2-2.75(m, 2H), 2.62-2.55(m, 2H), 2.17(t, J=10.9Hz, 2H), 2.06-1.93(m, 3H), 1.85-1.58(m, 10H).
[0337] Example 37: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-4-oxobutyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0338] Step 1: Synthesis of benzyl 4-bromobutanoate (2)
[0339] To a mixture of 4-bromobutanoate (5 g, 29.94 mmol) and phenylmethanol (4.21 g, 38.92 mmol, 4.05 mL) in cyclohexane (50 mL), TsOH (257.79 mg, 1.50 mmol) was added all at once at 20°C, and the resulting mixture was stirred at 90°C for 16 hours. LC-MS confirmed that the starting materials were completely consumed. It was confirmed that no peak with the desired mass was detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 5:1) confirmed that the starting material was completely consumed and that two novel spots were detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to obtain the title compound (6.5 g, 25.28 mmol, 84.43% yield) as a yellow oil.
[0340] 1 H NMR (400MHz, CDCl3)δ=7.46-7.32(m, 5H), 5.17(s, 2H), 3.49(t, J=6.5Hz, 2H), 2.59(t, J=7.2Hz, 2H), 2.18-2.25(m, 2H).
[0341] Step 2: Synthesis of benzyl 4-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)butanoate (3)
[0342] A mixture of benzyl 4-bromobutanoate (6.5 g, 25.28 mmol) and tert-butylpiperidine-4-ylcarbamate (7.59 g, 37.92 mmol) in dioxane (60 mL) was mixed with NaI (378.93 mg, 2.53 mmol) and DIPEA (9.80 g, 75.84 mmol, 13.21 mL) in a single addition at 20°C. The resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that all starting materials had been consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1, dichloromethane:methanol = 1 / 0 to 10 / 1) to obtain the title compound (6.8 g, 16.26 mmol, 64.30% yield, 90% purity) as a yellow solid. MS(M+H) + =377.4
[0343] Step 3: Synthesis of 4-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)butanoic acid (4)
[0344] A solution of benzyl 4-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)butanoate (3.4 g, 9.03 mmol) in methanol (40 mL) was mixed with Pd / C (340 mg, 10% purity) under N2. The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 20°C for 16 hours under H2 (15 psi). LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with methanol (40 mL) and filtered. The filtrate was concentrated under vacuum to obtain the title compound (2.7 g, crude) as a white oily substance. MS(M+H) + =287.2
[0345] Step 4: Synthesis of tert-butyl(1-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-4-oxobutyl)piperidine-4-yl)carbamate (6)
[0346] To a mixture of 4-amino-2-(2,6-dioxo-3-piperidyl)isoindorin-1,3-dione (1.5 g, 5.49 mmol) and 4-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)butanoic acid (2.04 g, 7.14 mmol) in DMF (15 mL), T3P (20.96 g, 32.94 mmol, 19.59 mL, 50% purity ethyl acetate solution) and Py (4.34 g, 54.90 mmol, 4.43 mL) were added all at once at 20°C, and the resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that 4-amino-2-(2,6-dioxo-3-piperidyl)isoindorin-1,3-dione was completely consumed and that one peak with the desired mass was detected. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL x 3). The organic layer was washed with brine (30 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1, dichloromethane / methanol = 1 / 0 to 10 / 1) to obtain the title compound (825 mg, 1.49 mmol, 27.19% yield, 98% purity) as a yellow solid. MS(M+H) + = 542.2
[0347] Step 5: Synthesis of 4-(4-aminopiperidine-1-yl)-N-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)butanamide (7)
[0348] To a mixture of tert-butyl(1-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-4-oxobutyl)piperidine-4-yl)carbamate (825 mg, 1.52 mmol) in dioxane (5 mL), HCl / dioxane (4 M, 10 mL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. TLC (silicon dioxide, dichloromethane:methanol = 10:1) confirmed that the starting material had been completely consumed and that a novel spot had been detected. The reaction mixture was concentrated under vacuum to obtain the title compound (730 mg, crude, HCl) as an off-white solid.
[0349] Step 6: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-4-oxobutyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 37)
[0350] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (3 mL), HATU (179.73 mg, 472.69 μmol) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) were added. The mixture was stirred at 20°C for 10 minutes. DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) was added to a solution of 4-(4-aminopiperidine-1-yl)-N-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)butanamide (246.62 mg, crude, HCl) in DMF (3 mL), and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Phenomenex luna C). 18 After purification using a 150*40mm*15um mobile phase (water (0.225% FA)-ACN), the compound was freeze-dried to obtain the title compound (116.9 mg, 124.94 μmol, 29.07% yield, 95% purity) as a white solid.
[0351] MS(M+H) + =888.7
[0352] 1 H NMR (400MHz, DMSO-d6) δ=11.16(s, 1H), 9.71(s, 1H), 8.48(d, J=8.3Hz, 1H), 8.30-8.25(m, 1H), 8.22(d, J=5.5Hz, 1H), 8.04(s, 1H), 7.91-7.77(m, 2H), 7.61(d, J=7.2Hz, 1H), 7.18(d, J=6.7Hz, 1H), 5.19-5.10(m, 1H), 4.89-4.75(m, 1H), 4 .13-4.02(m, 2H), 3.91(s, 3H), 3.81-3.63(m, 2H), 3.33(s, 3H), 2.94-2.81(m, 3 H), 2.69-2.54(m, 3H), 2.38-2.32(m, 2H), 2.09-1.93(m, 5H), 1.81-1.46(m, 12H)
[0353] Example 38: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(8-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-8-oxooctyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0354] Based on the above reaction equation, the title compound (230.9 mg) was obtained in the same manner as in the above-described examples. A pale yellow solid (239.45 μmol, 46.44% yield, 98% purity) was obtained.
[0355] MS(M+H) + =945.6
[0356] 1H NMR (400MHz, CD3OD) δ8.69-8.63(m, 1H) , 8.35-8.28(m, 1H), 8.23(s, 1H), 7.81(dd, J=7.4, 8.4Hz, 1H), 7.63-7.58(m, 1H), 7.37(d, J=6 .5Hz, 1H), 5.20-5.12(m, 1H), 5.07-5.00(m, 1H), 4.13(t, J=12.9Hz, 2H), 4.01(s, 3H), 3.72-3 .63(m, 2H), 3.42(s, 3H), 3.23-3.08(m, 4H), 2.96-2.85(m, 1H), 2.83-2.71(m, 2H), 2.55(t, J= 7.3Hz, 2H), 2.30(d, J=14.6Hz, 2H), 2.22-2.05(m, 4H), 1.94-1.71(m, 12H), 1.55-1.42(m, 6H)
[0357] Example 39: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)butanoyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka] Based on the above reaction equation, the title compound (202.8 mg, 221.31 μmol, 51.50% yield, 97% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0358] MS(M+H) + =889.0
[0359] 1H NMR(400MHz, CD3OD )δ=8.39(d, J=14.0Hz, 1H), 8.20(s, 1H), 7.56(dd, J=7.2, 8.6Hz, 1H), 7.32(d, J=6.6Hz, 1H), 7.12(d, J= 8.4Hz, 1H), 7.04(d, J=7.0Hz, 1H), 5.04(dd, J=5.0, 12.2Hz, 1H), 4.49(d, J=11.8Hz, 1H), 4.18-4.10(m, 1H), 4.07-4.00(m, 2H), 3.98(s, 3H), 3.52-3.41(m, 2H), 3.40(s, 3H), 3.25-3.17(m, 1H), 2.89-2.79(m, 2H), 2.78-2.68(m, 2H), 2.54(t, J=6.7Hz, 2H), 2.15-1.92(m, 8H), 1.87-1.62(m, 7H), 1.58-1.44(m, 2H)
[0360] Example 40: 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimide[4,5-b][1,4]diaze Synthesis of pin-2-yl)amino)-N-(1-(4-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)benzyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0361] Stage 1: 4-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoic acid Synthesis of ethyl(3)
[0362] Potassium carbonate (4.99 g, 36.11 mmol) was added to a solution of ethyl 4-hydroxybenzoate (3 g, 18.05 mmol) and benzyl (2-bromoethyl) carbamate (4.19 g, 16.25 mmol) in MeCN (70 mL). The reaction mixture was heated at 85 °C for 4 hours. One peak (69%) with the desired mass was confirmed by LC-MS. The reaction mixture was diluted with water (150 mL) and extracted with ethyl acetate (150 mL x 2). The combined organic layer was washed with sodium hydroxide (100 mL, 3 M), dried over sodium sulfate, and filtered. The filtrate was concentrated under vacuum to obtain the title compound (5 g, 14.56 mmol, 80.66% yield) as a white solid. MS(M+H) + =344.1
[0363] Step 2: Synthesis of benzyl(2-(4-(hydroxymethyl)phenoxy)ethyl)carbamate(4)
[0364] LiAlH4 (718.47 mg, 18.93 mmol) was partially added at 0°C to a solution of ethyl 4-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoate (5 g, 14.56 mmol) in THF (80 mL). The reaction mixture was stirred at 20°C for 2 hours. One major peak was identified by LC-MS. The reaction mixture was quenched with water (0.8 mL), sodium hydroxide (0.8 mL, 15% solution), and water (2.4 mL). The suspension was diluted with THF (120 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, PE / ethyl acetate = 30%~50%) to obtain the title compound (2.2 g, 7.15 mmol, 49.14% yield, 98% purity) as a white solid. MS(M-OH+H) + =284.1
[0365] Step 3: Synthesis of benzyl(2-(4-(chloromethyl)phenoxy)ethyl)carbamate (5)
[0366] To a mixture of benzyl (2-(4-(hydroxymethyl)phenoxy)ethyl) carbamate (1.5 g, 4.98 mmol) in DCM (15 mL), SOCl2 (710.65 mg, 5.97 mmol, 433.33 μL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that 75% of the starting material remained and one peak (21%) with the desired mass was observed. Further SOCl2 (710.65 mg, 5.97 mmol, 433.33 μL) was added, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that 70% of the starting material remained. Further SOCl2 (710.65 mg, 5.97 mmol, 433.33 μL) was added, and the resulting mixture was continued to stir at 20°C for 16 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 1:1) confirmed that the starting material was completely consumed and that a novel spot was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (1.6 g, crude) as a white solid. MS(M+Na) + =342.3
[0367] Step 4: Synthesis of tert-butyl N-[1-[[4-[2-(benzyloxycarbonylamino)ethoxy]phenyl]methyl]-4-piperidyl]carbamate (6)
[0368] A mixture of benzyl (2-(4-(chloromethyl)phenoxy)ethyl) carbamate (1.6 g, 5.00 mmol) and tert-butylpiperidine-4-yl carbamate (1.20 g, 6.00 mmol) in ACN (20 mL) was mixed with potassium carbonate (2.07 g, 15.01 mmol) in one step at 20°C, and the resulting mixture was stirred at 60°C for 2 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum. The residue was analyzed by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 5 / 1 to 0 / 1). The compound was purified by MS(M+H) to obtain the title compound (2.3 g, 4.71 mmol, 94.10% yield, 99% purity) as a white solid. +=484.4
[0369] Step 5: Synthesis of benzyl(2-(4-((4-aminopiperidine-1-yl)methyl)phenoxy)ethyl)carbamate (7)
[0370] To a mixture of tert-butyl N-[1-[[4-[2-(benzyloxycarbonylamino)ethoxy]phenyl]methyl]-4-piperidyl]carbamate (1 g, 2.07 mmol) in dioxane (5 mL), HCl / dioxane (4 M, 10 mL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that the starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (890 mg, crude, HCl salt) as a white solid. MS(M+H) + =384.2
[0371] Step 6: Synthesis of benzyl(2-(4-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)methyl)phenoxy)ethyl)carbamate (9)
[0372] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (0.5 g, 1.07 mmol) in DMF (5 mL), HATU (449.32 mg, 1.18 mmol) and DIPEA (277.69 mg, 2.15 mmol, 374.24 μL) were added, and the mixture was stirred at 20°C for 10 minutes. A solution of benzyl (2-(4-((4-aminopiperidine-1-yl)methyl)phenoxy)ethyl) carbamate (541.37 mg, 1.29 mmol, HCl salt) in DMF (5 mL) was added to DIPEA (277.69 mg, 2.15 mmol, 374.24 μL), and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting material had been completely consumed and that one peak with the desired mass was detected. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic layer was washed with brine (20 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1, dichloromethane / methanol = 1 / 0 to 10 / 1) to obtain the title compound (612 mg, 714.46 μmol, 66.51% yield, 97% purity) as a white oily substance. MS(M+H) + =831.1
[0373] Step 7: Synthesis of N-(1-(4-(2-aminoethoxy)benzyl)piperidine-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide (10)
[0374] To a mixture of benzyl(2-(4-((4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)methyl)phenoxy)ethyl)carbamate (612 mg, 736.56 μmol) in ACN (10 mL), TMSI (221.07 mg, 1.10 mmol, 150.39 μL) was added in one go at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. TEA (223.5) was added to the reaction mixture. 9 mg, 2.21 mmol, 307.56 μL) was added and the mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated under vacuum. The residue was separated by preparative HPLC (column: Phenomenex Luna C). 18 The sample was purified by (150*40mm*15um; mobile phase: [water (0.225% FA)-ACN]; B%: 10%~40%, 10 min), and the eluent was freeze-dried to obtain the title compound (393 mg, 547.12 μmol, 74.28% yield, 97% purity) as a white solid. MS(M+H) + =697.2
[0375] Step 8: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)benzyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 40)
[0376] A mixture of 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindoline-1,3-dione (150 mg, 543.05 μmol) and N-(1-(4-(2-aminoethoxy)benzyl)piperidine-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide (378.37 mg, 543.05 μmol) in DMSO (5 mL) was mixed with TEA (164.85 mg, 1.63 mmol, 226.75 μL) in one step, and the resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (12 mL) and extracted with ethyl acetate (12 mL x 3). The organic layer was washed with brine (12 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Phenomenex Luna C). 18 The sample was purified using a 150*40mm*15um mobile phase (water (0.225% FA)-ACN), with a B% concentration of 18% to 48% for 10 minutes. The eluent was then freeze-dried to obtain the title compound (30 mg, 29.59 μmol, 5.45% yield, 94% purity) as a yellow solid.
[0377] MS(M+H) + =953.3
[0378] 1H NMR(400MHz, CD3OD )δ=8.41(d, J=14.1Hz, 1H), 8.22(s, 1H), 7.59(dd, J=7.2, 8.5Hz, 1H), 7.35-7.28(m , 3H), 7.20(d, J=8.6Hz, 1H), 7.09(d, J=7.1Hz, 1H), 6.97(d, J=8.7Hz, 2H), 5.07(br dd, J=5.5, 12.5Hz, 1H), 4.97-4.93(m, 1H), 4.24(t, J=5.1Hz, 2H), 4.05(br t, J=13.5Hz, 2H), 4.00(s, 3H), 3.79-3.64(m, 4H), 3.42(s, 3H), 3.12-3.01(m, 2 H), 2.89-2.70(m, 2H), 2.54-2.29(m, 2H), 2.22-1.96(m, 6H), 1.90-1.64(m, 9H).
[0379] Example 41: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(2-(2-(2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethoxy)benzyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0380] Based on the above reaction equation, the title compound (112.4 mg, 92.44 μmol, 20.80% yield, 95% purity, TFA salt) was obtained as a yellow solid by the same method as in the examples described above.
[0381] MS(M+H) + =1042.1.
[0382] 1 H NMR (400MHz, CD3OD) δ=8.32(d, J=13.7Hz, 1H), 8.24-8.22(m, 1H), 7.55(dd, J 1=8.5Hz, J2=7.2Hz, 1H), 7.43-7.31(m, 3H), 7.14-7.07(m, 1H) ), 7.07-6.97(m, 3H), 5.07-4.99(m, 2H), 4.33-4.23(m, 2H), 4.22-4.05 (m, 5H), 4.03-3.97(m, 3H), 3.93-3.85(m, 2H), 3.78-3.68(m, 6H), 3.62 -3.46(m, 4H), 3.42(s, 3H), 3.20-3.03(m, 2H), 2.91-2.78(m, 1H), 2.75 -2.70(m, 1H), 2.34-2.20(m, 2H), 2.19-2.00(m, 4H), 1.92-1.67(m, 8H).
[0383] Example 42: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethyl)phenethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0384] Step 1: Synthesis of 2-(4-vinylphenyl)ethyl acetate (2)
[0385] To a mixture of ethyl 2-(4-bromophenyl) (10 g, 41.14 mmol) and potassium trifluoro(vinyl)boric acid (6.61 g, 49.36 mmol) in water (20 mL) and dioxane (100 mL), potassium carbonate (17.06 g, 123.41 mmol) and Pd(dppf)Cl2 (1.50 g, 2.06 mmol) were added all at once at 20 °C under N2. The suspension was degassed under vacuum, purged several times with N2, and the resulting mixture was stirred at 100 °C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that one peak with the desired mass was detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 10:1) confirmed that ethyl 2-(4-bromophenyl) was completely consumed and that two novel spots were detected. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 0 to 100 / 1) to obtain 2-(4-vinylphenyl)ethyl acetate (5.3 g, 25.91 mmol, 62.99% yield, 93% purity) as a yellow oil. MS(M+H) + =191.5
[0386] Step 2: Synthesis of 2-(4-(2-hydroxyethyl)phenyl)ethyl acetate (3)
[0387] To a mixture of ethyl 2-(4-vinylphenyl)(2.3g, 12.09 mmol) in THF (20 mL), BH3·Me2S (10 M, 1.81 mL) was added dropwise at 0°C under N2 conditions, and the resulting mixture was stirred at 20°C for 2 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 5:1) confirmed that the starting material was completely consumed and that one major novel spot was detected. Water (8.28 g, 459.61 mmol, 8.28 mL), sodium hydroxide (3 M, 4.60 mL), and H2O2 (9.77 g, 86.17 mmol, 8.28 mL, 30% purity) were then sequentially added to this reaction at 0°C, and the resulting mixture was stirred at 20°C for 2 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 5:1) confirmed that the starting material was completely consumed and that four novel spots were detected. The reaction mixture was quenched with saturated sodium sulfite (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1 to 5 / 1) to obtain the title compound (1.2 g, 4.84 mmol, 40.03% yield, 84% purity) as a white oily substance. MS(M+H) + =209.2
[0388] Step 3: Synthesis of 2-(4-(2-(tosyloxy)ethyl)phenyl)ethyl acetate (4)
[0389] To a mixture of ethyl 2-(4-(2-hydroxyethyl)phenyl)ethyl acetate (1.2 g, 4.84 mmol, 84% purity) in DCM (12 mL), TEA (1.47 g, 14.52 mmol, 2.02 mL) and TosCl (1.38 g, 7.26 mmol) were added in one step at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. LC-MS confirmed that ethyl 2-(4-(2-hydroxyethyl)phenyl)ethyl acetate had been completely consumed and that one peak with the desired mass was detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 5:1) confirmed that ethyl 2-(4-(2-hydroxyethyl)phenyl)ethyl acetate had been completely consumed and that three novel spots were detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1 to 5 / 1) to obtain the title compound (1.7 g, 4.60 mmol, 94.97% yield, 98% purity) as a white solid. MS(M+NH4) + =380.2
[0390] Step 4: Synthesis of 2-(4-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethyl)phenyl)ethyl acetate (5)
[0391] To a mixture of 2-(4-(2-(tosyloxy)ethyl)phenyl)ethyl acetate (1.7 g, 4.69 mmol) and tert-butyl N-(4-piperidyl)carbamate (1.88 g, 9.38 mmol) in dioxane (10 mL), NaI (140.61 mg, 938.09 μmol) and DIPEA (1.82 g, 14.07 mmol, 2.45 mL) were added in one step at 20°C, and the resulting mixture was stirred at 60°C for 16 hours. LC-MS confirmed the presence of residual 2-(4-(2-(tosyloxy)ethyl)phenyl)ethyl acetate and the detection of one peak with the desired mass. TLC (silicon dioxide, petroleum ether:ethyl acetate = 1:3) confirmed the presence of residual 2-(4-(2-(tosyloxy)ethyl)phenyl)ethyl acetate and the detection of four novel spots. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 2 / 1 to 1 / 3) to obtain the title compound (1.36 g, 3.27 mmol, 69.79% yield, 94% purity) as a white solid. MS(M+H) + =391.4
[0392] Step 5: Synthesis of 2-(4-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethyl)phenyl)acetic acid (6)
[0393] To a mixture of ethyl acetate (600 mg, 1.54 mmol) (2-(4-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethyl)phenyl) in ethyl acetate (6 mL) of EtOH (6 mL) and THF (6 mL), sodium hydroxide (2 M, 1.54 mL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that the starting material had been completely consumed and that a single peak with the desired mass was detected. HCl (12 N) was added to the reaction mixture at 0°C to adjust the pH to 7. The reaction mixture was concentrated under vacuum to obtain the title compound (710 mg, crude) as a white solid. MS (MH) + =361.0
[0394] Step 6: Synthesis of tert-butyl(1-(4-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethyl)phenethyl)piperidine-4-yl)carbamate (7)
[0395] To a mixture of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (400 mg, 1.46 mmol) and 2-(4-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethyl)phenyl)acetic acid (689.79 mg, 1.90 mmol) in DMF (5 mL), T3P (2.79 g, 8.78 mmol, 50% pure ethyl acetate in solution, 2.61 mL) and Py (1.16 g, 14.64 mmol, 1.18 mL) were added all at once at 20°C, and the resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that one peak with the desired mass was detected. TLC (silicon dioxide, dichloromethane:methanol = 10:1) confirmed that all starting materials were completely consumed and that one major novel spot was detected. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic layer was washed with brine (15 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1, dichloromethane / methanol = 1 / 0 to 10 / 1) to obtain the title compound (618 mg, 930.47 μmol, 63.56% yield, 93% purity) as a yellow solid. MS(M+H) + =618.2
[0396] Step 7: Synthesis of 2-(4-(2-(4-aminopiperidine-1-yl)ethyl)phenyl)-N-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)acetamide (8)
[0397] To a mixture of tert-butyl(1-(4-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethyl)phenethyl)piperidine-4-yl)carbamate (615 mg, 995.64 μmol) in dioxane (3 mL), HCl / dioxane (4 M, 9 mL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (556 mg, crude, HCl) as a white solid. MS(M+H) + = 518.2
[0398] Step 8: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-2-oxoethyl)phenethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 42)
[0399] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (250 mg, 537.14 μmol) in DMF (3 mL), HATU (224.66 mg, 590.86 μmol) and DIPEA (138.84 mg, 1.07 mmol, 187.12 μL) were added. The mixture was stirred at 20°C for 10 minutes, and a solution of 2-(4-(2-(4-aminopiperidine-1-yl)ethyl)phenyl)-N-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)acetamide (357.12 mg, crude, HCl) in DMF (3 mL) and DIPEA (138.84 mg, 1.07 mmol, 187.12 μL, 2 eq) was added. The resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic layer was washed with brine (15 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Phenomenex luna C). 18 After purification using a 150*40mm*15um mobile phase (water (0.225% FA)-ACN), the sample was freeze-dried to obtain the title compound (132.9 mg, 130.84 μmol, 24.36% yield, 95% purity) as an off-white solid.
[0400] MS(M + H) + =965.2
[0401] 1H NMR (400MHz, DMSO-d6)δ=11.33-10.96(m, 1H), 9.79(s, 1H), 8.49(d, J=8.4Hz, 1H), 8.30(s, 1H), 8.24(d, J =13.6Hz, 1H), 8.03(s, 1H), 7.88(dd, J=3.2, 7.2Hz, 1H), 7.82(t, J=7.9Hz, 1H), 7.60(d, J=7.2Hz, 1H), 7.31 -7.25(m, 2H), 7.23-7.16(m, 3H), 5.12(dd, J=5.4, 12.8Hz, 1H), 4.85-4.77(m, 1H), 4.07(t, J=13.9Hz, 2H), 3.91(s, 3H), 3.85-3.68(m, 4H), 3.33(s, 3H), 2.94-2.84(m, 3H), 2.76-2.56(m, 4H), 2.11-1.93(m, 5H), 1.8 5-1.48 (m, 11H)
[0402] Example 43: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(4-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0403] Step 1: Synthesis of 1-(3-((tert-butyldimethylsilyl)oxy)propyl)-1H-imidazole-4-carboxylate methyl(2)
[0404] Potassium carbonate (35 g, 253.25 mmol) and 3-bromoproxy-tert-butyl-dimethyl-silane (25.78 g, 101.80 mmol) were added to a solution of methyl 1H-imidazole-4-carboxylate (10 g, 79.29 mmol) in CH3CN (200 mL). The mixture was stirred at 25°C for 16 hours. One major peak with the desired mass was identified by LC-MS. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10:1-0:1) to obtain the title compound (8.2 g, 27.20 mmol, 34.30% yield, 99% purity) as a pale yellow oil. MS(M+H) + =299.1
[0405] Step 2: Synthesis of 1-(3-hydroxypropyl)-1H-imidazole-4-carboxylate methyl(3)
[0406] To a solution of 1-(3-((tert-butyldimethylsilyl)oxy)propyl)-1H-imidazole-4-carboxylate methyl (6.5 g, 21.78 mmol) in dioxane (20 mL), HCl / dioxane (4 M, 86.67 mL) was added at 25°C. The mixture was stirred at 25°C for 16 hours. LC-MS confirmed a single major peak with the desired mass. The reaction mixture was concentrated under reduced pressure to obtain the title compound (4.0 g, crude) as a pale yellow oil. MS(M+H) + =185.2
[0407] Step 3: Synthesis of 1-(3-(tosyloxy)propyl)-1H-imidazole-4-carboxylate methyl(4)
[0408] To a solution of methyl 1-(3-hydroxypropyl)-1H-imidazole-4-carboxylate (4 g, 21.72 mmol) in DCM (50 mL), TEA (18.18 g, 179.61 mmol, 25 mL) and TosCl (13.33 g, 69.94 mmol) were added at 25°C. The mixture was stirred at 25°C for 16 hours. A 26% peak at the desired mass was confirmed by LC-MS. The reaction mixture was concentrated under reduced pressure to obtain the residue. Water (40 mL) was then added, and the mixture was extracted with ethyl acetate (80 mL x 3). The combined organic layer was washed with 180 mL of brine (60 mL x 3), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silicon dioxide, petroleum ether:ethyl acetate = 5:1 to 0:1) to obtain the title compound (4.5 g, 13.30 mmol, 61.24% yield) as a pale yellow oily substance. MS(M+H) + =339.2
[0409] Step 4: Synthesis of 1-(3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)propyl)-1H-imidazole-4-carboxylate methyl (5)
[0410] To a solution of methyl 1-(3-(tosyloxy)propyl)-1H-imidazole-4-carboxylate (2 g, 5.91 mmol) in dioxane (40 mL), NaI (400.00 mg, 2.67 mmol), DIPEA (2.97 g, 22.96 mmol, 4.00 mL), and tert-butylpiperidine-4-ylcarbamate (2.00 g, 9.99 mmol) were added at 25°C. The mixture was stirred at 80°C for 16 hours. 56% of the peaks at the desired mass were confirmed by LC-MS. The reaction mixture was concentrated under reduced pressure to obtain the residue. The residue was separated by preparative HPLC (column: Waters Xbridge BEH C). 18 The sample was purified by a 250*50mm*10um (250mM*10um) column (mobile phase: [water (10mM ammonium bicarbonate)-ACN]; B%: 10%~40%, 25 minutes, column temperature: 30°C), followed by lyophilization to obtain the title compound (1.5g, 4.09 mmol, 69.25% yield) as a pale yellow oil. MS(M+H) + =367.1.
[0411] Step 5: Synthesis of tert-butyl(1-(3-(4-(hydroxymethyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (6)
[0412] A solution of methyl 1-(3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)propyl)-1H-imidazole-4-carboxylate (1.5 g, 4.09 mmol) in THF (20 mL) was mixed with LiAlH4 (300 mg, 7.90 mmol) at -20°C. The mixture was stirred at 20°C for 3 hours. LC-MS confirmed the presence of a major peak with mass [M+Li]. The reaction mixture was quenched at 0°C with water (2 mL) and sodium hydroxide solution (15%, 3 mL), then sodium sulfate (25 g) was added, and the mixture was filtered. The filtrate was concentrated under reduced pressure to obtain the title compound (1.3 g, crude) as a pale yellow oil. MS(M+Li) + =345.1.
[0413] Step 6: Synthesis of tert-butyl(1-(3-(4-(azidomethyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (7)
[0414] To a solution of tert-butyl(1-(3-(4-(hydroxymethyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (1.3 g, 3.84 mmol) in THF (30 mL), DPPA (2.54 g, 9.23 mmol, 2 mL) and DBU (2.02 g, 13.27 mmol, 2 mL) were added at 0°C. The mixture was stirred at 25°C for 16 hours under an N2 atmosphere. A 32% peak at the desired mass was confirmed by LC-MS. Water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (30 mL x 3), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silicon dioxide, ethyl acetate:methanol = 1:0-3:1) to obtain the title compound (850 mg, 2.34 mmol, 60.88% yield) as a pale yellow oily substance. MS(M+H) + =364.1
[0415] Step 7: Synthesis of tert-butyl(1-(3-(4-(aminomethyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (8)
[0416] A solution of tert-butyl(1-(3-(4-(azidomethyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (680 mg, 1.87 mmol, 1 eq) in THF (30 mL) was mixed with Pd / C (200 mg, 10% purity) at 25°C. The mixture was stirred at 25°C for 16 hours under an H2 atmosphere (15 Psi). LC-MS confirmed a 40% peak at the desired mass. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound (600 mg, crude) as a pale yellow oil. MS(M+H) + =338.3
[0417] Step 8: Synthesis of tert-butyl(1-(3-(4-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (9)
[0418] To a solution of tert-butyl(1-(3-(4-(aminomethyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (600 mg, 1.78 mmol) in DMSO (15 mL), TEA (727.00 mg, 7.18 mmol, 1 mL) and 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione (400 mg, 1.45 mmol) were added at 25 °C. The mixture was stirred at 100 °C for 16 hours under an N2 atmosphere. A 33% peak at the desired mass was confirmed by LC-MS. Water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic layer was washed with brine (30 mL x 3), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was analyzed by column chromatography (silicon dioxide, D The compound was purified by CM / methanol (30 / 1 to 10 / 1) to obtain the title compound (400 mg, 673.77 μmol, 37.90% yield) as a pale yellow oily substance. MS(M+H) + = 594.5
[0419] Step 9: Synthesis of 4-(((1-(3-(4-aminopiperidine-1-yl)propyl)-1H-imidazole-4-yl)methyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (10)
[0420] To a solution of tert-butyl(1-(3-(4-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)carbamate (400 mg, 673.77 μmol) in dioxane (10 mL), HCl / dioxane (4 M, 10 mL) was added at 25 °C. The mixture was stirred at 25 °C for 16 hours under an N2 atmosphere. LC-MS confirmed 63% of the peaks at the desired mass. The reaction mixture was concentrated under reduced pressure to obtain the title compound (350 mg, crude, 2HCl) as a pale yellow solid. MS(M+H) + =494.4
[0421] Step 10: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(4-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)-1H-imidazole-1-yl)propyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 43)
[0422] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL), HATU (400 mg, 1.05 mmol), DIPEA (445.20 mg, 3.44 mmol, 600 μL), and 4-(((1-(3-(4-aminopiperidine-1-yl)propyl)-1H-imidazole-4-yl)methyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (300 mg, 529.59 μmol, 2HCl) were added at 25°C. The mixture was stirred under an N2 atmosphere at 25°C for 16 hours. A 39% peak was confirmed by LC-MS at the desired mass. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic layer was washed with brine (30 mL x 3), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Waters Xbridge 150*25 mm*5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 42%~62%, 9 min, column temperature: 30°C), and then lyophilized to obtain the title compound (84.7 mg, 83.71 μmol, 19.48% yield, 93% purity) as a pale yellow solid.
[0423] MS(M+ H) + =941.7
[0424] 1 H NMR (400MHz, DMSO-d6) δ11.08(br s, 1H), 8.31(s, 1H), 8.25(d, J=13.3Hz, 1H), 8.04(s, 1H), 7.87(dd, J=3.1 , 7.7Hz, 1H), 7.61-7.50(m, 2H), 7.23-7.14(m, 2H), 7.09(s, 1H), 7.04(d, J =7.0Hz, 1H), 6.89(t, J=5.8Hz, 1H), 5.05(dd, J=5.5, 12.7Hz, 1H), 4.86-4. 77(m, 1H), 4.40-4.33(m, 2H), 4.08(t, J=13.9Hz, 2H), 3.97-3.93(m, 2H), 3 .92(s, 3H), 3.80-3.59(m, 1H), 3.34(s, 3H), 2.95-2.83(m, 1H), 2.81-2.73(m, 2H), 2.62- 2.54(m, 2H), 2.22-2.14(m, 2H), 2.06-1.87(m, 6H), 1.83-1.72(m, 5H), 1.64-1.47(m, 6H)
[0425] Example 44: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(2-(2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)-1H-1,2,3-triazole-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0426] Stage 1: 4-((2-(2-azidoethoxy)ethyl)amino)-2-(2,6-diode Synthesis of xopiperidine-3-yl)isoindoline-1,3-dione (2)
[0427] To a solution of 2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonic acid (2 g, 3.88 mmol) in DMF (20 mL), NaN3 (450 mg, 6.92 mmol) was added. The mixture was stirred at 70°C for 16 hours. The major peak at the desired mass was confirmed by LC-MS. Water (20 mL) was poured over the reaction mixture and extracted with EA (30 mL x 3). The combined organic layers were washed with brine (30 mL x 3). The organic layers were dried over sodium sulfate, filtered, and concentrated to obtain the title compound (1.40 g, crude) as a pale yellow solid. MS(M+H) + =387.1
[0428] 1 H NMR (400MHz, DMSO-d6) δ11.15(s, 1H), 7.64(dd, J=7.2, 8.4Hz, 1H), 7.21(d, J=8.6Hz, 1H), 7.10(d, J=7.0Hz, 1H), 6.68(t, J=5.9Hz, 1H), 5 .15-5.05(m, 1H), 3.74-3.66(m, 4H), 3.55(q, J=5.5Hz, 2H), 3.49-3.43(m, 2H), 2.99-2.89(m, 1H), 2.69-2.57(m, 2H), 2.12-2.04(m, 1H).
[0429] Step 2: Synthesis of tert-butyl(1-((1-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)-1H-1,2,3-triazole-4-yl)methyl)piperidine-4-yl)carbamate (4)
[0430] To a solution of tert-butyl(1-(prof-2-in-1-yl)piperidine-4-yl)carbamate (900 mg, 3.78 mmol) in methanol (20 mL), CuSO4 (750 mg, 4.70 mmol, 721.15 μL), sodium L-ascorbylate (1 g, 5.05 mmol), and 4-((2-(2-azidoethoxy)ethyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (1.2 g, 3.11 mmol) were added at 25°C. The mixture was stirred at 25°C for 16 hours. 90% peaks at the desired mass were confirmed by LC-MS. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10um; mobile phase: [water (10mM ammonium bicarbonate)-ACN]; B%: 32%~62%, 14 min, column temperature: 30°C), and then lyophilized to obtain the title compound (1.5g, 2.40 mmol, 63.59% yield) as a pale yellow solid. MS(M+H) + =625.5
[0431] Step 3: Synthesis of 4-((2-(2-(4-((4-aminopiperidine-1-yl)methyl)-1H-1,2,3-triazole-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (5)
[0432] To a solution of tert-butyl(1-((1-(2-(2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)-1H-1,2,3-triazole-4-yl)methyl)piperidine-4-yl)carbamate (500 mg, 800.40 μmol) in dioxane (10 mL), HCl / dioxane (4 M, 10 mL) was added. The mixture was stirred at 25°C for 16 hours. LC-MS confirmed 82% of the peaks at the desired mass. The reaction mixture was concentrated to obtain the residue, and the title compound (450 mg, crude, 2HCl) was obtained as a pale yellow solid.
[0433] MS(M+H)+ = 525.4
[0434] Step 4: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethyl)-1H-1,2,3-triazole-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 44)
[0435] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL), HATU (400 mg, 1.05 mmol), DIPEA (445.20 mg, 3.44 mmol, 600 μL) and 4-((2-(2-(4-((4-aminopiperidine-1-yl)methyl)-1H-1,2,3-triazole-1-yl)ethoxyethyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (350 mg, 585.78 μmol, 2HCl) were added. The mixture was stirred at 25°C for 16 hours. LC-MS confirmed a 46% peak at the desired mass. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic layer was washed with 90 mL (30 mL x 3) of brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was separated by preparative HPLC (column: 3_Phenomenex Luna C). 18 The sample was purified by a 75*30mm*3um (mobile phase: [water (0.1% TFA)-ACN]; B%: 32%~52%, 7 min, column temperature: 30°C) and then freeze-dried to obtain the title compound (101.3 mg, 0.0886 mmol, 20.62% yield, 95% purity, TFA) as a pale yellow solid. MS(M+H) + =972.7
[0436] 1 H NMR (400MHz, DMSO-d6) δ11.12(s, 1H), 9.95-9.72(m, 1H), 8.35-8.08(m, 5H), 7.58(t, J=7.8Hz, 1H), 7. 17-7.05(m, 2H), 6.56(s, 1H), 5.11-5.06(m, 1H), 4.88-4.79(m, 1H), 4.62(t, J=4.9Hz, 2H), 4.44-4.36( m, 2H), 4.13-4.06(m, 1H), 3.94-3.92(m, 2H), 3.91(s, 3H), 3.89-3.88(m, 2H), 3.68-3.60(m, 2H), 3.51- 3.43(m, 4H), 3.33(s, 3H), 3.12-2.91(m, 2H), 2.68-2.55(m, 2H), 2.16-1.83(m, 6H), 1.78-1.53(m, 8H).
[0437] Example 45: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(2-(2-(2-(2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazole-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0438] Based on the above reaction equation, the title compound (75.3 mg, 66.77 μmol, 15.54% yield, 94% purity, TFA) was obtained as a pale yellow solid by the same method as in the examples described above.
[0439] MS(M+H) + =1060.8
[0440] 1H NMR (400MHz, DMSO-d6) δ11.10(s, 1H), 9.91 -9.71(m, 1H), 8.32-8.09(m, 5H), 7.62-7.53(m, 1H), 7.16-7.04(m, 2H), 6.60(s, 1H), 5.06(dd, J =5.2, 13.0Hz, 1H), 4.89-4.79(m, 1H), 4.62-4.55(m, 2H), 4.48-4.39(m, 2H), 4.09(t, J=13.9Hz, 1H), 3.94-3.92(m, 2H), 3.91-3.89(m, 3H), 3.86-3.82(m, 2H), 3.64-3.61(m, 2H), 3.56-3.44(m, 12H), 3.34(s, 3H), 3.14-2.90(m, 2H), 2.67-2.53(m, 2H), 2.11-1.91(m, 6H), 1.78-1.55(m, 8H).
[0441] Example 46: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(4-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)-4-oxobutyl)-1H-1,2,3-triazole-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0442] Based on the above reaction equation, the title compound (42.5 mg, 36.85 μmol, 8.58% yield, 94% purity, TFA) was obtained as a white solid by the same method as in the examples described above.
[0443] MS(M+H) + =970.2
[0444] 1H NMR (400MHz, DMSO-d6)δ=11.15(s, 1H), 9.93-9.67(m, 2H), 8.39(d, J=8.2Hz, 1H), 8.30(d, J=5.8Hz, 1H), 8.28-8.17(m, 2H), 8.11 (s, 1H), 7.84(t, J=7.8Hz, 1H), 7.64(d, J=7.4Hz, 1H), 7.23-7.15(m, 1H), 5.13(dd, J=5.2, 12.8Hz, 1H), 4.85-4.79(m, 1H), 4.52( t, J=7.0Hz, 2H), 4.46-4.39(m, 2H), 4.13-4.09(m, 1H), 4.08(t, J=13.8Hz, 2H), 4.02-3.93(m, 2H), 3.91(s, 3H), 3.33(s, 3H), 3.3 0-3.03(m, 4H), 2.65-2.53(m, 4H), 2.22-2.12(m, 2H), 2.10-2.00(m, 2H), 2.00-1.90(m, 2H), 1.80-1.68(m, 4H), 1.66-1.56(m, 4H)
[0445] Example 47: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(2-(2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)acetamido)ethyl)-1H-1,2,3-triazole-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0446] Based on the above reaction equation, the title compound (7.5 mg, 7.46 μmol, 3.19% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0447] MS(M+H) + =985.3
[0448] 1H NMR (400MHz, CDCl3)δ=8.45-8.28(m, 1H), 8.13-7.97(m, 2H), 7.58-7.48(m, 2H), 7.26-7.22(m, 1H), 7.18(d, J=7.3Hz, 1H), 7.15-7.10(m, 1H), 7.07(d, J=7.3Hz, 1H), 6.87-6.74(m, 1H), 5.02-4.81(m, 2H), 4.63-4.45(m , 2H), 4.41-5.36(m, 1H), 4.34-4.21(m, 2H), 4.13-4.02(m, 1H), 4.00-3.86(m, 6H), 3.85-3.71(m, 3H), 3.44- 3.41(m, 3H), 2.91-2.71(m, 3H), 2.28-2.22(m, 2H), 2.24-2.07(m, 3H), 1.80-1.78(m, 4H), 1.68-1.59(m, 7H).
[0449] Example 48: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(((1R,2S)-2-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)cyclopropyl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0450] Step 1: Synthesis of (1R,2S)-2-carbamoylcyclopropanecarboxylic acid (2)
[0451] A solution of 3-oxabicyclo[3.1.0]hexane-2,4-dione (5 g, 44.61 mmol) in NH3·H2O (50 mL) was stirred in a 100 mL sealed tube at 20 °C for 16 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 1:2) confirmed that the starting material was completely consumed and that a novel spot was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (6.2 g, crude) as an off-white solid.
[0452] 1 H NMR (400MHz, DMSO-d6) δ=8.37(br s, 1H), 6.82-6.38(m, 2H), 1.71-1.63(m, 1H), 1.59-1.50(m, 1H), 1.20-1.10(m, 1H), 1.10-1.00(m, 1H)
[0453] Step 2: Synthesis of benzyl(((1S,2R)-2-(hydroxymethyl)cyclopropyl)methyl)carbamate (3)
[0454] To a mixture of (1R,2S)-2-carbamoylcyclopropanecarboxylic acid (6.2 g, 48.02 mmol) in THF (100 mL), BH3·Me2S (10 M, 48.02 mL) was added dropwise under N2 at 20 °C, and the resulting mixture was stirred at 60 °C for 16 hours. The reaction mixture was quenched with HCl (1 N) and stirred at 60 °C for 4 hours. Sodium hydroxide (2 M, 72.03 mL) and CbzCl (12.29 g, 72.03 mmol, 10.24 mL) were added to the reaction mixture at 20 °C, and the mixture was stirred at 60 °C for 12 hours. LC-MS confirmed that all starting materials were completely consumed and that a peak was detected at the desired mass. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The crude product was purified by reverse-phase HPLC (method: FA), followed by lyophilization to obtain the title compound (5.4 g, 22.49 mmol, 46.84% yield, 98% purity) as a white oily substance. MS(M+Na) + =258.4
[0455] Step 3: Synthesis of ((1R,2S)-2-((((benzyloxy)carbonyl)amino)methyl)cyclopropyl)methyl 4-methylbenzenesulfonic acid (4)
[0456] A mixture of benzyl (((1S,2R)-2-(hydroxymethyl)cyclopropyl)methyl)carbamate (2.7g, 11.48 mmol) in DCM (30 mL) is mixed with TEA. (3.48 g, 34.43 mmol, 4.79 mL) and TosCl (3.28 g, 17.21 mmol) were added in one step at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 5 / 1~0 / 1) to obtain the title compound (2.4 g, 6.16 mmol, 53.70% yield) as a yellow oil. MS(M+Na) + =412.1
[0457] Step 4: Synthesis of tert-butyl N-[1-[[2-(benzyloxycarbonylaminomethyl)cyclopropyl]methyl]-4-piperidyl]carbamate (5)
[0458] A mixture of ((1R,2S)-2-((((benzyloxy)carbonyl)amino)methyl)cyclopropyl)methyl 4-methylbenzenesulfonic acid and tert-butyl N-(4-piperidyl)carbamate (1.60 g, 8.01 mmol) in dioxane (30 mL) was mixed with DIPEA (2.39 g, 18.49 mmol, 3.22 mL) and NaI (184.74 mg, 1.23 mmol) at 20 °C, and the resulting mixture was stirred at 80 °C for 16 hours. LC-MS was used to analyze the ((1R,2S)-2-((((benzyloxy We confirmed that carbonyl)amino)methyl)cyclopropyl)methyl-4-methylbenzenesulfonic acid was completely consumed and that one peak with the desired mass was detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1~0 / 1) to obtain the title compound (1.4 g, 3.15 mmol, 51.15% yield, 94% purity) as a white oily substance. MS(M+H) + =418.3
[0459] Step 5: Synthesis of tert-butyl(1-(((1R,2S)-2-(aminomethyl)cyclopropyl)methyl)piperidine-4-yl)carbamate (6)
[0460] A solution of tert-butyl N-[1-[[2-(benzyloxycarbonylaminomethyl)cyclopropyl]methyl]-4-piperidyl]carbamate (1.40 g, 3.35 mmol) in methanol (15 mL) was mixed with Pd / C (0.2 g, 10% purity) under N2. The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 20°C for 16 hours under H2 (15 psi). LCMS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was methanol. The solution was diluted with (60 mL) and filtered. The filtrate was concentrated under vacuum to obtain the title compound (920 mg, crude) as a white oily substance. MS(M+H) + =284.3
[0461] Step 6: Synthesis of tert-butyl(1-(((1R,2S)-2-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)cyclopropyl)methyl)piperidine-4-yl)carbamate (8)
[0462] To a mixture of 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione (0.8 g, 2.90 mmol) and tert-butyl(1-(((1R,2S)-2-(aminomethyl)cyclopropyl)methyl)piperidine-4-yl)carbamate (902.90 mg, 3.19 mmol) in DMSO (5 mL), TEA (879.20 mg, 8.69 mmol, 1.21 mL) was added all at once at 20°C, and the resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindorin-1,3-dione was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic layer was washed with brine (15 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1 to 1 / 4) to obtain the title compound (850 mg, 1.56 mmol, 53.84% yield, 99% purity) as a green solid. MS(M+H) + =540.2
[0463] Step 7: Synthesis of 4-((((1S,2R)-2-((4-aminopiperidine-1-yl)methyl)cyclopropyl)methyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (9)
[0464] To a mixture of tert-butyl(1-(((1R,2S)-2-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)cyclopropyl)methyl)piperidine-4-yl)carbamate (850 mg, 1.58 mmol) in dioxane (4 mL), HCl / dioxane (4 M, 8 mL, 20.32 eq) was added in one step at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (760 mg, crude, HCl) as a green solid. MS(M+H)+ =440.3
[0465] Step 8: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(((1R,2S)-2-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)methyl)cyclopropyl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 48)
[0466] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL), HATU (163.39 mg, 429.71 μmol) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) were added. The mixture was stirred at 20°C for 10 minutes, and a solution of 4-((((1S,2R)-2-((4-aminopiperidine-1-yl)methyl)cyclopropyl)methyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (226.63 mg, crude, HCl) in DMF (4 mL) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) was added dropwise at 20°C. The resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (12 mL) and extracted with ethyl acetate (12 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Phenomenex luna C). 18 Purified by HPLC (150*40mm*15um; mobile phase: [water (0.1% TFA)-ACN]; B%: 30%~40%, 10 min), followed by preparative HPLC (column: 3_Phenomenex Luna C)18 After purification using a 75*30mm*3um mobile phase (water (0.1% TFA)-ACN), the sample was freeze-dried to obtain the title compound (104 mg, 100.79 μmol, 23.45% yield, 97% purity, TFA) as a yellow solid.
[0467] MS(M+H) + =887.2
[0468] 1 H NMR (400MHz, CD3OD) δ=8.33(d, J=13.6Hz, 1H), 8.21(s, 1H), 7.64-7.57(m, 1H), 7.38-7.34(m, 1H), 7.16-7.08(m, 2 H), 5.12-5.06(m, 1H), 5.04-4.91(m, 2H), 4.25-4.14(m, 1H), 4.09(t, J=13.0Hz, 2H), 4.00(s, 3H), 3.79(d, J=12.4H) z, 1H), 3.60-3.45(m, 2H), 3.40(s, 3H), 3.29-3.12(m, 4H), 2.94-2.82(m, 1H), 2.79-2.66(m, 2H), 2.38-2.19(m, 2H) , 2.17-2.05(m, 3H), 1.99-1.67(m, 8H), 1.64-1.53(m, 1H), 1.36-1.26(m, 1H), 1.17-1.11(m, 1H), 0.59-0.51(m, 1H)
[0469] Example 49: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-((2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethyl)(methyl)amino)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0470] Step 1: Synthesis of N-(2-(2-hydroxyethoxy)ethyl)formamide (2)
[0471] A solution of 2-(2-aminoethoxy)ethanol (7 g, 66.58 mmol, 6.67 mL) in ethyl formate (32.24 g, 435.15 mmol, 35.00 mL) was stirred at 90°C for 12 hours. The reaction was confirmed to be complete by LC-MS. The mixture was concentrated with a pilot (0.5 g scale) to obtain the title compound (8 g, 60.08 mmol, 90.24% yield) as a yellow oil.
[0472] MS(M+H) + =134.1
[0473] Step 2: Synthesis of 2-(2-(methylamino)ethoxy)ethanol (3)
[0474] A mixture of LAH (2.57 g, 67.60 mmol) in THF (100 mL) was mixed with a solution of N-(2-(2-hydroxyethoxy)ethyl)formamide (6 g, 45.06 mmol) in THF (10 mL), and the resulting mixture was stirred at 20°C for 3 hours. The completion of the reaction was confirmed by TLC (ethyl acetate / methanol = 10 / 1). The mixture was quenched in the following order: water (2.5 mL), 15% sodium hydroxide in 2.5 mL of water, and water (7.5 mL). The mixture was stirred at 25°C for 30 minutes, and the mixture was filtered. The filtrate was concentrated under vacuum to obtain the title compound (9.7 g, crude) as a yellow oil.
[0475] Step 3: Synthesis of benzyl(2-(2-hydroxyethoxy)ethyl)(methyl)carbamate (4)
[0476] A mixture of 2-(2-(methylamino)ethoxy)ethanol (9.7 g, 81.40 mmol) and potassium carbonate (22.50 g, 162.80 mmol) in THF (40 mL) and water (20 mL) was mixed with CbzCl (20.83 g, 122.10 mmol, 17.36 mL), and the resulting mixture was stirred at 20 °C for 12 hours. The completion of the reaction was confirmed by LC-MS. The mixture was combined with a pilot sample (1.3 g scale), water (100 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain the title compound (7.6 g, 30.00 mmol, 36.86% yield) as a yellow oil.
[0477] Step 4: Synthesis of 2-(2-(((benzyloxy)carbonyl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonic acid (5)
[0478] To a mixture of benzyl(2-(2-hydroxyethoxy)ethyl)(methyl)carbamate (7.6 g, 30.00 mmol) and TEA (9.11 g, 90.01 mmol, 12.53 mL) in DCM (50 mL), TosCl (8.58 g, 45.01 mmol) was added, and the resulting mixture was stirred at 20°C for 12 hours. The completion of the reaction was confirmed by LC-MS. The mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain the title compound (7.6 g, 14.92 mmol, 49.73% yield, 80% purity) as a yellow oil. MS(M+H) + =408.1
[0479] Step 5: Synthesis of benzyl(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethyl)(methyl)carbamate (6)
[0480] 2-(2-(((benzyloxy)carbonyl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonic acid (4g, 7.85 mmol) in dioxane (20mL) A mixture of (80% purity) and tert-butylpiperidine-4-ylcarbamate (2.36 g, 11.78 mmol) was mixed with NaI (117.71 mg, 785.31 μmol) and DIPEA (2.03 g, 15.71 mmol, 2.74 mL). The resulting mixture was stirred at 80°C for 12 hours. The completion of the reaction was confirmed by LC-MS. The mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (ethyl acetate) to obtain the title compound (1.8 g, 4.05 mmol, 51.57% yield, 98% purity) as a yellow oil. MS(M+H) + =436.1
[0481] Step 6: Synthesis of tert-butyl(1-(2-(2-(methylamino)ethoxy)ethyl)piperidine-4-yl)carbamate (7)
[0482] To a solution of benzyl(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethyl)(methyl)carbamate (1.8 g, 4.13 mmol) in methanol (20 mL), Pd / C (0.2 g, 4.13 mmol, 10% purity) was added, and the resulting mixture was stirred at 20 °C for 12 hours under H2 (15 psi). The completion of the reaction was confirmed by LC-MS. The mixture was filtered and concentrated to obtain the title compound (1.2 g, 3.98 mmol, 96.33% yield) as a brown oil. MS(M+H) + =302.2
[0483] Step 7: Synthesis of tert-butyl N-[1-[2-[2-[2-(benzyloxycarbonylamino)ethyl-methyl-amino]ethoxy]ethyl]-4-piperidyl]carbamate (9)
[0484] A solution of tert-butyl(1-(2-(2-(methylamino)ethoxy)ethyl)piperidine-4-yl)carbamate (1 g, 3.32 mmol) and benzyl(2-bromoethyl)carbamate (1.03 g, 3.98 mmol) in dioxane (4 mL) was mixed with NaI (49.73 mg, 331.76 μmol) and DIPEA (857.55 mg, 6.64 mmol, 1.16 mL). The resulting mixture was stirred at 80°C for 12 hours. Reaction completion was confirmed by LC-MS. The mixture was concentrated along with a pilot (0.2 g scale) sample. The residue was purified by reverse-phase column chromatography (method: FA, MeCN / water) to obtain the title compound (0.9 g, 1.77 mmol, 53.28% yield, 94% purity) as a red oil. MS(M+H) + =479.4
[0485] Step 8: Synthesis of tert-butyl(1-(2-(2-((2-aminoethyl)(methyl)amino)ethoxy)ethyl)piperidine-4-yl)carbamate (10)
[0486] To a solution of tert-butyl N-[1-[2-[2-[2-(benzyloxycarbonylamino)ethyl-methyl-amino]ethoxy]ethyl]-4-piperidyl]carbamate (0.9 g, 1.88 mmol) in methanol (10 mL), Pd / C (0.1 g, 10% purity) was added, and the resulting mixture was stirred at 20°C for 12 hours under H2 (15 psi). The completion of the reaction was confirmed by LC-MS. The mixture was filtered and concentrated to obtain the title compound (0.5 g, 1.45 mmol, 77.19% yield) as a yellow oil. MS(M+H) + =345.2
[0487] Step 9: Synthesis of tert-butyl(1-(2-(2-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethyl)(methyl)amino)ethoxy)ethyl)piperidine-4-yl)carbamate (11)
[0488] 2-(2,6-dioxo-3-piperidyl)-4-fluoro- in DMSO (5 mL) To a solution of isoindoline-1,3-dione (0.3 g, 1.09 mmol) and tert-butyl (1-(2-(2-((2-aminoethyl)(methyl)amino)ethoxy)ethyl)piperidine-4-yl)carbamate (340 mg, 986.96 μmol), TEA (329.70 mg, 3.26 mmol, 453.51 μL) was added, and the resulting mixture was stirred at 60°C for 12 hours. The completion of the reaction was confirmed by TLC (ethyl acetate / methanol = 10 / 1). The mixture was combined with a pilot (50 mg scale), water (30 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate / methanol = 10 / 1) to obtain the title compound (0.12 g, 193.77 μmol, 17.84% yield, 97% purity) as a yellow oil. MS(M+H) + =601.3
[0489] Step 10: Synthesis of 4-((2-((2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)(methyl)amino)ethyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (12)
[0490] A mixture of tert-butyl(1-(2-(2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethyl)(methyl)amino)ethoxy)ethyl)piperidine-4-yl)carbamate (120 mg, 199.77 μmol) in dioxane (5 mL) was mixed with HCl / dioxane (4 M, 5 mL), and the resulting mixture was stirred at 20 °C for 1 hour. The completion of the reaction was confirmed by LC-MS. The mixture was concentrated to obtain the title compound (110 mg, crude, HCl) as a yellow oil.
[0491] Step 11: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-((2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)amino)ethyl)(methyl)amino)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 49)
[0492] 4-((2-((2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)(methyl)amino)ethyl)amino)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (110 mg, 204.82 μmol, HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8 To a solution of ,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (95.33 mg, 204.82 μmol), HATU (155.76 mg, 409.65 μmol) and DIPEA (105.89 mg, 819.29 μmol, 142.71 μL) were added, and the mixture was stirred at 20°C for 1 hour. The completion of the reaction was confirmed by LC-MS. Water (20 mL) was poured over the mixture, and it was extracted with ethyl acetate (20 mL x 3). The combined organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Unisil 3-100C). 18The compound was purified by (μLtra 150*50mm*3um; mobile phase: [water (0.225% FA)-ACN]; B%: 30%~50%, 10 min), and the eluent was lyophilized. The solid was dissolved in DMF, and the pH of the mixture was adjusted to 8 with DIPEA. The resulting mixture was re-purified by preparative HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10mM ammonium bicarbonate)-ACN]; B%: 43%~76%, 8 min), and then by preparative TLC (ethyl acetate / methanol = 6 / 1) to obtain the title compound (10.7 mg, 10.61 μmol, 15.03% yield, 94% purity) as a yellow solid.
[0493] MS(M+H) + =948.3
[0494] 1 H NMR (400MHz, DMSO-d6)δ= 11.09(s, 1H), 8.30(s, 1H), 8.24(d, J=13.2Hz, 1H), 8.03(s, 1H), 7.86-7.84(m, 1H), 7.58-7.56(m, 1H), 7.18(d, J=7. 2Hz, 1H), 7.08(d, J=8.8Hz, 1H), 7.02(d, J=6.8Hz, 1H), 6.75-6.71(m, 1H), 5.07-5.04(m, 1H), 4.84-4.79(m, 1H), 4.1 1-4.03(m, 3H), 3.91(s, 3H), 3.73-3.65(m, 2H), 3.52-3.45(m, 4H), 2.91-2.80(m, 3H), 2.65-2.58(m, 2H), 2.58-2.55 (m, 4H), 2.45-2.42(m, 2H), 2.26(s, 3H), 2.01-1.98(m, 6H), 1.77-1.72(m, 5H), 1.70-1.60(m, 4H), 1.49-1.41(m, 3H).
[0495] Example 50: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-5-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0496] Based on the above reaction equation, the title compound (69 mg, 69.37 μmol, 18.18% yield, 94% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0497] MS(M+H) + =935.4.
[0498] 1 H NMR (400MHz, CDCl3) δ=8.29(d, J=14.9Hz, 1H), 8.00(s, 1H), 7.74(s, 1H), 7.54(d, J=8.3Hz, 1H), 7.48(d, J=7.2Hz, 1H), 6.97-6.91(m, 1H), 6.71(dd, J=2.1, 8.3Hz, 1H), 6.68-6.60(m, 1H), 5.33-5.24(m, 1H), 4.88-4.72(m, 2H), 4.0 4-3.92(m, 1H), 3.90(s, 3H), 3.87-3.80(m, 2H), 3.67(t, J=5.0Hz, 2H), 3.62-3.53(m, 6H), 3.37-3.30(m, 5H), 2.91 -2.61(m, 5H), 2.56(t, J=5.4Hz, 2H), 2.27-2.11(m, 2H), 2.08-1.95(m, 5H), 1.77-1.63(m, 5H), 1.55-1.47(m, 3H).
[0499] Example 51: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-5-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0500] Based on the above reaction equation, the title compound (45.6 mg, 36.89 μmol (TFA salt) was obtained as a brown solid with a yield of 9.03% and a purity of 92%.
[0501] MS(M+H) + =1023.3.
[0502] 1 H NMR (400MHz, CD3OD) δ=8.29(d, J=13.8Hz, 1H), 8.23-8.15(m, 1H), 7.55-7.53(m, 1H), 7.36(d, J=6.7Hz, 1H), 7. 01(d, J=1.9Hz, 1H), 6.83(dd, J1=8.4Hz, J2=2.1Hz, 1H), 5.05-5.00(m, 2H), 4.09(t, J=13.1Hz, 3H), 4.01-3.95 (m, 3H), 3.83-3.79(m, 2H), 3.74-3.62(m, 16H), 3.53-3.46(m, 1H), 3.44-3.35(m, 7H), 3.19-3.13(m, 1H), 2.92 -2.81(m, 1H), 2.75-2.70(m, 1H), 2.35-2.21(m, 2H), 2.18-2.02(m, 4H), 1.98-1.77(m, 4H), 1.78-1.67(m, 4H).
[0503] Examples 52 and 53: 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(15(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadeca-14-in-1-yl)piperidine-4-yl)-2-fluoro-5-methyl Synthesis of xybenzamide and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(15(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka] [ka]
[0504] Step 1: Synthesis of 4-iodoisobenzofuran-1,3-dione(2)
[0505] A mixture of 3-iodophthalic acid (25 g, 85.61 mmol) in Ac2O (100 mL) was stirred at 80°C for 16 hours. The completion of the reaction was confirmed by LC-MS. The reaction mixture was concentrated under vacuum. The crude product was washed with petroleum ether (40 mL x 5) and dried under vacuum to obtain the title compound (22.4 g, crude) as a white solid. MS(M+Na) + =296.2
[0506] Step 2: Synthesis of 2-(2,6-dioxopiperidine-3-yl)-4-iodoisoindoline-1,3-dione(3)
[0507] To a solution of 4-iodoisobenzofuran-1,3-dione (10 g, 36.49 mmol) in acetic acid (100 mL), 3-aminopiperidine-2,6-dione (6.61 g, 40.14 mmol, HCl) and NaOAc (3.59 g, 43.79 mmol) were added all at once, and the mixture was stirred at 140 °C for 16 hours. The completion of the reaction was confirmed by TLC (ethyl acetate). The reaction mixture was filtered, the cake was washed with water (100 mL x 3), and dried under vacuum to obtain the title compound (13 g, crude) as a black solid.
[0508] 1 H NMR (400MHz, DMSO-d6) δ=11.2(s, 1H), 8.27(d, J=7.6, 1H), 7.92(d, J=7.2, 1H), 7.58(d , J=7.6, 1H), 5.18-5.14(m, 1H), 2.96-2.83(m, 1H), 2.63-2.53(m, 2H), 2.09-2.05(m, 1H).
[0509] Step 3: Synthesis of 2-(2,6-dioxopiperidine-3-yl)-4-(1-hydroxy-3,6,9,12-tetraoxapentadeca-14-in-15-yl)isoindoline-1,3-dione (4)
[0510] A mixture of 2-(2,6-dioxopiperidine-3-yl)-4-iodoisoindoline-1,3-dione (2 g, 5.21 mmol) and 2-[2-[2-(2-prop-2-inoxyethoxy)ethoxy]ethoxy]ethanol (1.81 g, 7.81 mmol) in DMF (20 mL) was mixed with Pd(PPh3)2Cl2 (380.97 mg, 520.67 μmol), CuI (198.32 mg, 1.04 mmol), and TEA (5.27 g, 52.07 mmol, 7.25 mL). The mixture was stirred at 60°C for 0.5 hours under microwave and N2 conditions. The completion of the reaction was confirmed by LC-MS. The reaction mixture was concentrated. The residue was purified by silica gel column (ethyl acetate) to obtain the title compound (2 g, 4.09 mmol, 78.64% yield) as a yellow oily substance. MS(M+H) + =489.1
[0511] Step 4: Synthesis of 15-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadeca-14-in-1-yl4-methylbenzenesulfonic acid (5)
[0512] To a mixture of 2-(2,6-dioxopiperidine-3-yl)-4-(1-hydroxy-3,6,9,12-tetraoxapentadeca-14-in-15-yl)isoindorin-1,3-dione (2 g, 4.09 mmol) and TEA (1.24 g, 12.28 mmol, 1.71 mL) in DCM (10 mL), TosCl (1.17 g, 6.14 mmol) was added, and the mixture was stirred at 20 °C for 16 hours. The completion of the reaction was confirmed by LC-MS. The reaction mixture was concentrated. The residue was purified on a silica gel column (ethyl acetate) to obtain the title compound (1.8 g, 2.49 mmol, 60.88% yield, 89% purity) as a yellow oil. MS(M+H) + =643.1
[0513] Step 5: Synthesis of tert-butyl(1-(15(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadeca-14-in-1-yl)piperidine-4-yl)carbamate (6)
[0514] To a solution of 15-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadeca-14-in-1-yl-4-methylbenzenesulfonic acid (1 g, 1.56 mmol) and tert-butylpiperidine-4-yl carbamate (467.45 mg, 2.33 mmol) in dioxane (10 mL), NaI (23.32 mg, 155.60 μmol) and DIPEA (402.21 mg, 3.11 mmol, 542.06 μL) were added, and the resulting mixture was stirred at 80°C for 12 hours. The completion of the reaction was confirmed by TLC (ethyl acetate / methanol = 10 / 1). The mixture was concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate / methanol = 10 / 1) to obtain the title compound (0.9 g, 1.29 mmol, 82.78% yield, 96% purity) as a yellow oily substance.
[0515] MS(M+H) + =671.2
[0516] Step 6: Synthesis of 4-(1-(4-aminopiperidine-1-yl)-3,6,9,12-tetraoxapentadeca-14-in-15-yl)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (7)
[0517] A solution of tert-butyl(1-(15-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadeca-14-in-1-yl)piperidine-4-yl)carbamate (0.9 g, 1.34 mmol) in dioxane (10 mL) is prepared by adding HCl / dioxane (4 M, 10 mL). The mixture was then stirred at 25°C for 2 hours after adding the ), and the reaction was confirmed to be complete by LC-MS. The mixture was concentrated under vacuum to obtain the title compound (0.8 g, 1.32 mmol, 98.21% yield, HCl) as a yellow oil.
[0518] MS(M+H) + = 571.2
[0519] Step 7: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(15-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadeca-14-in-1-yl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 52)
[0520] 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimide[4,5 -b) [1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (300 mg, 644.57 μmol), 4-(1-(4-aminopiperidine-1-yl)-3,6,9,12-tetraoxapentadeca-14-in-15-yl)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (391.32 mg, 644.57 μmol, HCl) and HATU (490.17 mg, 1.29 mmol) were mixed with DIPEA (249.91 mg, 1.93 mmol, 336.81 μL), and the resulting mixture was stirred at 25°C for 12 hours. The completion of the reaction was confirmed by LC-MS. Water (20 mL) was added to the mixture and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was separated and subjected to preparative HPLC (column: Phenomenex Luna C). 18 The sample was purified using a 150*40mm*15um mobile phase (water (0.225% FA)-ACN), with a B% of 27% to 57% concentration for 10 minutes. The eluent was then freeze-dried to obtain the title compound (229.4 mg, 218.57 μmol, 33.91% yield, 97% purity) as a yellow solid.
[0521] MS(M+H) + =1018.6
[0522] 1H NMR (400MHz, DMSO-d6)δ=11.15(s, 1H), 9.38-9.09(m, 1H), 8.30(s, 1H), 8.28-8.08(m, 3H), 7.94-7.83(m, 3H), 7.26-7.1 4(m, 1H), 5.16(dd, J=5.3, 12.8Hz, 1H), 4.83(t, J=7.9Hz, 1H), 4.55-4.47(m, 2H), 4.10(t, J=13.8Hz, 2H), 4.04-3.96(m, 1 H), 3.94-3.89(m, 3H), 3.80-3.70(m, 4H), 3.64-3.53(m, 12H), 3.34(s, 3H), 3.27(d, J=4.6Hz, 2H), 3.12(d, J=12.0Hz, 1H ), 2.95-2.85(m, 1H), 2.65-2.54(m, 2H), 2.10-2.04(m, 2H), 1.98(d, J=5.4Hz, 3H), 1.87-1.70(m, 4H), 1.57-1.47(m, 4H).
[0523] Step 8: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(15-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 53)
[0524] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(15(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)-3,6,9,12-tetraoxapentadeca-14-in-1-yl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (70 mg, 68.76 μmol) in ethyl acetate (5 mL), Pd / C (20 mg, 10% purity) was added, and the resulting mixture was stirred at 25 °C for 12 hours under H2 (15 psi). Completion of the reaction was confirmed by LC-MS. The mixture was filtered together with a pilot (50 mg scale). The filtrate is concentrated, and the residue is separated by HPLC (column: Phenomenex Synergi C). 18 The sample was purified using a 150*25mm*10um mobile phase (water (0.225% FA)-ACN), with a B% of 19% to 49% (min), and the eluent was freeze-dried to obtain the title compound (23 mg, 21.60 μmol, 31.42% yield, 96% purity, FA salt) as a white solid.
[0525] MS(M+H) + =1022.7
[0526] 1H NMR (400MHz, DMSO-d6)δ=11.12(s, 1H), 8.30(s, 1H), 8.24(t, J=6.6Hz, 2H), 8.03(s, 1H), 7.87(dd, J=3.3, 7.6Hz, 1H), 7. 80-7.73(m, 2H), 7.72-7.69(m, 1H), 7.19(d, J=6.8Hz, 1H), 5.18-5.04(m, 1H), 4.87-4.76(m, 1H), 4.08(t, J=13.9Hz, 2H) , 3.91(s, 3H), 3.79-3.67(m, 1H), 3.53-3.48(m, 18H), 3.34(s, 3H), 3.10-3.03(m, 2H), 2.95-2.80(m, 4H), 2.65-2.53(m, 2H), 2.48-2.45(m, 2H), 2.11-2.03(m, 2H), 1.99-1.93(m, 2H), 1.89-1.82(m, 2H), 1.80-1.71(m, 4H), 1.61-1.52(m, 4H).
[0527] Example 54: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-((3-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)prop-2-in-1-yl)oxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide
[0528] [ka]
[0529] Based on the above reaction equation, the title compound (36.2 mg, 36.35 μmol, 6.29% yield, 98% purity, FA salt) was obtained as a white solid by the same method as in the examples described above.
[0530] MS(M+H) + =930.3.
[0531] 1H NMR (400MHz, CD3OD) δ=8.49(br s, 1H), 8.40(d, J=14.2Hz, 1H), 8.21(s, 1H), 7.86-7.74(m, 3H), 7.30(d, J=6.8Hz, 1H), 5.1 5-5.11(m, 1H), 4.98-4.96(m, 1H), 4.66-5.47(m, 2H), 4.55(s, 2H), 4.08-3.99(m, 5 H), 3.97-3.92(m, 1H), 3.91-3.74(m, 5H), 3.51(d, J=11.8Hz, 2H), 3.41(s, 3H), 3.2 5-3.16(m, 2H), 3.07-2.94(m, 2H), 2.94-2.83(m, 1H), 2.81-2.64(m, 2H), 2.18-2.09(m, 4H), 1.90-1.77(m, 4H), 1.76-1.65(m, 4H).
[0532] Example 55: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(3-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)propoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0533] Based on the above reaction equation, the title compound (118.1 mg, 121.39 μmol, 42.33% yield, 96% purity) was obtained as a white solid by the same method as in the examples described above.
[0534] MS(M+H) + =934.7.
[0535] 1H NMR (400MHz, DMSO-d6) δ=11.13(s, 1H), 8.30(s, 1H), 8.24(d, J=13.2Hz, 1H), 8.03(s, 1H), 7.90-7.84(m, 1H), 7.81-7.72 (m, 2H), 7.72-7.65(m, 1H), 7.18(d, J=6.8Hz, 1H), 5.16-5.08(m, 1H), 4.87-4.77(m, 1H), 4.07(t, J=13.8Hz, 2H), 3.91(s , 3H), 3.76-3.66(m, 1H), 3.54-3.45(m, 6H), 3.42(t, J=6.4Hz, 2H), 3.33(s, 3H), 3.07(t, J=7.6Hz, 2H), 2.97-2.77(m, 3H) ), 2.67-2.51(m, 3H), 2.45(t, J=5.8Hz, 2H), 2.06-1.93(m, 4H), 1.89-1.80(m, 2H), 1.79-1.68(m, 4H), 1.67-1.50(m, 6H).
[0536] Example 56: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0537] Step 1: Synthesis of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (2)
[0538] 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetic acid (6.95 g, 20.93 mmol) and 2-(2-aminoethoxy)ethanol (2.0 g, 19.02 mmol, 1. To a solution of 90 mL of EDCI (5.47 g, 28.53 mmol), HOBt (3.86 g, 28.53 mmol), and TEA (11.55 g, 114.14 mmol, 15.89 mL), the mixture was stirred at 25°C for 12 hours. The reaction was confirmed to be complete by LC-MS. The mixture was concentrated under vacuum. The residue was purified by reverse-phase HPLC (0.1% FA conditions, MeCN, water) to obtain the title compound (5.6 g, 13.35 mmol, 70.19% yield) as a gray solid. MS(M+H) + =420.0
[0539] Step 2: Synthesis of 2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)ethoxy)4-methylbenzenesulfonate ethyl (3)
[0540] To a solution of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (2.5 g, 5.96 mmol) in DCM (20 mL), TEA (723.84 mg, 7.15 mmol, 995.65 μL) and TosCl (1.36 g, 7.15 mmol) were added, and the mixture was stirred at 25°C for 12 hours. The completion of the reaction was confirmed by LC-MS. The mixture was filtered, the filtrate was diluted with water (20 mL), and extracted with DCM (50 mL x 3). The combined organic layers were diluted with brine (15 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (25g SepaFlash® Silica Flash Column, eluent 20-60% ethyl acetate / petroleum ether gradient @ 60 mL / min) to obtain the title compound (2.0 g, 4.77 mmol, 80.00% yield) as a gray solid. MS(M+H)+ =574.0
[0541] Step 3: Synthesis of tert-butyl(1-(2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)ethoxy)ethyl)piperidine-4-yl)carbamate (4)
[0542] To a solution of 2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)ethoxy)4-methylbenzenesulfonate ethyl (350 mg, 610.21 μmol) and tert-butylpiperidine-4-yl carbamate (183.32 mg, 915.32 μmol) in dioxane (5 mL), NaI (9.15 mg, 61.02 μmol) and DIPEA (78.87 mg, 610.21 μmol, 106.29 μL) were added, and the resulting mixture was stirred at 60°C for 24 hours. The completion of the reaction was confirmed by LC-MS. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, eluent 30-100% ethyl acetate / petroleum ether gradient @ 60 mL / min) to obtain the title compound (166 mg, 275.91 μmol, 45.22% yield) as a white solid.
[0543] MS(M+H) + =602.2
[0544] Step 4: Synthesis of N-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (5)
[0545] tert-butyl(1-(2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl) in dioxane (2 mL) A solution of oxy(acetamido)ethoxy(ethyl)piperidine-4-yl)carbamate (166 mg, 275.91 μmol) was mixed with HCl / dioxane (4 M, 3 mL), and the resulting mixture was stirred at 25°C for 2 hours. TLC (EA / methanol = 10:1) confirmed the completion of the reaction. The mixture was concentrated to obtain the title compound (150 mg, crude, HCl) as a white solid. MS(M+H) + =502.2
[0546] Step 5: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 56)
[0547] N-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (150 mg, 278.81 μmol, HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9- To a solution of tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (129.77 mg, 278.81 μmol), HATU (212.03 mg, 557.63 μmol) and DIPEA (108.10 mg, 836.44 μmol, 145.69 μL) were added, and the resulting mixture was stirred at 20°C for 1 hour. The completion of the reaction was confirmed by LC-MS. Water (20 mL) was added to the mixture, and it was extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Unisil 3-100 C). 18 The compound was purified using a μLtra 150*50mm*3um; mobile phase: [water (0.225% FA)-ACN]; B%: 28%~48%, 10 min), and the eluent was freeze-dried to obtain the title compound (114 mg, 118.93 μmol, 42.66% yield, 99% purity, FA) as a yellow solid.
[0548] MS(M+H) + =949.2.
[0549] 1H NMR (400MHz, DMSO-d6) δ=11.13(s, 1H), 9.19(br s, 1H), 8.31(s, 1H), 8.27(d, J=13.2Hz, 1H), 8.14(s, 1H), 8.06(s, 1H), 8.01(t, J=5.5Hz, 1H), 7.83(dd, J =7.5, 8.4Hz, 1H), 7.52(d, J=7.2Hz, 1H), 7.43(d, J=8.6Hz, 1H), 7.18(s, 1H), 5.18-5.06(m, 1H), 4.89-4.7 7(m, 3H), 4.09(t, J=13.9Hz, 2H), 3.92(s, 4H), 3.75(s, 2H), 3.55(t, J=5.4Hz, 2H), 3.43-3.37(m, 3H), 3.3 4(s, 3H), 3.29-3.05(m, 3H), 2.96-2.84(m, 1H), 2.65-2.52(m, 5H), 2.13-1.93(m, 5H), 1.82-1.55(m, 7H).
[0550] Example 57: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0551] Stage 1: 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-N-(2-(2-(2-(2-hydroxyethoxy Synthesis of ethoxyethyl acetamide (2)
[0552] To a solution of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetic acid (1.89 g, 5.69 mmol) and 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethanol (1 g, 5.17 mmol) in DMF (10 mL), EDCI (1.49 g, 7.76 mmol), HOBt (1.05 g, 7.76 mmol), and TEA (3.14 g, 31.05 mmol, 4.32 mL) were added, and the resulting mixture was stirred at 25 °C for 16 hours. The completion of the reaction was confirmed by LC-MS. The mixture was purified by reverse-phase column chromatography (0.1% FA conditions, MeCN / water) to obtain the title compound (1.63 g, 3.18 mmol, 61.45% yield, 99% purity) as a white solid. MS(M+H) + = 508.1
[0553] Step 2: Synthesis of 1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl4-methylbenzenesulfonic acid (3)
[0554] To a solution of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-N-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)acetamide (1.63 g, 3.21 mmol) in DCM (20 mL), TosCl (1.22 g, 6.42 mmol) and TEA (975.02 mg, 9.64 mmol, 1.34 mL) were added, and the mixture was stirred at 25°C for 40 hours. LC-MS confirmed that some of the starting material remained. TosCl (1.22 g, 6.42 mmol) and TEA (975.02 mg, 9.64 mmol, 1.34 mL) were added to the reaction mixture, and the resulting mixture was stirred at 25°C for 40 hours. LC-MS confirmed that the reaction was complete. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (silicon dioxide, ethyl acetate / methanol = 1 / 0 to 10 / 1) to obtain the title compound (1.56 g, 2.05 mmol, 63.86% yield, 87% purity) as a white solid. MS(M+H) + =662.1
[0555] Step 3: Synthesis of tert-butyl(1-(((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl)piperidine-4-yl)carbamate (4)
[0556] A solution of 1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl4-methylbenzenesulfonic acid (1.56 g, 2.36 mmol) and tert-butylpiperidine-4-yl carbamate (708.28 mg, 3.54 mmol) in dioxane (15 mL) was prepared by adding NaI (35.34 mg, 235.77 μmol) and DIPEA (304.71 mg, 2.36 mmol, 410.66 μL). The mixture was stirred at 80°C for 16 hours. The completion of the reaction was confirmed by LC-MS. Water (50 mL) was poured over the reaction mixture and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silicon dioxide, ethyl acetate / methanol = 1 / 0 to 10 / 1) to obtain the title compound (1.15 g, 1.57 mmol, 66.47% yield, 94% purity) as a red solid. MS(M+H) + =690.3
[0557] Stage 4: N-(2-(2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidine-3-yl) Synthesis of (5)-1,3-dioxoisoindoline-4-yl)oxy)acetamide
[0558] To a solution of tert-butyl(1-(1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl)piperidine-4-yl)carbamate (1.15 g, 1.67 mmol) in dioxane (10 mL), HCl / dioxane (4 M, 20.03 mL) was added, and the mixture was stirred at 25 °C for 16 hours. The completion of the reaction was confirmed by LC-MS. The mixture was concentrated under vacuum to obtain the title compound (1.1 g, crude, HCl) as a white solid. MS(M+H) + =590.2
[0559] Step 5: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecane-14-yl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 57)
[0560] N-(2-(2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (250 mg, 399.30 μmol, HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo) in DMF (4 mL) To a solution of -6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (185.84 mg, 399.30 μmol), HATU (303.65 mg, 798.60 μmol) and DIPEA (154.82 mg, 1.20 mmol, 208.65 μL) were added, and the resulting mixture was stirred at 20°C for 1 hour. The completion of the reaction was confirmed by LC-MS. Water (20 mL) was added to the mixture, and it was extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Unisil 3-100 C). 18 The compound was purified using a μLtra 150*50mm*3um; mobile phase: [water (0.225% FA)-ACN]; B%: 28%-48%, 10 min), and the eluent was freeze-dried to obtain the title compound (170.3 mg, 162.57 μmol, 40.71% yield, 99% purity, FA) as a yellow solid.
[0561] MS(M+H) + =1037.2.
[0562] 1 H NMR (400MHz, DMSO-d6)δ=11.13(s, 1H), 9.53-9.03(m, 1H), 8.31(s, 1H), 8.26(d, J=13.3Hz, 1H), 8.14(s, 1H), 8 .05(s, 1H), 7.99(t, J=5.0Hz, 1H), 7.81(t, J=8.0Hz, 1H), 7.51(d, J=7.1Hz, 1H), 7.40(d, J=8.4Hz, 1H), 7.19(br d, J=6.1Hz, 1H), 5.17-5.06(m, 1H), 4.88-4.76(m, 3H), 4.09(t, J=13.8Hz, 2H), 4.02-3.90(m, 4H), 3.73(s, 2H), 3.61-3.52(m, 9H) , 3.50-3.46(m, 3H), 3.34(s, 3H), 3.21-3.00(m, 4H), 2.97-2.85(m, 1H), 2.71-2.53(m, 5H), 2.13-1.90(m, 5H), 1.78-1.57(m, 7H).
[0563] Example 58: 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimide[4,5-b][1,4]diaze Synthesis of pin-2-yl)amino)-N-(1-(1-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)-2-oxo-6,9,12,15,18,21,24-heptaoxa-3-azahexacosan-26-yl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0564] Based on the above reaction equation, the title compound (43.2 mg, 31.25 μmol, 9.70% yield, 96% purity, TFA) was obtained as a white solid by the same method as in the examples described above.
[0565] MS(M+H) + =1213.7
[0566] 1 H NMR (400MHz, DMSO-d6)δ=11.11(s, 1H), 9.52-9.29(m, 1H), 8.30(s, 1H), 8.28-8.24(m, 1H), 8.23-8.19(m, 1H), 8.15(s, 1H), 8.00(t, J=5.6Hz, 1H), 7.81(dd, J=7.3, 8.4Hz, 1H), 7.50(d, J=7.2Hz, 1H), 7.40(d, J=8.4Hz, 1H), 7.25-7.16(m, 1H), 5.11(dd, J=5.4, 12.8Hz, 1H), 4.86- 4.78(m, 3H), 4.13-4.05(m, 4H), 3.91(s, 3H), 3.77-3.74(m, 2H), 3.61-3.58(m, 2H), 3.57(br d, J=1.7Hz, 2H), 3.53-3.47(m, 22H), 3.47-3.43(m, 2H), 3.33(s, 3H), 3.31(br d, J=5.7Hz, 2H), 3.29-3.25(m, 2H), 3.21-3.03(m, 2H), 2.94-2.85(m, 1H), 2.64-2.54 (m, 2H), 2.07-2.03(m, 2H), 1.99-1.95(m, 2H), 1.86-1.69(m, 4H), 1.68-1.57(m, 4H).
[0567] Example 59: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(5-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)pentyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0568] Step 1: Synthesis of benzyl(5-hydroxypentyl)carbamate (2)
[0569] To a solution of 5-aminopentan-1-ol (10 g, 96.93 mmol) and sodium bicarbonate (24.43 g, 290.80 mmol, 11.31 mL) in THF (100 mL) and water (20 mL), CbzCl (21.50 g, 126.02 mmol, 17.91 mL) was added at 0°C, and the reaction mixture was stirred at 20°C for 16 hours. One peak (60%) with the desired mass was confirmed by LC-MS. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 2). The combined organic layers were dried over sodium sulfate and filtered. The filtrate was concentrated under vacuum to obtain the title compound (22 g, crude) as a colorless oil.
[0570] Step 2: Synthesis of 5-(((benzyloxy)carbonyl)amino)pentyl 4-methylbenzenesulfonic acid (3)
[0571] To a solution of benzyl(5-hydroxypentyl)carbamate (10 g, 42.14 mmol) in DCM (120 mL), TEA (8.53 g, 84.28 mmol, 11.73 mL) and TosCl (10.44 g, 54.78 mmol) were added. The mixture was stirred at 20°C for 16 hours. One peak (72%) with the desired mass was confirmed by LC-MS. The reaction mixture was diluted with water (60 mL), and the DCM layer was separated. The organic layer was dried over sodium sulfate and filtered. The filtrate was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, PE / ethyl acetate = 10 / 1 to 3 / 1) to obtain the title compound (7.8 g, 17.53 mmol, 41.61% yield, 88% purity) as a colorless oil. MS(M+H) + =392.1
[0572] Step 3: Synthesis of tert-butyl N-[1-[5-(benzyloxycarbonylamino)pentyl]-4-piperidyl]carbamate (5)
[0573] To a solution of 5-(((benzyloxy)carbonyl)amino)pentyl 4-methylbenzenesulfonic acid (5 g, 12.77 mmol) in dioxane (60 mL), tert-butylpiperidine-4-ylcarbamate (3.33 g, 16.60 mmol), DIPEA (4.95 g, 38.32 mmol, 6.67 mL), and NaI (191.45 mg, 1.28 mmol) were added. The reaction mixture was heated at 60°C for 16 hours. The presence of the starting material was confirmed by LC-MS. An additional 3 g of the reaction mixture was added, and the reaction mixture was stirred at 60°C for 16 hours. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 2). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by reverse-phase HPLC (FA) to obtain the title compound (5 g, 11.92 mmol, 93.31% yield) as a white solid. MS(M+H) + =420.2
[0574] Step 4: Synthesis of tert-butyl(1-(5-aminopentyl)piperidine-4-yl)carbamate (6)
[0575] To a solution of tert-butyl N-[1-[5-(benzyloxycarbonylamino)pentyl]-4-piperidyl]carbamate (5 g, 11.92 mmol) in EtOH (60 mL), Pd / C (500 mg, 10% purity) was added under an N2 atmosphere. The reaction mixture was stirred at 20°C for 16 hours under H2 (15 psi). Consumption of the starting material was confirmed by TLC (DCM / methanol = 10 / 1). The reaction mixture was filtered, and the filtrate was concentrated under vacuum to obtain the title compound (3.4 g, crude) as a colorless oil.
[0576] Step 5: Synthesis of tert-butyl(1-(5-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)pentyl)piperidine-4-yl)carbamate (8)
[0577] HATU (686.61 mg, 1.81 mmol) and DIPEA (583.46 mg, 4.51 mmol, 786.34 μL) were added to a solution of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetic acid (500 mg, 1.50 mmol) and tert-butyl(1-(5-aminomethyl)piperidine-4-yl)carbamate (515.42 mg, 1.81 mmol) in DMF (8 mL). The reaction mixture was stirred at 20 °C for 16 hours. One major peak with the desired mass was identified by LC-MS. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum to obtain the title compound (1 g, crude) as a brown oil. MS(M+H) + =600.2
[0578] Step 6: Synthesis of N-(5-(4-aminopiperidine-1-yl)pentyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (9)
[0579] tert-butyl(1-(5-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)pentyl)piperidine-4-yl)carbamate (1 g, 1.67 mmol) was dissolved in HCl / dioxane (4 M, 416.89 μL), and the reaction mixture was stirred at 15°C for 1 hour. LC-MS confirmed a single major peak with the desired mass. The reaction mixture was concentrated under vacuum, and the title compound (1 g, crude, HCl salt) was obtained as a brown oily substance. MS(M+H) + =500.4
[0580] Step 7: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(5-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)pentyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 59)
[0581] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (250 mg, 537.14 μmol) in DMF (4 mL), HATU (204.24 mg, 537.14 μmol) and DIPEA (138.84 mg, 1.07 mmol, 187.12 μL) were added. The mixture was stirred at 20°C for 10 minutes, and a solution of N-(5-(4-aminopiperidine-1-yl)pentyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (575.84 mg, 1.07 mmol, HCl salt) in DMF (4 mL) and DIPEA (138.84 mg, 1.07 mmol, 187.12 μL) was added. The resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic layer was washed with brine (15 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Phenomenex luna C). 18 The sample was purified using a 150*40mm*15um mobile phase (water (0.225% FA)-ACN); B%: 18%~48%, 10 min), and the eluent was freeze-dried to obtain the title compound (82.2 mg, 78.12 μmol, 14.54% yield, 90% purity, FA salt) as a white solid.
[0582] MS(M+H)+ =946.7
[0583] 1 H NMR (400MHz, CD3OD) δ=8.41(d, J=14.0Hz, 1H), 8.21(s, 1H), 7.83(dd, J=7.4, 8.4Hz, 1H), 7.56(d, J=7.0Hz, 1H), 7.46(d, J=8.5Hz, 1H), 7.33(d, J=6.6Hz, 1H), 5.14(dd, J=5.6, 12.4Hz, 1H), 4.93(br d, J=8.4Hz, 1H), 4.78(s, 2H), 4.18-4.00(m, 3H), 3.99(s, 3H), 3.52-3.43(m, 2H), 3.40(s, 3H), 3 .39-3.35(m, 2H), 3.03-2.67(m, 7H), 2.23-2.06(m, 5H), 1.91-1.63(m, 12H), 1.49-1.39(m, 2H).
[0584] Example 60: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-((7-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)amino)-3-oxopropyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0585] Step 1: Synthesis of benzyl 3-bromopropanoate (2)
[0586] To a mixture of 3-bromopropanoic acid (5 g, 32.69 mmol, 3.38 mL) and phenylmethanol (4.59 g, 42.49 mmol, 4.42 mL) in hexane (100 mL), TsOH (281.42 mg, 1.63 mmol) was added all at once at 20°C, and the resulting mixture was stirred at 90°C for 16 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 5:1) confirmed that the starting material had been completely consumed and two novel spots were detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to obtain the title compound (7.8 g, 32.09 mmol, 98.17% yield) as a white oily substance.
[0587] 1 H NMR (400MHz, CDCl3)δ=7.44-7.35(m, 5H), 5.21(s, 2H), 3.62(t, J=6.8Hz, 2H), 2.99(t, J=6.8Hz, 2H)
[0588] Step 2: Synthesis of benzyl 3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)bromopropanoate (3)
[0589] A mixture of benzyl 3-bromopropanoate (7.8 g, 32.09 mmol) and tert-butyl N-(4-piperidyl)carbamate (7.71 g, 38.50 mmol) in dioxane (80 mL) was mixed with DIPEA (12.44 g, 96.26 mmol, 16.77 mL) and NaI (961.90 mg, 6.42 mmol) in a single addition at 20°C. The resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed the complete consumption of the starting materials and the detection of the desired mass. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1~1 / 2) to obtain the title compound (9.3 g, 25.66 mmol, 79.97% yield) as an orange solid. MS(M+H) + =363.4
[0590] Step 3: Synthesis of 3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)propanoic acid (INT1)
[0591] A solution of benzyl 3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)bromopropanoate (9.3 g, 25.66 mmol) in methanol (100 mL) was added under N2. The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 20°C for 16 hours under H2 (15 psi). LC-MS confirmed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was filtered, and the filtrate was concentrated under vacuum to obtain the title compound (6.7 g, 24.60 mmol, 95.88% yield) as a white solid. MS(M+H) + =273.2
[0592] Step 4: Synthesis of benzyl(7-aminoheptyl)carbamate (INT2)
[0593] To a solution of heptane-1,7-diamine (9 g, 69.11 mmol) in DCM (396 mL), methanol (396 mL) was added at 5°C. Then, a solution of CbzCl (10.61 g, 62.20 mmol, 8.84 mL) in methanol (396 mL) was added dropwise at 5°C, and the resulting mixture was stirred at 20°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum. The crude product was purified by reverse-phase HPLC (method: 0.1% FA, MeCN / water) to obtain the title compound (4.1 g, 15.04 mmol, 21.77% yield, 97% purity) as a white solid. MS(M+H) + =265. 4
[0594] Step 5: Synthesis of benzyl(7-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)carbamate (6)
[0595] A mixture of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetic acid (1 g, 3.01 mmol), benzyl(7-aminoheptyl)carbamate (1.03 g, 3.91 mmol), EDCI (865.43 mg, 4.51 mmol), HOBt (610.01 mg, 4.51 mmol), and TEA (913.63 mg, 9.03 mmol, 1.26 mL) in DMF (10 mL) was stirred at 20°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic layer was washed with brine (20 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 3 / 1 to 0 / 1) to obtain the title compound (1.7 g, 2.67 mmol, 88.84% yield, 91% purity) as a yellow oily substance.
[0596] MS(M+H) + = 579.2
[0597] Step 6: Synthesis of N-(7-aminoheptyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (7)
[0598] To a solution of benzyl (7-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)carbamate (1.7 g, 2.94 mmol) in ACN (10 mL), TMSI (1.76 g, 8.81 mmol, 1.20 mL) was added at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that the starting material was completely consumed and that one peak with the desired mass was detected. TEA (891.90 mg, 8.81 mmol, 1.23 mL) was added to the reaction mixture at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. The reaction mixture was concentrated under vacuum. The residue was separated by preparative HPLC (column: Phenomenex luna C). 18 After purification by MS(M+H) in a 150*40mm*15um mobile phase (water (0.1% TFA)-ACN), the sample was freeze-dried to obtain the title compound (920 mg, 2.07 mmol, 70.45% yield) as a yellow solid. + =445.2
[0599] Step 7: Synthesis of tert-butyl(1-(3-((7-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)amino)-3-oxopropyl)piperidine-4-yl)carbamate (8)
[0600] To a solution of 3-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)propanoic acid (500 mg, 1.84 mmol) and N-(7-aminoheptyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (816.04 mg, 1.84 mmol) in DMF (5 mL), EDCI (527.93 mg, 2.75 mmol), HOBt (372.12 mg, 2.75 mmol), and TEA (557.33 mg, 5.51 mmol, 766.62 μL) were added at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. LCMS This confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic layer was washed with brine (15 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1, dichloromethane / methanol = 1 / 0 to 10 / 1) to obtain the title compound (1.1 g, 1.43 mmol, 78.02% yield, 91% purity) as a yellow oil. MS(M+H) + =699.2
[0601] Step 8: Synthesis of 3-(4-aminopiperidine-1-yl)-N-(7-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)propanamide (9)
[0602] To a mixture of tert-butyl(1-(3-((7-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)amino)-3-oxopropyl)piperidine-4-yl)carbamate (1.1 g, 1.57 mmol) in dioxane (10 mL), HCl / dioxane (4 M, 10 mL) was added all at once at 20 °C, and the resulting mixture was stirred at 20 °C for 1 hour. LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (1 g, crude, HCl) as a yellow solid. MS(M+H) + = 599.2
[0603] Step 9: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-((7-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)amino)3-oxopropyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 60)
[0604] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL), HATU (179.73 mg, 472.69 μmol) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) were added. The mixture was stirred at 20°C for 10 minutes, and a solution of 3-(4-aminopiperidine-1-yl)-N-(7-(2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)heptyl)propanamide (327.52 mg, crude, HCl) in DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) was added, and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (12 mL), and ethyl acetate (12 mL x 3) was extracted. The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: 3_Phenomenex Luna C). 18 After purification to a 75*30mm*3um mobile phase (water (0.1% TFA)-ACN), the mixture was freeze-dried to obtain the title compound (48.5 mg, 40.97 μmol, 9.53% yield, 98% purity, TFA) as a white solid.
[0605] MS(M+H)+ =1046.7
[0606] 1 H NMR (400MHz, CD3OD) δ=8.34(d, J=13.8Hz, 1H), 8.21(s, 1H), 7.85-7.77(m, 1H), 7.54(d, J=7 .4 Hz, 1H), 7.43(d, J=8.4Hz, 1H), 7.35(d, J=6.7Hz, 1H), 5.14(dd, J=5.6, 12.6Hz, 1H), 5.02-4.94(m , 1H), 4.75(s, 2H), 4.25-4.14(m, 1H), 4.08(t, J=13.2Hz, 2H), 3.99(s, 3H), 3.79-3.62(m, 2H), 3.5 6-3.47(m, 1H), 3.46-3.41(m, 2H), 3.40(s, 3H), 3.24-3.12(m, 4H), 2.96-2.84(m, 1H), 2.80(s, 1H) ), 2.76-2.70(m, 3H), 2.38-2.21(m, 2H), 2.19-2.04(m, 4H), 1.99-1.86(m, 2H), 1.85-1.78(m, 2H), 1.76-1.65(m, 4H), 1.62-1.48(m, 4H), 1.44-1.28(m, 6H).
[0607] Example 61: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-((2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)benzyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0608] Step 1: Synthesis of benzyl 3-(hydroxymethyl)benzylcarbamate (2)
[0609] Sodium carbonate (1.55 g, 14.58 mmol) was added at 20°C to a mixture of (3-(aminomethyl)phenyl)methanol (1 g, 7.29 mmol) in THF (10 mL) and water (5 mL). Then CbzCl (1.37 g, 8.02 mmol, 1.14 mL) was added dropwise at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. LC-MS confirmed that (3-(aminomethyl)phenyl)methanol was completely consumed and that one peak with the desired mass was detected. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was analyzed by column chromatography (silicon dioxide). The compound was purified using petroleum ether / ethyl acetate (10 / 1~2 / 1) to obtain the title compound (1.7 g, 5.89 mmol, 80.80% yield, 94% purity) as a white solid. MS(M+Na) + =294.3
[0610] Step 2: Synthesis of benzyl 3-(chloromethyl)benzylcarbamate (3)
[0611] To a mixture of benzyl 3-(hydroxymethyl)benzylcarbamate (1.7 g, 6.27 mmol) in DCM (15 mL), SOCl2 (1.12 g, 9.40 mmol, 681.81 μL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 2:1) confirmed that the starting material had been completely consumed and that a novel spot had been detected. The reaction mixture was concentrated under vacuum to obtain the title compound (1.6 g, 5.52 mmol, 88.13% yield) as a white solid.
[0612] Step 3: Synthesis of tert-butyl N-[1-[[3-(benzyloxycarbonylaminomethyl)phenyl]methyl]-4-piperidyl]carbamate (4)
[0613] Potassium carbonate (2.29 g, 16.57 mmol) was added all at once at 20°C to a mixture of benzyl 3-(chloromethyl)benzylcarbamate (1.6 g, 5.52 mmol) and tert-butylpiperidine-4-ylcarbamate (1.44 g, 7.18 mmol) in ACN (20 mL), and the resulting mixture was stirred at 20°C for 4 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 5 / 1~1 / 4) to obtain the title compound (2.4 g, 5.29 mmol, 95.82% yield) as a white solid. MS(M+H) + =454.3
[0614] Step 4: Synthesis of benzyl 3-((4-aminopiperidine-1-yl)methyl)benzylcarbamate (5)
[0615] To a mixture of tert-butyl N-[1-[[3-(benzyloxycarbonylaminomethyl)phenyl]methyl]-4-piperidyl]carbamate (2.4 g, 5.29 mmol) in dioxane (10 mL), HCl / dioxane (4 M, 20 mL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that the starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (2.1 g, crude, HCl) as a white solid. MS(M+H) + =354.4
[0616] Stage 5: Benzyl 3-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamine Synthesis of (6) piperidine-1-yl)methyl)benzylcarbamate
[0617] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (0.7 g, 1.50 mmol) in DMF (5 mL), HATU (629.05 mg, 1.65 mmol) and DIPEA (388.76 mg, 3.01 mmol, 523.94 μL) were added. The reaction mixture was stirred at 20°C for 10 minutes and added to a solution of benzyl 3-((4-aminopiperidine-1-yl)methyl)benzylcarbamate (821.01 mg, 2.11 mmol, HCl) in DMF (5 mL) and DIPEA (388.76 mg, 3.01 mmol, 523.94 μL). The resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic layer was washed with brine (20 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 3 / 1~1 / 2) to obtain the title compound (362 mg, 424.89 μmol, 28.25% yield, 94% purity) as a white oily substance. MS(M+H) + =801.4
[0618] Step 6: Synthesis of N-(1-(3-(aminomethyl)benzyl)piperidine-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide (7)
[0619] To a mixture of benzyl 3-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)methyl)benzylcarbamate (360 mg, 449.51 μmol) in ACN (2 mL), TMSI (179.89 mg, 899.03 μmol, 122.37 μL) was added in one step at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed the presence of residual starting material, with the detection of a single peak having the desired mass. TMSI (89.94 mg, 449.51 μmol, 61.19 μL) was added to the reaction mixture at 20°C, and the resulting mixture was stirred at 20°C for 12 hours. LC-MS confirmed that the starting material was completely consumed and that the desired mass was detected. TEA (136.46 mg, 1.35 mmol, 187.70 μL) was added to the reaction mixture at 20°C. The reaction mixture was stirred at 20°C for 2 hours. The reaction mixture was concentrated under vacuum to obtain the title compound (330 mg, crude) as an orange solid. MS(M+H) + =667.3
[0620] Step 7: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-((2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)benzyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 61)
[0621] To a solution of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetic acid (150 mg, 451.45 μmol) in DMF (2 mL), HATU (188.82 mg, 496.59 μmol) and DIPEA (175.04 mg, 1.35 mmol, 235.90 μL) were added. The mixture was incubated at 20°C for 1 The mixture was stirred for 0 minutes, and a solution of N-(1-(3-(aminomethyl)benzyl)piperidine-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide (316.05 mg, 474.02 μmol) in DMF (2 mL) was added. The resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (12 mL) and extracted with ethyl acetate (12 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: 3_Phenomenex Luna C). 18 The product was purified using a 75*30mm*3um column (mobile phase: [water (0.1% TFA)-ACN]; B%: 32%~52%, 7 min), then lyophilized to obtain two batches of product with purities of 59% and 42%. These were re-purified using preparative HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10mM ammonium bicarbonate)-ACN]; B%: 46%~76%, 10 min), the eluents were combined and lyophilized to obtain a 75% pure product by LC-MS and HPLC. This was then subjected to preparative HPLC (column: 3_Phenomenex Luna C 18 After repurification to a 75*30mm*3um mobile phase (water (0.1% TFA)-ACN), the sample was freeze-dried to obtain the title compound (9.5 mg, 9.59 μmol, 2.12% yield, 99% purity, TFA) as a white solid.
[0622] MS(M+H) + =981.2
[0623] 1H NMR(400MHz, CD3OD)δ=8.33(br d, J=13.7Hz, 1H), 8.20(s, 1H), 7.85-7.78(m, 1H), 7.56(d, J=7.3Hz, 1H), 7.51-7.40(m, 5H), 7.33(d, J=6.6H) z, 1H), 5.12(dd, J=5.4, 12.8Hz, 1H), 4.98-4.93(m, 2H), 4.57(s, 2H), 4.44-4.32(s, 2H), 4.28-4.13(m, 1H), 4 .07(t, J=13.1Hz, 2H), 3.98(s, 3H), 3.55(d, J=12.5Hz, 2H), 3.40(s, 3H), 3.16(t, J=12.4Hz, 2H), 2.93-2.82 (m, 1H), 2.78-2.62(m, 2H), 2.24(d, J=13.3Hz, 2H), 2.17-2.03(m, 4H), 1.91-1.79(m, 4H), 1.77-1.64(m, 4H).
[0624] Example 62: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((5-((2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)pyridine-3-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka] [ka]
[0625] Step 1: Synthesis of 2-((5-bromopyridine-3-yl)methyl)isoindoline-1,3-dione (2)
[0626] To a mixture of (5-bromo-3-pyridyl)methanol (7 g, 37.23 mmol), phthalimide (5.48 g, 37.23 mmol), and PPh3 (14.65 g, 55.84 mmol) in THF (50 mL), DEAD (9.73 g, 55.84 mmol, 10.15 mL) was added dropwise under N2 at 0°C, and the resulting mixture was stirred at 20°C for 12 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with brine (150 mL) and extracted with ethyl acetate (150 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1 to 4 / 1) to obtain the title compound (8.2 g, 25.86 mmol, 69.46% yield) as a white solid. MS(M+H) + =317.0
[0627] Step 2: Synthesis of (5-bromopyridine-3-yl)methaneamine (3)
[0628] To a mixture of 2-((5-bromopyridine-3-yl)methyl)isoindoline-1,3-dione (8.2 g, 25.86 mmol) in EtOH (80 mL), hydrazine hydrate (15.23 g, 258.56 mmol, 14.78 mL, 85% purity) was added all at once at 20°C, and the resulting mixture was stirred at 80°C for 4 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 3:1) confirmed that the starting material had been completely consumed and that a novel spot had been detected. The reaction mixture was diluted with EtOH (160 mL) and filtered. The filtrate was concentrated under vacuum. The residue was diluted with DCM (160 mL) and filtered. The filtrate was concentrated under vacuum to obtain the title compound (7.2 g, crude) as a yellow oil.
[0629] Step 3: Synthesis of benzyl((5-bromopyridine-3-yl)methyl)carbamate (4)
[0630] Potassium carbonate (10.64 g, 76.99 mmol) was added at 20°C to a mixture of (5-bromopyridine-3-yl)methaneamine (7.2 g, 38.50 mmol) in THF (70 mL) and water (35 mL). CbzCl (7.22 g, 42.34 mmol, 6.02 mL) was then added dropwise at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. LC-MS confirmed that all starting materials had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (70 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to obtain the title compound (4.4 g, 12.33 mmol, 32.03% yield, 90% purity) as a yellow oil. MS(M+H) + =321.0
[0631] Step 4: Synthesis of methyl 5-(((((benzyloxy)carbonyl)aminomethyl)nicotinate (5)
[0632] To a solution of benzyl((5-bromopyridine-3-yl)methyl)carbamate (4.4 g, 13.70 mmol) in methanol (50 mL), Pd(dppf)Cl2 (501.22 mg, 685.00 μmol) and TEA (4.16 g, 41.10 mmol, 5.72 mL, 3 eq) were added. The suspension was degassed under vacuum and purged several times with CO. The mixture was stirred at 80°C for 16 hours under CO (50 psi). LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with methanol (200 mL) and filtered. The filtrate was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 5 / 1 to 1 / 1) to obtain the title compound (3.42 g, 9.79 mmol, 71.49% yield, 86% purity) as a yellow oily substance. MS(M+H) + =301.1
[0633] Step 5: Synthesis of benzyl((5-(hydroxymethyl)pyridine-3-yl)methyl)carbamate (6)
[0634] A suspension of LiAlH4 (554.32 mg, 14.60 mmol) in THF (30 mL) was added dropwise to a solution of methyl 5-((((benzyloxy)carbonyl)aminomethyl)nicotinate (3.4 g, 9.74 mmol, 86% purity) in THF (15 mL) at 0°C, and the resulting mixture was stirred at 20°C for 2 hours. TLC (silicon dioxide, petroleum ether:ethyl acetate = 1:2) confirmed the complete consumption of the starting material and the detection of a novel spot. The reaction mixture was quenched with water (1 mL), sodium hydroxide (15% aq, 1 mL), and water (3 mL). The reaction mixture was filtered. The filtrate was concentrated under vacuum to obtain the title compound (3 g, crude) as a yellow oil. MS(M+H) + =273.3
[0635] Step 6: Synthesis of benzyl((5-(chloromethyl)pyridine-3-yl)methyl)carbamate (7)
[0636] To a mixture of benzyl((5-(hydroxymethyl)pyridine-3-yl)methyl)carbamate (2.8 g, 10.28 mmol) in DCM (20 mL), SOCl2 (1.47 g, 12.34 mmol, 895.13 μL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that the starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (3 g, crude) as a yellow solid. MS(M+H) + =291. 3
[0637] Step 7: Synthesis of tert-butyl N-[1-[[5-(benzyloxycarbonylaminomethyl)-3-pyridyl]methyl]-4-piperidyl]carbamate (8)
[0638] Potassium carbonate (3.85 g, 27.86 mmol) was added in a single addition at 20°C to a mixture of benzyl((5-(chloromethyl)pyridine-3-yl)methyl)carbamate (2.7 g, 9.29 mmol) and tert-butyl N-(4-piperidyl)carbamate (2.23 g, 11.14 mmol) in ACN (30 mL). The resulting mixture was stirred at 60°C for 4 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was filtered, and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1) to obtain the title compound (3.7 g, 7.49 mmol, 80.64% yield, 92% purity) as an off-white solid. MS(M+H) + =455.4
[0639] Step 8: Synthesis of benzyl((5-((4-aminopiperidine-1-yl)methyl)pyridine-3-yl)methyl)carbamate (9)
[0640] To a solution of tert-butyl N-[1-[[5-(benzyloxycarbonylaminomethyl)-3-pyridyl]methyl]-4-piperidyl]carbamate (1 g, 2.20 mmol) in dioxane (5 mL), HCl / dioxane (4 M, 10 mL) was added at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that the starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (910 mg, crude, HCl) as an orange solid. MS(M+H) + =355.3
[0641] Step 9: Synthesis of benzyl((5-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)methyl)pyridine-3-yl)methyl)carbamate (11)
[0642] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (525.24 mg, 1.13 mmol) in DMF (4 mL), HATU (472.01 mg, 1.24 mmol) and DIPEA (291.71 mg, 2.26 mmol, 393.14 μL) were added. The mixture was stirred at 20°C for 10 minutes, and a solution of benzyl((5-((4-aminopiperidine-1-yl)methyl)pyridine-3-yl)methyl)carbamate (400.00 mg, crude, HCl) in DMF (4 mL) and DIPEA (291.71 mg, 2.26 mmol, 393.14 μL) was added. The resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (12 mL) and extracted with ethyl acetate (12 mL x 3). The organic layer was washed with brine (12 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 1 to 0 / 1, dichloromethane / methanol = 1 / 0 to 10 / 1) to obtain the title compound (426 mg, 531.27 μmol, 47.08% yield) as an off-white solid. MS(M+H) + =802.1
[0643] Step 10: Synthesis of N-(1-((5-(aminomethyl)pyridine-3-yl)methyl)piperidine-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide (12)
[0644] To a mixture of benzyl((5-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)methyl)pyridine-3-yl)methyl)carbamate (426 mg, 531.27 μmol) in ACN (10 mL), TMSI (159.45 mg, 796.90 μmol, 108.47 μL) was added all at once at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. TEA (161.28 mg, 1.59 mmol, 221.84 μL) was added to the reaction mixture at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated under vacuum. The residue was separated by preparative HPLC (column: Phenomenex Luna C). 18 After purification by MS (150*40mm*15um; mobile phase: [water (0.225% FA)-ACN]; B%: 7%~37%, 10 min), the sample was freeze-dried to obtain the title compound (212 mg, 307.97 μmol, 57.97% yield, 97% purity) as a white solid. MS(M + H) + =668.2
[0645] Step 11: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((5-((2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)pyridine-3-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 62)
[0646] 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetic acid (100 mg, 300.97 μmol) and N-(1-((5-(aminomethyl)pyridine-3-yl)methyl)piperidine-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6) in DMF (4 mL) To a mixture of ,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide (211.01 mg, 316.01 μmol), T3P (1.15 g, 1.81 mmol, 1.07 mL, 50% purity ethyl acetate solution) and Py (238.06 mg, 3.01 mmol, 242.92 μL) were added in one step at 20°C, and the resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with water (12 mL) and extracted with ethyl acetate (12 mL x 3). The organic layer was washed with brine (12 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Phenomenex luna C). 18 After purification by 150*40mm*15um; mobile phase: [water (0.225% FA)-ACN]; B%: 18%~48%, 10 min), the sample was freeze-dried, and product A (24 mg) and product B (72 mg) were obtained with 89% purity by LC-MS and HPLC. Product A was then subjected to preparative HPLC (column: 3_Phenomenex Luna C 18 The sample was re-purified by 75*30mm*3um; mobile phase: [water (0.1% TFA)-ACN]; B%: 28%~48%, 7 min). Product B was further purified by preparative HPLC (column: 3_Phenomenex Luna C). 18 The sample was re-purified using a 75*30mm*3um mobile phase (water (0.1% TFA)-ACN); B%: 30%~50%, 7 mins. The eluents from the two batches were combined, lyophilized, and the title compound (64.4 mg, 64.27 μmol, 21. A 35% yield, 98% purity TFA salt was obtained as a white solid.
[0647] MS(M + H)+ =981.7
[0648] 1 H NMR (400MHz, CD3OD) δ=8.71(d, J=1.7Hz, 1H), 8.64(d, J=1.8Hz, 1H), 8.27(d, J=13.4Hz, 1H), 8.21(s, 1H), 8.03(s, 1H), 7 .86-7.78(m, 1H), 7.56(d, J=7.2Hz, 1H), 7.46(d, J=8.6Hz, 1H), 7.34(d, J=6.6Hz, 1H), 5.13(dd, J=5.4, 12.8Hz, 1H), 5.0 5-4.90(m, 2H), 4.81-4.74(m, 1H), 4.63(s, 2H), 4.44(s, 2H), 4.25-4.04(m, 3H), 3.98(s, 3H), 3.69-3.45(m, 2H), 3.40(s , 3H), 3.26-3.11(m, 2H), 2.93-2.83(m, 1H), 2.80-2.67(m, 2H), 2.31-2.18(m, 2H), 2.17-2.06(m, 3H), 1.98-1.66(m, 8H).
[0649] Example 63: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(7-(3-((2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)phenyl)heptyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0650] Step 1: Synthesis of benzyl 3-bromobenzylcarbamate (2)
[0651] A solution of (3-bromophenyl)methaneamine (5 g, 26.87 mmol) in THF (50 mL) was mixed with a solution of potassium carbonate (7.43 g, 53.75 mmol) in water (25 mL), followed by CbzCl (5.50 g, 32.25 mmol, 4.58 mL) at 25°C. The resulting mixture was stirred at 25°C for 12 hours. LC-MS confirmed that the starting material was completely consumed and that one peak with the desired mass was detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 5:1) confirmed that the starting material was completely consumed and that two novel spots were detected. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to obtain the title compound (6.8 g, 20.60 mmol, 76.66% yield, 97% purity). MS(M+H) + =320.0
[0652] Step 2: Synthesis of benzyl 3-(7-hydroxyhepto-1-in-1-yl)benzylcarbamate (4)
[0653] To a mixture of benzyl 3-bromobenzylcarbamate (6 g, 18.74 mmol) and hept-6-in-1-ol (3.15 g, 28.11 mmol) in DMF (60 mL), CuI (713.78 mg, 3.75 mmol), TEA (5.69 g, 56.22 mmol, 7.82 mL), and Pd(PPh3)4 (1.08 g, 936.97 μmol) were added in one step at 20°C under N2, and the resulting mixture was stirred at 80°C for 16 hours. LC-MS confirmed that all starting materials were completely consumed and that one peak with the desired mass was detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 1:1) confirmed that all starting materials were completely consumed and that three novel spots were detected. The reaction mixture was diluted with water (120 mL) and extracted with ethyl acetate (120 mL x 3). The organic layer was washed with brine (120 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to obtain the title compound (6.8 g, 16.06 mmol, 85.70% yield, 83% purity) as a yellow oil. MS(M+Na) + =374.4
[0654] Step 3: Synthesis of 7-(3-(((((benzyloxy)carbonyl)aminomethyl)phenyl)hept-6-in-1-yl4-methylbenzenesulfonate (5)
[0655] To a mixture of benzyl 3-(7-hydroxyhepto-1-in-1-yl)benzylcarbamate (6.8 g, 16.06 mmol, 83% purity) in DCM (70 mL), TEA (4.88 g, 48.18 mmol, 6.71 mL) and TosCl (4.59 g, 24.09 mmol) were added in one step at 20°C, and the resulting mixture was stirred at 20°C for 16 hours. LC-MS confirmed that all starting material had been completely consumed and that the desired mass had been detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 2:1) confirmed that all starting material had been completely consumed and that one major novel spot had been detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1 to 2 / 1) to obtain the title compound (6.2 g, 12.02 mmol, 74.83% yield, 98% purity) as a yellow oil. MS(M+H) + =506.4
[0656] Step 4: Synthesis of tert-butyl N-[1-[7-[3-(benzyloxycarbonylaminomethyl)phenyl]hept-6-inyl]-4-piperidyl]carbamate (6)
[0657] To a mixture of 7-(3-((((benzyloxy)carbonyl)aminomethyl)phenyl)hept-6-in-1-yl-4-methylbenzenesulfonate (3.1 g, 6.13 mmol) and tert-butylpiperidine-4-ylcarbamate (2.46 g, 12.26 mmol) in dioxane (40 mL), NaI (91.90 mg, 613.10 μmol) and DIPEA (2.38 g, 18.39 mmol, 3.20 mL) were added in one step at 20°C under N2, and the resulting mixture was stirred at 60°C for 16 hours. LC-MS confirmed that all the starting material had been completely consumed and that one peak with the desired mass was detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 1:2) confirmed that the starting material had been completely consumed and that three novel spots were detected. The reaction mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 10 / 1~1 / 2) to obtain the title compound (2.4 g, 4.50 mmol, 73.35% yield) as a yellow oily substance. MS(M+H) + = 534.3
[0658] Step 5: Synthesis of tert-butyl(1-(7-(3-(aminomethyl)phenyl)heptyl)piperidine-4-yl)carbamate (7)
[0659] A solution of tert-butyl N-[1-[7-[3-(benzyloxycarbonylaminomethyl)phenyl]hept-6-inyl]-4-piperidyl]carbamate (2.4 g, 4.50 mmol) in methanol (24 mL) was mixed with Pd / C (1 g, 10% purity) under N2. The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 20°C for 16 hours under H2 (15 psi). LC-MS confirmed that the starting material was completely consumed and that a single peak with the desired mass was detected. The reaction mixture was diluted with methanol (80 mL) and filtered. The filtrate was concentrated under vacuum to obtain the title compound (1.3 g, crude) as a white oily substance. MS(M+H) + =404.5
[0660] Step 6: Synthesis of tert-butyl(1-(7-(3-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)phenyl)heptyl)piperidine-4-yl)carbamate (9)
[0661] To a mixture of 2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetic acid (800 mg, 2.41 mmol) and tert-butyl(1-(7-(3-(aminomethyl)phenyl)heptyl)piperidine-4-yl)carbamate (1.17 g, 2.89 mmol) in DMF (10 mL), HATU (915.49 mg, 2.41 mmol) and DIPEA (933.54 mg, 7.22 mmol, 1.26 mL) were added at 20°C in one step, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that all the starting material was completely consumed and that one peak with the desired mass was detected. TLC (silicon dioxide, petroleum ether:ethyl acetate = 1:3) confirmed that the starting material was completely consumed and that four novel spots were detected. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL x 3). The organic layer was washed with brine (30 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (silicon dioxide, petroleum ether / ethyl acetate = 5 / 1 to 0 / 1) to obtain the title compound (1.17 g, 1.63 mmol, 67.69% yield) as a yellow oil. MS(M+H) + =718.2
[0662] Step 7: Synthesis of N-(3-(7-(4-aminopiperidine-1-yl)heptyl)benzyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (10)
[0663] Dioxane (5 mL) contains tert-butyl (1-(7-(3-((2-((2-(2 A mixture of 6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamido)methyl)phenyl)heptyl)piperidine-4-yl)carbamate (1.17 g, 1.63 mmol) was mixed with HCl / dioxane (4 M, 10 mL) in one step at 20°C, and the resulting mixture was stirred at 20°C for 1 hour. LC-MS confirmed that the starting material had been completely consumed and that a single peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (1.5 g, crude, HCl) as a yellow solid.
[0664] MS(M+H) + =618.2
[0665] Step 8: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(7-(3-((2-((2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)phenyl)heptyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 63)
[0666] 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimide[4,5 -b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (250 mg, 537.14 μmol) and N-(3-(7-(4-aminopiperidine-1-yl)heptyl)benzyl)-2-((2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide (421.68 mg, crude, HCl) were mixed together, to which HATU (224.66 mg, 590.86 μmol) and DIPEA (208.27 mg, 1.61 mmol, 280.68 μL) were added in one step at 20°C, and the resulting mixture was stirred at 20°C for 2 hours. LC-MS confirmed that the starting material had been completely consumed and that the desired mass had been detected. The reaction mixture was diluted with toluene (15 mL) and concentrated under vacuum. Separation of residue by HPLC (column: Phenomenex Luna C) 18 After purification by HPLC (150*40mm*15um; mobile phase: [water (0.225% FA)-ACN]; B%: 30%~60%, 10 min), the product was freeze-dried to obtain a 59% pure product (192 mg). Product A was separated by preparative HPLC (column: Shim-pack). C 18 After repurification with a solution of 150*25*10 μm (mobile phase: water (0.225% FA)-ACN), the solution was freeze-dried to obtain the title compound (81.2 mg, 72.42 μmol, 69.25% yield, 95% purity) as a white solid.
[0667] MS(M+H) + =1065.4
[0668] 1H NMR (400MHz, DMSO-d6)δ=11.11(s, 1H), 8.50(t, J=6.0Hz, 1H), 8.30(s, 1H), 8.26(d, J=13.4Hz, 1H), 8.13(s, 1H), 8.06(s, 1H), 7 .81(dd, J=7.4, 8.4Hz, 1H), 7.51(d, J=7.2Hz, 1H), 7.41(d, J=8.6Hz, 1H), 7.27-7.14(m, 2H), 7.12-7.01(m, 3H), 5.11(dd, J=5.4 , 12.8Hz, 1H), 4.87(s, 2H), 4.85-4.76(m, 1H), 4.34(d, J=6.0Hz, 2H), 4.14-4.03(m, 2H), 4.02-3 .95(m, 1H), 3.92(s, 3H), 3.33(s, 3H), 3.00-2.81(m, 4H), 2.69-2.51(m, 7H), 2.09-1.88(m, 5H), 1 84-1.67(m, 4H), 1.67-1.48(m, 8H), 1.35-1.21(m, 6H).
[0669] Example 64: 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxy Synthesis of so-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(7-(5-((2-((2-((2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)oxy)acetamide)methyl)pyridine-3-yl)heptyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0670] Based on the above reaction equation, the title compound (161.2 mg) was obtained in the same manner as in the above-described examples. A white solid was obtained (137.59 μmol, 32.02% yield, 91% purity).
[0671] MS(M+H) + =1065.6
[0672] 1 H NMR (400MHz, DMSO-d6)δ=11.12(br s, 1H), 8.58(t, J=5.9Hz, 1H), 8.34-8.28(m, 3H), 8.25(d, J=13.3Hz, 1H), 8.20(s, 1H), 8.03(s, 1H), 7.88(dd, J=3.5, 7.5Hz, 1H), 7.80(dd, J=7.4, 8.4Hz, 1H), 7.53-7.46(m, 2H), 7.40(d, J=8.4Hz, 1H), 7.20(d, J=6.8Hz, 1H), 5.11(dd, J=5.4, 12.9Hz, 1H), 4.88 (s, 2H), 4.86-4.77(m, 1H), 4.37(d, J=6.0Hz, 2H), 4.08(t, J=13.9Hz, 2H), 3.92(s, 3H), 3.34(s, 3H), 2.97-2.79(m, 4H), 2.58-2. 54(m, 3H), 2.28(t, J=7.3Hz, 2H), 2.06-1.94(m, 5H), 1.83-1.70(m, 4H), 1.66-1.50(m, 8H), 1.46-1.37(m, 2H), 1.32-1.20(m, 6H).
[0673] Example 65: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperidine-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0674] Step 1: Synthesis of benzyl 4-((4-((tert-butoxycarbonyl)amino)piperidine-1-yl)methyl)piperidine-1-carboxylate (3)
[0675] Benzyl 4-formylpiperidine-1-carboxylate (5) in DCE (80 mL) To a solution of (g, 20.22 mmol), tert-butylpiperidine-4-ylcarbamate (4.50 g, 22.47 mmol) and HOAc (1.21 g, 20.22 mmol, 1.16 mL) were added. The mixture was stirred at 20°C for 2 hours. Then, NaBH(OAc)3 (16.00 g, 75.49 mmol) was added to the mixture at 20°C, and the mixture was stirred at 20°C for 14 hours. LC-MS confirmed the consumption of the starting material and the presence of a major peak with the desired mass. Water (100 mL) was added to the reaction mixture at 0°C, and the pH was adjusted to 9 at 0°C with saturated sodium carbonate solution. After extracting the aqueous phase with ethyl acetate (200 mL x 3), the combined organic layers were washed with brine (250 mL x 2), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the residue. The crude product was solidified in petroleum ether:ethyl acetate = 5:1 (120 mL) at 20°C for 30 minutes, and then filtered. The cake was dried under reduced pressure to obtain the title compound (8 g, 18.54 mmol, 91.68% yield) as a white solid. MS(M+H) + =432.3
[0676] Step 2: Synthesis of tert-butyl(1-(piperidine-4-ylmethyl)piperidine-4-yl)carbamate (4)
[0677] To a solution of benzyl 4-((4-((tert-butoxycarbonyl)amino)piperidine-1-yl)methyl)piperidine-1-carboxylate (4 g, 9.27 mmol) in methanol (100 mL), Pd / C (0.4 g, 10% purity) and Pd(OH)2 / C (0.4 g, 20% purity) were added, and the mixture was stirred at 20°C for 16 hours under an H2 atmosphere (15 Psi). LC-MS confirmed the consumption of the starting material and the detection of the desired mass. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound (2.6 g, crude) as a pale yellow oil. MS(M+H) + =298.3
[0678] Step 3: Synthesis of tert-butyl(1-((1-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperidine-4-yl)methyl)piperidine-4-yl)carbamate (5)
[0679] To a solution of 2-(2,6-dioxopiperidine-3-yl)-4-fluoroisoindoline-1,3-dione (800 mg, 2.90 mmol) in DMSO (3 mL), TEA (1.16 g, 11.50 mmol, 1.60 mL) and tert-butyl(1-(piperidine-4-ylmethyl)piperidine-4-yl)carbamate (1.0 g, 3.36 mmol) were added. The mixture was stirred at 100 °C for 16 hours under an N2 atmosphere. LC-MS confirmed the consumption of the starting material and identified a single major peak with the desired mass. Water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (40 mL x 3), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage; 10g SepaFlash® silica flash column, eluent 0-10% methanol:ethyl acetate gradient, 50 mL / min) to obtain the title compound (1.5 g, 2.71 mmol, 93.55% yield) as a yellow oily substance. MS(M+H) + = 554.5
[0680] Step 4: Synthesis of 4-(4-((4-aminopiperidine-1-yl)methyl)piperidine-1-yl)-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (6)
[0681] A solution of tert-butyl(1-((1-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperidine-4-yl)methyl)piperidine-4-yl)carbamate (1.5 g, 2.71 mmol) in DCM (10 mL) was mixed with HCl / dioxane (4 M, 10 mL) at 20 °C. The mixture was incubated at 20 °C for 16 minutes. The mixture was stirred for a period of time under an N2 atmosphere. LC-MS confirmed the consumption of the starting material and identified a single major peak with the desired mass. The reaction mixture was concentrated under reduced pressure to obtain the title compound (1.4 g, crude, 2HCl) as a pale yellow solid. MS(M+H) + =454.5
[0682] Step 5: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperidine-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 65)
[0683] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (150 mg, 322.29 μmol) in DMF (4 mL), HATU (245.09 mg, 644.58 μmol), DIPEA (222.60 mg, 1.72 mmol, 300 μL), and 4-(4-((4-aminopiperidine-1-yl)methyl)piperidine-1-yl)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (200 mg, 379.90 μmol, 2HCl) were added at 25°C. The mixture was stirred under an N2 atmosphere at 25°C for 2 hours. LC-MS confirmed the consumption of the starting material and identified a single major peak with the desired mass. Water (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic layer was washed with 90 mL (30 mL x 3) of brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was separated by preparative HPLC (column: Waters Xbridge 150*25 mm*5 μm; mobile phase: water (10 mM)). The compound was purified by ammonium bicarbonate (ACN) [B%: 48%~81%, 9 min; column temperature: 30°C], followed by lyophilization to obtain the title compound (123.3 mg, 127.28 μmol, 39.49% yield, 93% purity) as a pale yellow solid.
[0684] MS(M+ H) + =901.6
[0685] 1 H NMR (400MHz, DMSO-d6) δ11.10(s, 1H), 8.35-8.22(m, 2H), 8.04(s, 1H), 7.95-7.83(m, 1H), 7.68(t, J=7.8Hz, 1H), 7.33(t, J=7.3Hz, 2H), 7.20(d, J=6.6Hz, 1H), 5.09(dd, J=5.3, 12.9Hz, 1H), 4.88-4. 78(m, 1H), 4.09(t, J=13.9Hz, 2H), 3.92(s, 3H), 3.83-3.67(m, 3H), 3.32(s, 3H), 2.93-2.75(m, 5H) , 2.63-2.57(m, 2H), 2.25-2.14(m, 2H), 2.08-1.95(m, 5H), 1.84-1.56(m, 13H), 1.37-1.25(m, 2H).
[0686] Example 66: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperazine-1-yl)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0687] Step 1: Synthesis of tert-butyl(1-(2-chloroethyl)piperidine-4-yl)carbamate (2)
[0688] A mixture of tert-butylpiperidine-4-ylcarbamate (10 g, 49.93 mmol), 1-bromo-2-chloroethane (10.74 g, 74.90 mmol, 6.21 mL), and potassium carbonate (20.70 g, 149.79 mmol) in acetone (100 mL) was stirred at 15°C for 16 hours. LC-MS confirmed that the reaction products were completely consumed and that 100% of the desired mass was detected. The reaction mixture was filtered, and the filtrate was concentrated under vacuum. The residue was purified by flash silica gel chromatography (25 g SepaFlash® silica flash column, eluent 20-51% ethyl acetate / petroleum ether gradient @ 100 mL / min) to obtain the title compound (2 g, 7.61 mmol, 15.24% yield) as a white solid.
[0689] 1 H NMR (400MHz, DMSO-d6) δ=6.75(br d, J=7.5Hz, 1H), 3.64(t, J=6.8Hz, 2H), 3.26-3.12(m, 1H), 2.80(br d, J=11.5Hz, 2H), 2.59(br t, J=6.8Hz, 2H), 2.05-1.95(m, 2H), 1.65(br d, J=11.0Hz, 2H), 1.41-1.29(m, 11H).
[0690] Step 2: Synthesis of tert-butyl(1-(2-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperazine-1-yl)ethyl)piperidine-4-yl)carbamate (4)
[0691] To a solution of 2-(2,6-dioxopiperidine-3-yl)-4-(piperazine-1-yl)isoindorin-1,3-dione (200 mg, 527.97 μmol, HCl salt) in DMF (3 mL), DIEA (204.71 mg, 1.58 mmol, 275.89 μL) and tert-butyl(1-(2-chloroethyl)piperidine-4-yl)carbamate (194.23 mg, 739.16 μmol) were added, and the mixture was stirred at 15°C for 16 hours. LC-MS confirmed that 15% of the reaction product remained and 66% of the desired mass was detected. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (80 mL x 5), dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by flash silica gel chromatography (12g SepaFlash® Silica Flash Column, eluent 0-18% methanol / ethyl acetate gradient @ 60 mL / min) to obtain the title compound (110 mg, 193.44 μmol, 36.64% yield) as a yellow solid. MS(M+H) + =569.6.
[0692] Step 3: Synthesis of 4-(4-(2-(4-aminopiperidine-1-yl)ethyl)piperazine-1-yl)-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione (5)
[0693] To a solution of tert-butyl(1-(2-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperazine-1-yl)ethyl)piperidine-4-yl)carbamate (110 mg, 193.44 μmol) in dioxane (5 mL), HCl / dioxane (4 M in dioxane, 10 mL) was added, and the mixture was stirred at 15°C for 16 hours. LC-MS confirmed that the reactants were completely consumed and that the desired mass was detected. The reaction mixture was concentrated under vacuum to obtain the title compound (160 mg, crude, HCl salt) as a yellow solid. MS(M+H) + =469.2.
[0694] Step 4: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperazine-1-yl)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 66)
[0695] 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimide[4,5 -b) [1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (90 mg, 193.37 μmol) solution was mixed with HATU (110.29 mg, 290.06 μmol) and DIEA (99.97 mg, 773.49 μmol, 134.73 μL), and the mixture was stirred at 15°C for 15 minutes. Then, 4-(4-(2-(4-aminopiperidine-1-yl)ethyl)piperazine-1-yl)-2-(2,6-dioxopiperidine-3-yl)isoindorin-1,3-dione (156.25 mg, 309.39 μmol, HCl salt) was added, and the resulting mixture was stirred at 15°C for 1 hour. LC-MS confirmed that the reactants were completely consumed and that 91% of the desired mass was detected. CH3COOH was added to the mixture to adjust the pH to <7. The resulting mixture is separated by HPLC (column: W Aters Xbridge 150*25mm*5um; mobile phase: [water (10mM ammonium bicarbonate)-ACN]; B%: 40%~70%, 8 min), followed by preparative HPLC (column: Phenomenex luna C 18 The sample was purified using a 150*25mm*10um mobile phase (water (0.225% FA)-ACN), with a B% concentration of 18% to 38% for 10 minutes, yielding the title compound (32.4 mg, 32.54 μmol, 16.83% yield, 92% purity) as a yellow solid.
[0696] MS(M+H) + =916.3.
[0697] 1 H NMR (400MHz, DMSO-d6) δ=11.09(s, 1H), 8.30(s, 1H), 8.24(d, J=13.4Hz, 1H), 8.03(s, 1H), 7.89(br dd, J 1= 3.3, J 2= 7.5Hz, 1H), 7.70(dd, J 1= 7.3, J 2= 8.3Hz, 1H), 7.40-7.28(m, 2H), 7.19(d, J=6.6Hz, 1H), 5.09(dd, J 1= 5.5, J 2= 12.8Hz, 1H), 4.90-4.76(m, 1H), 4.08(br t, J=13.9Hz, 2H), 3.91(s, 3H), 3.80-3.67(m, 1H), 3.31-3.23(m, 4H), 2.96-2.78(m, 3H), 2.6 5-2.57(m, 4H), 2.57-2.51(m, 9H), 2.09-1.91(m, 5H), 1.85-1.68(m, 4H), 1.68-1.48(m, 6H).
[0698] Example 67: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-((1-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-5-yl)piperidine-4-yl)methyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0699] Based on the above reaction equation, the title compound (129.2 mg, 130.50 μmol, 40.49% yield, 91% purity) was obtained as a pale yellow solid by the same method as in the examples described above.
[0700] MS(M+ H) + =901.5
[0701] 1 H NMR (400MHz, DMSO-d6) δ11.07(br s, 1H), 8.31-8.22(m, 2H), 8.03(s, 1H), 7.87(dd, J=3.4, 7.5Hz, 1H), 7.64(d, J=8.5Hz, 1H) , 7.29(d, J=1.6Hz, 1H), 7.24-7.18(m, 2H), 5.06(dd, J=5.4, 12.9Hz, 1H), 4.87-4.78(m, 1H) , 4.12-3.98(m, 4H), 3.91(s, 3H), 3.78-3.70(m, 1H), 3.33(s, 3H), 2.99-2.79(m, 5H), 2.63- 2.54(m, 2H), 2.15-2.08(m, 2H), 2.03-1.93(m, 5H), 1.81-1.55(m, 13H), 1.18-1.09(m, 2H).
[0702] Example 68: 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimide[4,5-b][1,4]diaze Synthesis of pin-2-yl)amino)-N-(1-(2-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-5-yl)piperazine-1-yl)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0703] Based on the above reaction equation, the title compound (79.1 mg, 84.63 μmol, 39.39% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0704] MS(M+H) + =917.0
[0705] 1H NMR (400MHz, DMSO-d6) δ11.09(s, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.04(d, J=1.3Hz, 1H), 7.90(dd, J=7.8, 3.4Hz, 1H), 7.68(d, J=8.5 Hz, 1H), 7.34(d, J=2.2Hz, 1H), 7.25(dd, J=8.7, 2.3Hz, 1H), 7.19(d, J=6.7Hz, 1H), 5.07(dd, J=12.9, 5.3Hz, 1H), 4.91-4.74(m, 1H), 4.08(t, J =13.9Hz, 2H), 3.91(s, 3H), 3.80-3.67(m, 1H), 3.50-3.37(m, 4H), 3.31(s, 3H), 2.97-2.78(m, 3H) , 2.65-2.51(m, 6H), 2.47-2.44(m, 4H), 2.08-1.92(m, 5H), 1.83-1.68(m, 4H), 1.66-1.49(m, 6H).
[0706] Example 69: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperazine-1-carbonyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0707] Based on the above reaction equation, the title compound (78.3 mg, 83.78 μmol (25.99% yield, 98% purity) was obtained as a pale yellow solid.
[0708] MS(M+H) + =916.6
[0709] 1H NMR (400MHz, DMSO- d6)δ11.07(br s, 1H), 8.34-8.23(m, 2H), 8.04(s, 1H), 7.96(dd, J=3.0, 7.7Hz, 1H), 7.73(d d, J=7.3, 8.2Hz, 1H), 7.38(dd, J=7.8, 12.0Hz, 2H), 7.21(d, J=6.7Hz, 1H), 5 .11(dd, J=5.4, 12.9Hz, 1H), 4.87-4.75(m, 1H), 4.08(t, J=13.9Hz, 2H), 4.0 2-3.97(m, 1H), 3.92(s, 3H), 3.65(d, J=12.7Hz, 2H), 3.40-3.37(m, 2H), 3.32 -3.30(m, 5H), 2.96-2.84(m, 3H), 2.64-2.52(m, 6H), 2.06-1.90(m, 3H), 1.86-1.79(m, 2H), 1.75-1.50(m, 8H).
[0710] Example 70: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperazine-1-yl)acetyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0711] Based on the above reaction equation, the title compound (81.8 mg, 86.20 μmol, 33.43% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0712] MS(M+H) + =930.1
[0713] 1H NMR (400MHz, DMSO-d6) δ=11.08(s, 1H), 8.31-8.22(m, 2H), 8.07-7.93(m, 2H), 7.70(dd, J=7.2 , 8.2Hz, 1H), 7.39-7.31(m, 2H), 7.19(d, J=6.8Hz, 1H), 5.14-5.04(m, 1H), 4.87-4.76(m, 1H), 4.35-4.24(m, 1H), 4.12-4.01(m, 4H), 3.91 (s, 3H), 3.33(s, 3H), 3.19-3.10(m, 2H), 2.95-2.68(m, 3H), 2.65-2.53(m, 10H), 2.04-1.81(m, 5H), 1.72-1.50(m, 7H), 1.46-1.32(m, 1H).
[0714] Example 71: 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimide[4,5-b][1,4]diaze Synthesis of pin-2-yl)amino)-N-(1-(3-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-4-yl)piperazine-1-yl)propanoyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0715] Based on the above reaction equation, the title compound (62.2 mg, 64.57 μmol, 25.05% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0716] MS(M+H) + =943.9
[0717] 1H NMR (400MHz, DMSO-d6) δ=11.08(s, 1H), 8.34-8.23(m, 2H), 8.06-7.93(m, 2H), 7.73-7.67(m, 1H), 7.35(t, J=7.0Hz, 2H) ), 7.20(d, J=6.6Hz, 1H), 5.09(dd, J=5.4, 12.6Hz, 1H), 4.88-4.76(m, 1H), 4.36-4.26(m, 1H), 4.11-4.04(m, 2H), 3.91 (s, 3H), 3.33(s, 3H), 3.27-3.06(m, 5H), 2.89-2.82(m, 1H), 2.78-2.70(m, 1H), 2.69-2.65(m, 1H), 2.65-2. 51(m, 10H), 2.07-1.78(m, 6H), 1.76-1.68(m, 2H), 1.68-1.56(m, 4H), 1.53-1.45(m, 1H), 1.42-1.32(m, 1H).
[0718] Example 72: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-5-yl)piperazine-1-carbonyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0719] Based on the above reaction equation, the title compound (39.9 mg, 42.69 μmol (13.25% yield, 98% purity) was obtained as a pale yellow solid.
[0720] MS(M+H) + =916.6
[0721] 1H NMR (400MHz, DMSO-d6)δ11.06(br s, 1H), 8.32-8.24(m, 2H), 8.04(s, 1H), 7.98(dd, J=3.0, 7.5Hz, 1H), 7.71(d, J=8.5Hz, 1H), 7.36(d, J=1.8Hz, 1H), 7.26(dd, J=2.0, 8.7Hz, 1H), 7.21(d, J=6.8Hz, 1H), 5.08(dd, J=5.3, 12.9Hz, 1H), 4.83(t, J=8.0Hz, 1H), 4.08(t, J=13.9Hz, 2H), 4.02-3.97(m, 1H), 3.92(s, 3H), 3.65(d, J=13.1Hz, 2H), 3.53-3.45(m, 4H), 3.32-3.2 9(m, 3H), 2.97-2.85(m, 3H), 2.65-2.51(m, 6H), 2.04-1.91(m, 3H), 1.83(d, J=10.4Hz, 2H), 1.76-1.52(m, 8H).
[0722] Example 73: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-5-yl)piperazine-1-yl)acetyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0723] Based on the above reaction equation, the title compound (51.8 mg, 54.59 μmol, 25.41% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0724] MS(M+H) + =930.7.
[0725] 1 H NMR (400MHz, DMSO-d6)δ=11.06(br s, 1H)
[0726] , 8.45-8.16(m, 2H), 8.13-7.91(m, 2H), 7.68(d, J=8.6Hz, 1H), 7.35(d, J=1.7Hz, 1H), 7.25(dd, J 1= 1.9, J 2= 8.7Hz, 1H), 7.19(d, J=6.7Hz, 1H), 5.07(dd, J 1= 5.4, J 2= 12.8Hz, 1H), 4.81(br t, J=7 .9Hz, 1H), 4.29(brd, J=11.7Hz, 1H)
[0727] , 4.16-3.97(m, 4H), 3.91(s, 3H), 3.52-3.35(m, 8H), 3.20-3.06(m, 2H), 2.94-2.82(m, 1H), 2.81-2.71(m, 1H), 2. 63-2.53(m, 6H), 2.10-1.91(m, 3H), 1.91-1.75(m, 2H), 1.71-1.60(m, 2H), 1.67-1.47(m, 5H), 1.46-1.30(m, 1H).
[0728] Example 74: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(3-(4-(2-(2,6-dioxopiperidine-3-yl)-1,3-dioxoisoindorin-5-yl)piperazine-1-yl)propanoyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0729] Based on the above reaction equation, the title compound (29.8 mg, 30.94 μmol, 28.80% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0730] MS(M+H) + =944.8.
[0731] 1 H NMR (400MHz, DMSO-d6) δ=11.07(s, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.04(s, 1H), 7.97(br dd, J 1= 2.7, J 2= 7.2Hz, 1H), 7.67(d, J=8.4Hz, 1H), 7.34(s, 1H), 7.31-7.23(m, 1H), 7.20(d, J=6.7Hz, 1H), 5.07(dd, J 1= 5.4, J 2= 12.8Hz, 1H), 4.82(br t, J=8.1Hz, 1H), 4.31(br d, J=12.6Hz, 1H), 4.14-3.99(m, 3H), 3.98-3.84(m, 4H), 3.48-3.38(m, 7H), 3.15(br t, J=12.5Hz, 1H), 2.94-2.81(m, 1H), 2.74(br t, J=11.4Hz, 1H), 2.63-2.54(m, 10H), 2.09-1.92(m, 3H), 1.91-1.78(m, 2H), 1.72(br d, J=1.2Hz, 2H), 1.68-1.54(m, 4H), 1.53-1.43(m, 1H), 1.43-1.29(m, 1H).
[0732] Example 75: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0733] Step 1: tert-butyl(1-(2-(2-(2-hydroxyethoxy)ethoxy) Synthesis of ethyl)piperidine-4-yl)carbamate (2)
[0734] A solution of 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (4.0 g, 13.14 mmol) and tert-butyl N-(4-piperidyl)carbamate (3.95 g, 19.71 mmol) in dioxane (20 mL) was prepared by adding NaI (197.00 mg, 1.31 mmol) and DIPEA (1.70 g, 13.14 mmol, 2.29 mL). The resulting mixture was stirred at 60°C for 12 hours. The reaction was confirmed to be complete by LC-MS. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (300 mL x 3). The combined organic layer was washed with brine (100 mL x 1), dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (5.55 g, crude) as a yellow solid. MS(M+H) + =333.4
[0735] Step 2: Synthesis of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate (3)
[0736] To a solution of tert-butyl(1-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (5.55 g, 16.70 mmol) in DCM (30 mL), TEA (5.07 g, 50.09 mmol, 6.97 mL) was added, followed by TosCl (6.37 g, 33.39 mmol). The mixture was stirred at 15°C for 16 hours. The reaction was confirmed to be complete by LC-MS. The mixture was concentrated under vacuum. The residue was purified by column chromatography (silicon dioxide, ethyl acetate / methanol = 10 / 1) to obtain the title compound (4.27 g, 8.77 mmol, 52.56% yield) as a brown oil. MS(M+H) + =487.2
[0737] Step 3: Synthesis of tert-butyl(1-(2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (4)
[0738] To a solution of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate (4.27 g, 8.77 mmol) and 3-(4-amino-1-oxo-isoindorin-2-yl)piperidine-2,6-dione (2.73 g, 10.53 mmol) in DMF (30 mL), DIEA (1.13 g, 8.77 mmol, 1.53 mL) was added, and the mixture was stirred at 110 °C for 16 hours. The completion of the reaction was confirmed by LC-MS. The reaction mixture was diluted with water (30 mL), extracted with ethyl acetate (500 mL x 3), and the combined organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (0.1% FA conditions, MeCN / water) to obtain the title compound (200 mg, 0.322 mmol, 3.68% yield, FA) as a brown solid. MS(M+H) + =574.3
[0739] Step 4: Synthesis of 3-(4-((2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (5)
[0740] A mixture of tert-butyl(1-(2-(2-(2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (200 mg, 348.63 μmol) in dioxane (2 mL) was mixed with HCl / dioxane (4 M, 2 mL), and the resulting mixture was stirred at 25 °C for 0.5 hours. The completion of the reaction was confirmed by LC-MS. The mixture was concentrated to obtain the title compound (178 mg, crude, HCl salt) as a yellow oil. MS(M+H) + =474.2
[0741] Step 5: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(2-(2-(2-((2-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 75)
[0742] A mixture of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (160 mg, 343.77 μmol), 3-(4-((2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindorin-2-yl)piperidine-2,6-dione (175.33 mg, 343.77 μmol, HCl salt) and HATU (261.42 mg, 687.54 μmol) in DMF (4 mL) contains DIPEA (133.29 (mg, 1.03 mmol, 179.64 μL) was added, and the resulting mixture was stirred at 20°C for 12 hours. The completion of the reaction was confirmed by LC-MS. Water (50 mL) was poured over the mixture and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered, and concentrated. The residue was separated by preparative HPLC (column: Phenomenex luna C 18 The sample was purified using a 150*40mm*15um mobile phase (water (0.225% FA)-ACN), with a B% of 18% to 48% for 10 minutes. The eluent was freeze-dried to obtain the title compound (44.3 mg, 44.73 μmol, 13.01% yield, 93% purity) as a dark brown solid.
[0743] MS(M+H) + =921.7.
[0744] 1H NMR (400MHz, DMSO-d6) δ11.02(s, 1H), 8.30(s, 1H), 8.25(d, J=13.3Hz, 1H), 8.16(s, 1H), 8.05(s, 1H), 7.94(dd, J=7.8, 3.3Hz, 1H), 7.29(t , J=7.8Hz, 1H), 7.19(d, J=6.7Hz, 1H), 6.95(d, J=7.4Hz, 1H), 6.81(d, J=8.1Hz, 1H), 5.61(t, J=5.7Hz, 1H), 5.12(dd, J=13.3, 5.1Hz, 1H), 4. 91-4.74(m, 1H), 4.23(d, J=17.2Hz, 1H), 4.17-4.02(m, 3H), 3.91(s, 3H), 3.82-3.73(m, 1H), 3.62-3.58(m, 2H), 3.58-3.51(m, 7H), 3.32(s, 3H), 3.00-2.85(m, 3H), 2.66-2.54(m, 3H), 2.38-2.16(m, 3H), 2.08-1 .90(m, 3H), 1.87-1.77(m, 2H), 1.76-1.69(m, 2H), 1.68-1.53(m, 6H).
[0745] Example 76: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0746] Based on the above reaction equation, the title compound (41.3 mg, 34.20 μmol, 6.20% yield, 93% purity, TFA salt) was obtained as a light brown solid by the same method as in the examples described above.
[0747] MS(M+H) + =1009.1
[0748] 1 H NMR (400MHz, CD3OD)δ=8.30-8.13(m, 2H) , 7.42-7.23(m, 2H), 7.13-7.00(m, 1H), 6.86(d, J=8.0Hz, 1H), 5.21-5.10(m, 1H), 5.05- 4.97(m, 1H), 4.38-4.22(m, 2H), 4.21-4.05(m, 3H), 4.01-3.94(m, 3H), 3.85-3.54(m, 18 H), 3.48-3.35(m, 6H), 3.28-3.25(m, 1H), 3.12-3.06(m, 1H), 2.98-2.85(m, 1H), 2.83-2 .74(m, 1H), 2.5-2.38(m, 1H), 2.33-2.14(m, 3H), 2.13-2.00(m, 3H), 1.98-1.65(m, 8H).
[0749] Example 77: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(8-((2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindorin-4-yl)amino)octyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0750] Based on the above reaction equation, the title compound (17.7 mg, 18.14 μmol, 8.44% yield, 94% purity) was obtained by the same method as in the examples described above.
[0751] MS(M+H) + =917.8.
[0752] 1 H NMR (400MHz, DMSO-d6) δ=11.01(br s, 1H), 8.30(s, 1H), 8.25(d, J=13.3Hz, 1H), 8.04(s, 1H), 7.88(br dd, J=3.3, 7.6Hz, 1H), 7.28 (t, J= 7.7Hz, 1H), 7.19(d, J=6.6Hz, 1H), 6.93(d, J=7.4Hz, 1H), 6.74(d, J=7.9Hz, 1H), 5.56(br t, J=5.2Hz, 1H), 5.12(dd, J=5.0, 13.3Hz, 1H), 4.89-4.75(m, 1H), 4.27-4.11(m, 2H), 4.11-4.02(m, 2 H), 3.92(s, 3H), 3.79-3.67(m, 1H), 3.33-3.29(m, 3H), 3.15-3.08(m, 2H), 2.98-2.88(m, 1H), 2.81(br d, J=11.4Hz, 2H), 2.65-2.59(m, 1H), 2.35-2.28(m, 1H), 2.24(br t, J=7.4Hz, 2H), 2.08-1.89(m, 5H), 1.90-1.65(m, 4H), 1.68-1.48(m, 8H), 1.45-1.22(m, 10H).
[0753] Example 78: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(14-((3-(2,6-dioxopiperidine-3-yl)-4-oxo-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0754] Step 1: Synthesis of 3-(5-((14-hydroxy-3,6,9,12-tetraoxatetradecyl)amino)-4-oxobenzo[d][1,2,3]triazine-3(4H)-yl)piperidine-2,6-dione(2)
[0755] 3-(5-fluoro-4-oxobenzo[d][1,2,3]triazine-3(4H)-yl)piperidine-2,6-dione (1g, 3.62m) in dioxane (10mL) To a solution of (mol) and TEA (1.10 g, 10.86 mmol, 1.51 mL), 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethanol (944.97 mg, 3.98 mmol) was added at 25°C, and the resulting mixture was stirred at 110°C for 14 hours. The major peak with the desired mass was identified by LC-MS. The mixture was concentrated under reduced pressure. The residue was analyzed by flash silica gel chromatography (Silica). The compound was purified by flash column chromatography (eluent 0-15% ethyl acetate / methanol @ 30 mL / min) to obtain the title compound (1.6 g, 3.05 mmol, 84.18% yield, 94% purity) as a yellow oil. MS(M+H) + =494.2
[0756] Steps 2-5: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b] [1,4]diazepine-2-yl)amino)-N-(1-(14-((3-(2,6-dioxopiperidine-3-yl)-4-oxo-3,4-dihydrobenzo[d] [1,2,3]triazine-5-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (compound 78)
[0757] From step 1 onward, based on the above reaction formula, 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(14-((3-(2,6-dioxopiperidine-3-yl)-4-oxo-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide (25.8 mg, 24.21 μmol, 11.27% yield, 96% purity) was obtained as a yellow solid in the same manner as in the above-described examples.
[0758] MS(M+H) +=1023.3
[0759] 1 H NMR (400MHz, DMSO-d6)δ=11.20(br s, 1H), 8.32(t, J=5.4Hz, 1H), 8.29(s, 1H), 8.23(d, J=13.6Hz, 1H), 8.05(s, 1H), 7.96-7.86(m, 1H), 7.79(t, J=8.0Hz , 1H), 7.19(dd, J=7.2, 18.8Hz, 2H), 7.00(d, J=8.8Hz, 1H), 5.86(dd, J=4.8, 11.6Hz, 1H), 4.97-4.69(m, 1H), 4.08(br t, J=14.0Hz, 2H), 3.90(s, 3H), 3.66:(br t, J=5.2Hz, 3H), 3.59-3.53(m, 4H), 3.50-3.46(m, 7H), 3.46-3.44(m, 3H), 3.34-3.31(m, 4H), 3.01-2.88(m, 1H), 2.83(br d, J=11.6Hz, 2H), 2.71-2.61(m, 2H), 2.43(t, J=5.8Hz, 2H), 2.29-2.17(m, 1H), 2.05-1.90(m, 4H), 1.82-1.42(m, 11H).
[0760] Example 79: Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-N-(1-(8-((3-(2,6-dioxopiperidine-3-yl)-4-oxo-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)amino)octyl)piperidine-4-yl)-2-fluoro-5-methoxybenzamide [ka]
[0761] Based on the above reaction equation, the title compound (49.1 mg, 51.68 μmol, 24.05% yield, 98% purity) was obtained as a yellow solid by the same method as in the examples described above.
[0762] MS(M+H)+ =931.8.
[0763] 1 H NMR (400MHz, DMSO-d6) δ=11.18(s, 1H), 8.30(s, 1H), 8.27-8.16(m, 2H), 8.03(s, 1H), 7.86(dd, J 1= 7.8Hz, J 2= 3.4Hz, 1H), 7.79(t, J=8.2Hz, 1H), 7.19(dd, J 1= 8.3Hz, J 2= 7.4Hz, 2H), 6.96(d, J=8.5Hz, 1H), 5.86(dd, J 1= 11.9Hz, J 2= 5.2Hz, 1H), 4.90-4.73(m, 1H), 4.07(t, J=13.9Hz, 2H), 3.91(s, 3H), 3.78-3.65(m, 1H), 3.33(s, 3H), 3.25-3.20(m, 2H), 2.99-2.88(m, 1H), 2.80(d, J=11.1Hz, 2H), 2.70-2.61(m, 2H), 2.28-2.18(m, 3H), 2.01-1 .88(m, 4H), 1.82-1.68(m, 4H), 1.66-1.44(m, 8H), 1.43-1.23(m, 10H).
[0764] Example 80: Synthesis of (2S, 4R)-1-((S)-2-(2-(2-(2-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)ethoxy)ethoxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide [ka]
[0765] Step 1: 2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethyl acetate (2) synthesis
[0766] To a solution of 2-(2-hydroxyethoxy)ethyl 4-methylbenzenesulfonate (500 mg, 1.92 mmol) and Rh(OAc)2 (42 mg, 190.05 μmol) in DCM (10 mL), 2-diazoethyl acetate (327.00 mg, 2.87 mmol, 300 μL) was added, and the mixture was stirred at 20°C for 14 hours. LC-MS confirmed the detection of the desired mass and the presence of the starting material. Further 2-diazoethyl acetate (218.00 mg, 1.91 mmol, 200 μL) was added, and the mixture was stirred at 30°C for 3 hours. TLC (petroleum ether:ethyl acetate = 1:1) confirmed the consumption of the starting material and the detection of novel spots. The mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5g SepaFlash® Silica Flash Column, eluent 10-30% ethyl acetate / petroleum ether gradient @ 50 mL / min) to obtain the title compound (460 mg, 1.33 mmol, 69.14% yield) as a yellow oily substance. MS(M+H) + =347.3
[0767] Step 2: Synthesis of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)ethyl acetate (3)
[0768] To a solution of 2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethyl acetate (460 mg, 1.33 mmol) and tert-butylpiperidine-4-yl carbamate (240 mg, 1.20 mmol) in dioxane (10 mL), NaI (39.87 mg, 266.00 μmol) and potassium carbonate (551.44 mg, 3.99 mmol) were added, and the mixture was stirred at 80°C for 14 hours. The desired mass was confirmed by LC-MS. The mixture was filtered, and the filtered cake was washed with ethyl acetate (30 mL). The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® silica flash column, eluent 20-90% methanol / ethyl acetate gradient @ 50 mL / min) to obtain the title compound (370 mg, 938.66 μmol, 70.58% yield, 95% purity) as a yellow oil. MS(M+H) + =375.5.
[0769] Step 3: Synthesis of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)acetic acid (4)
[0770] A solution of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)ethyl acetate (370 mg, 988.06 μmol) in THF (3 mL) was added to a solution of LiOH·H2O (49.76 mg, 1.19 mmol) in water (1.5 mL), and the mixture was stirred at 40°C for 14 hours. The desired mass was confirmed by LC-MS. The mixture was concentrated under reduced pressure to obtain the title compound (350 mg, crude) as a yellow solid.
[0771] Step 4: Synthesis of tert-butyl(1-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazole-5-yl)benzyl)carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (5)
[0772] Add HATU (647.47 mg, 1.70 mmol) and DIPEA (222.60 mg, 1.72 mmol, 300.00 μL) to a solution of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)ethoxy)ethoxy)acetic acid (300 mg, 851.42 μmol) in DMF (3 mL), and incubate the mixture at 20°C for 15 minutes. The mixture was stirred. Next, a solution of (2S, 4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (360 mg, 770.84 μmol, HCl salt) and DIPEA (222.60 mg, 1.72 mmol, 300.00 μL) in DMF (3 mL) was added, and the mixture was stirred at 20°C for 14 hours. LC-MS confirmed that the starting material remained and that a trace amount of the desired mass was detected. Furthermore, HATU (647.47 mg, 1.70 mmol) was added, and the mixture was stirred at 40°C for 14 hours. LC-MS confirmed that the desired mass was detected. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with water (10 mL) and brine (10 mL x 2), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® silica flash column, eluent 50-100% ethyl acetate / petroleum ether - 0-50% methanol / ethyl acetate gradient @ 50 mL / min), followed by preparative HPLC (column: Waters Xbridge C). 18 The sample was re-purified using a 150*50mm*10um mobile phase (water (10mM ammonium bicarbonate)-ACN), with a concentration of 26% to 56% (min), to obtain the title compound (80 mg, 100.14 μmol, 11.76% yield, 95% purity) as a yellow solid. MS(M+H) + =759.8.
[0773] Step 5: Synthesis of (2S, 4R)-1-((S)-2-(2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (6)
[0774] To a solution of tert-butyl(1-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazole-5-yl)benzyl)carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (80 mg, 105.41 μmol) in dioxane (2 mL), HCl / dioxane (4 M, 2 mL) was added, and the mixture was stirred at 20 °C for 1 hour. After treatment, the desired mass was confirmed by LC-MS. The reaction product was concentrated under reduced pressure, and the title compound (70 mg, HCl salt) was obtained as a yellow solid. MS(M+H) + =659.7.
[0775] Step 6: Synthesis of (2S, 4R)-1-((S)-2-(2-(2-(2-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)ethoxy)ethoxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (compound 80)
[0776] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (45 mg, 96.69 μmol) in DMF (1 mL), HATU (55 mg, 144.65 μmol) and DIPEA (22.26 mg, 172.23 μmol, 30 μL) were added, and the mixture was stirred at 20°C for 15 minutes. Next, a solution of (2S,4R)-1-((S)-2-(2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (70 mg, 95.66 μmol, HCl salt) in DMF (1 mL) was added, and the mixture was stirred at 20°C for 1 hour. The desired results were obtained by LC-MS. The mass was confirmed to have been detected. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layer was washed with water (10 mL) and brine (10 mL x 2), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The crude product was separated and subjected to preparative HPLC (column: Waters Xbridge 150*25 mm*5 μm; mobile phase: water (10 mM ammonium bicarbonate)). The compound was purified by [-ACN]; B%: 43%~73%, 10 min), and the eluent was freeze-dried to obtain the title compound (23.8 mg, 20.44 μmol, 21.37% yield, 95% purity) as a white solid.
[0777] MS(M+H) + =1106.6.
[0778] 1H NMR (400MHz, DMSO-d6) δ=8.98(s, 1H), 8.62-8.57(m, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.03(s, 1H), 7.88-7.82(m, 1H), 7.45-7.38(m, 5H), 7.19(d, J=6.6Hz, 1H), 5.17-5.14(m, 1H), 4.86-4.79(m, 1H), 4.57(br d, J=9.7Hz, 1H), 4.47-4.41(m, 1H), 4.39-4.34(m, 1H), 4.29-4.23(m, 1H), 4.08(br t, J=13.9Hz, 3H), 3.98(s, 2H), 3.94-3.89(s, 4H), 3.71-3.65(m, 2H), 3.64-3.59(m, 4H), 3.58-3.54(m, 2H), 3.30(br s, 3H), 2.86-2.80(m, 2H), 2.53-2.52(m, 2H), 2.44(s, 3H), 2.09-1.90(m, 6H), 1.79-1.69(m, 4H), 1.65-1.49(m, 6H), 0.95(s, 9H).
[0779] Example 81: Synthesis of (2S, 4R)-1-((S)-2-(tert-butyl)-14-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylazole-5-yl)benzyl)pyrrolidine-2-carboxamide [ka]
[0780] Based on the above reaction equation, the title compound (51.9 mg, 41.06 μmol (27.41% yield, 91% purity) was obtained as a white solid.
[0781] MS(M+H) +=1150.7
[0782] 1 H NMR (400MHz, DMSO-d6) δ=8.97(s, 1H), 8.59(t, J=6.0Hz, 1H), 8.29(s, 1H), 8.23(d, J=13.3Hz, 1H), 8.02(s, 1H), 7.86(br s, 1H), 7.44-7.35(m, 5H), 7.18(d, J=6.8Hz, 1H), 5.15(d, J=3.4Hz, 1H), 4.85-4. 77(m, 1H), 4.56(d, J=9.7Hz, 1H), 4.47-4.32(m, 3H), 4.28-4.19(m, 1H), 4.07(br t, J=13.8Hz, 2H), 3.96(s, 2H), 3.90(s, 3H), 3.69-3.43(m, 15H), 2.82(br s, 2H), 2.43(s, 3H), 2.10-1.85(m, 7H), 1.82-1.44(m, 12H), 0.96-0.91(m, 9H).
[0783] Example 82: Synthesis of (2S, 4R)-1-((S)-2-(tert-butyl)-17-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide [ka]
[0784] Based on the above reaction equation, the title compound (14.1 mg, 11.33 μmol, 4.40% yield, 96% purity) was obtained as a white solid by the same method as in the examples described above.
[0785] MS(M+H) + =1194.6
[0786] 1 H NMR (400MHz, DMSO-d6) δ=8.98(s, 1H), 8.59(br t, J=6.0Hz, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.02(s, 1H), 7.86(br dd, J=3.4, 7.6Hz, 1H), 7.46-7.36(m, 5H), 7.19(d, J=6.7Hz, 1H), 5.17(br s, 1H), 4.82(br t, J=8.2Hz, 1H), 4.56(d, J=9.7Hz, 1H), 4.47-4.32(m, 3H), 4.26(m, 1H), 4.07(br t, J=13.9Hz, 2H), 3.97(s, 2H), 3.91(s, 3H), 3.66-3.57(m, 6H), 3.56-3.52(m, 4H), 3.50-3.45(m, 6H), 3.33(br s, 3H), 2.83(br d, J=11.4Hz, 2H), 2.44(s, 3H), 2.11-1.99(m, 4H), 1.98-1.86(m, 3H), 1.82-1.67(m, 5H), 1.67-1.48(m, 7H), 0.97-0.91(s, 9H).
[0787] Example 83: Synthesis of (2S, 4R)-1-((S)-2-(tert-butyl)-20-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)-4-oxo-6,9,12,15,18-pentaoxa-3-azaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide [ka] Based on the above reaction equation, the title compound (31.7 mg, 25.34 μmol, 9.83% yield, 99% purity) was obtained as a white solid by the same method as in the examples described above.
[0788] MS(M+H) + =1238.9
[0789] 1 H NMR (400MHz, DMSO-d6) δ8.98(s, 1H), 8.59(t, J=6.1Hz, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.02(s, 1H), 7.87(dd, J=3.3, 7.8Hz, 1H), 7.43-7.37(m, 5H), 7.19(d, J=6.6Hz, 1H), 5.16-5.14(m, 1H), 4.84-4.76(m, 1H), 4 .57-4.55(m, 1H), 4.47-4.33(m, 3H), 4.28-4.21(m, 1H), 4.07(t, J=13.9Hz, 2H), 3 .96(s, 2H), 3.91(s, 3H), 3.71-3.51(m, 13H), 3.50-3.46(m, 10H), 3.33(s, 3H), 2. 85-2.82(m, 2H), 2.44(s, 3H), 2.08-1.91(m, 6H), 1.76-1.52(m, 10H), 0.94(s, 9H).
[0790] Example 84: Synthesis of (2S, 4R)-1-((S)-2-(2-((8-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)octyl)oxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide [ka]
[0791] Stage 1: 2-((8-(4-((tert-butoxycarbonyl)amino)piperidine Synthesis of ethyl acetate (2) -1-yl)octyl)oxy)
[0792] A solution of tert-butyl(1-(8-hydroxyoctyl)piperidine-4-yl)carbamate (5.5 g, 16.74 mmol) and Rh(OAc)2 (37.00 mg, 167.43 μmol) in DCM (50 mL) was added dropwise at 0°C to a solution of 2-ethyl 2-diazoethyl acetate (2.48 g, 21.77 mmol, 2.28 mL) in DCM (10 mL). The mixture was stirred at 25°C for 12 hours. LC-MS confirmed that most of the starting material remained. Another portion of Rh(OAc)2 (185.01 mg, 837.17 μmol) was added to the reaction mixture at 25°C. The resulting mixture was stirred at 40°C for 6 hours. LC-MS confirmed that 76% of the desired mass was achieved. The mixture solution was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (1000 mesh silica gel, eluent petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to obtain 2-((8-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)octyl)oxy)ethyl acetate (4.5 g, crude) as a yellow oily substance, which was used directly in the next step. MS(M+H) + =415.2
[0793] Step 2: Synthesis of 2-((8-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)octyl)oxy)acetic acid (3)
[0794] A mixture of 2-((8-(4-((tert-butoxycarbonylamino)piperidine-1-yl)octyl)oxy)ethyl acetate (4.5 g, 10.85 mmol) and LiOH (519.89 mg, 21.71 mmol) in THF (30 mL) and water (30 mL) was stirred at 45°C for 12 hours. Complete consumption of the starting materials was confirmed by LC-MS. The reaction solution was concentrated to remove the organic phase. The residual aqueous solution was washed with ethyl acetate (50 mL x 3). A 1 M aqueous HCl solution was added to adjust the pH of the suspension to 6. The aqueous layer was extracted with ethyl acetate (50 mL x 4). The combined organic layers were dried over sodium sulfate and concentrated. The crude product was purified by reverse-phase HPLC (0.1% NH3·H2O conditions, MeCN / water) to obtain the title compound (1.8 g, 4.66 mmol, 42.90% yield, 100% purity) as a white solid, which was used directly in the next step. MS(MH) + =385.4
[0795] Step 3: Synthesis of tert-butyl(1-(8-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazole-5-yl)benzyl)carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)octyl)piperidine-4-yl)carbamate (5)
[0796] To a solution of 2-((8-(4-((tert-butoxycarbonyl)amino)piperidine-1-yl)octyl)oxy)acetic acid (300 mg, 776.15 μmol) in DMF (5 mL), HATU (442.67 mg, 1.16 mmol) and DIPEA (300.93 mg, 2.33 mmol, 405.56 μL) were added. The mixture was stirred at 25°C for 10 minutes. (2S, 4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (289.98 mg, 620.92 μmol, 0.8 eq, HCl) was added to the mixture. The mixture was stirred at 25°C for 12 hours. 63% of the peaks were confirmed by LC-MS at the desired mass. The solution was diluted with ethyl acetate (30 mL) and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (20 g SepaFlash® silica flash column, eluent 0-100% ethyl acetate / petroleum ether gradient @ 100 mL / min; eluent 0-50% ethyl acetate / methanol gradient @ 100 mL / min) to obtain the title compound (0.5 g, crude) as a brown oily substance, which was used directly in the next step. MS(M+H) + =799.4
[0797] Step 4: Synthesis of (2S, 4R)-1-((S)-2-(2-((8-(4-aminopiperidine-1-yl)octyl)oxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (6)
[0798] To a solution of tert-butyl(1-(8-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazole-5-yl)benzyl)carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)octyl)piperidine-4-yl)carbamate (0.5 g, 625.73 μmol) in dioxane (2 mL), HCl / dioxane (4 M, 10 mL, 63.93 eq) was added at 25 °C. The resulting mixture was stirred at 25 °C for 0.5 hours. LC-MS confirmed the complete consumption of the starting material and a single major peak with the desired mass. The mixture solution was concentrated under reduced pressure to obtain the title compound (380 mg, crude, HCl) as a brown solid, which was used directly in the next step. MS(M+H) + =699.4
[0799] Step 5: Synthesis of (2S, 4R)-1-((S)-2-(2-((8-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)octyl)oxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (compound 84)
[0800] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (70 mg, 150.40 μmol) in DMF (5 mL), HATU (85.78 mg, 225.60 μmol) and DIPEA (58.31 mg, 451.20 μmol, 78.59 μL) were added. The mixture was stirred at 25°C for 10 minutes. (2S, 4R)-1-((S)-2-(2-((8-(4-aminopiperidine-1-yl)octyl)oxy)acetamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (110.61 mg, 150.40 μmol, HCl) was added to the mixture. The mixture was stirred at 25°C for 12 hours. One major peak with the desired mass was identified by LC-MS. The mixture solution was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10mM ammonium bicarbonate)-ACN]; B%: 58%~88%, 10 min), lyophilized, and the title compound (22.9 mg, 19.18 μmol, 12.75% yield, 96% purity) was obtained as a white solid.
[0801] MS(M+H) + =1146.4
[0802] 1H NMR (400MHz, DMSO-d6) δ=8.98(s, 1H), 8.62(t, J=5.9Hz, 1H), 8.34-8.17(m, 2H), 8.03(s, 1H), 7 .86(dd, J=3.4, 7.7Hz, 1H), 7.44-7.36(m, 4H), 7.34(d, J=9.6Hz, 1H), 7.19(d, J=6.8Hz, 1H), 5. 29-5.07(m, 1H), 4.88-4.70(m, 1H), 4.55(d, J=9.6Hz, 1H), 4.48-4.32(m, 3H), 4.30-4.18(m, 1H) ), 4.07(t, J=13.9Hz, 2H), 3.94-3.87(m, 5H), 3.77-3.55(m, 3H), 3.50-3.45(m, 2H), 2.77(d, J= 11.0Hz, 2H), 2.46-2.42(m, 4H), 2.19(t, J=7.3Hz, 2H), 2.11-2.02(m, 1H), 2.00-1.80(m, 5H) ), 1.82-1.69(m, 4H), 1.66-1.43(m, 9H), 1.40-1.31(m, 4H), 1.30-1.15(m, 7H), 0.94(s, 9H).
[0803] Example 85: Synthesis of (2S, 4R)-N-(2-(2-(2-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)ethoxy)ethoxy)-4-(4-methylthiazole-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide [ka]
[0804] Step 1: 2-(2-hydroxyethoxy)ethyl 4-methylbenzene sulfonate (3 ) synthesis
[0805] To a solution of 2,2'-oxydiethanol (20 g, 188.47 mmol, 17.86 mL) in DCM (200 mL), TosCl (35.93 g, 188.47 mmol), KI (6.26 g, 37.69 mmol), and silver oxide (65.51 g, 282.71 mmol) were added. The mixture was stirred at 20°C for 14 hours. The desired mass was confirmed by LC-MS. The mixture was filtered, and the filtered cake was washed with ethyl acetate (100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (120 g SepaFlash® silica flash column, eluent 0-100% ethyl acetate / petroleum ether - 0-50% methanol / ethyl acetate gradient @ 80 mL / min) to obtain the title compound (27.1 g, 104.11 mmol, 55.24% yield) as a yellow oil. MS(M+H) + =261.1.
[0806] Step 2: Synthesis of (2S, 4R)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-(2-(2-hydroxyethoxy)ethoxy)-4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (4)
[0807] To a solution of (2S, 4R)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (500 mg, 938.74 μmol) and 2-(2-hydroxyethoxy)ethyl 4-methylbenzene sulfonate (293 mg, 1.13 mmol) in DMF (10 mL), NaI (70.35 mg, 469.37 μmol) and potassium carbonate (389.23 mg, 2.82 mmol) were added. The reaction mixture was stirred at 100 °C for 14 hours. The desired mass was confirmed by LC-MS. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with water (10 mL) and brine (10 mL x 2), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® silica flash column, eluent 50-100% ethyl acetate / petroleum ether - 0-20% methanol / ethyl acetate gradient @ 50 mL / min) to obtain the title compound (460 mg, 741.06 μmol, 78.94% yield) as a yellow oil. MS(M+H) + =621.4.
[0808] Step 3: Synthesis of 2-(2-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide)methyl)-5-(4-methylthiazole-5-yl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (5)
[0809] To a solution of (2S, 4R)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-(2-(2-hydroxyethoxy)ethoxy)-4-(4-methylthiazole-5-yl)benzyl)pyrrolidine-2-carboxamide (510 mg, 821.61 μmol) in DCM (8 mL), TEA (501.63 mg, 4.96 mmol, 690 μL) and a solution of TosCl (469.91 mg, 2.46 mmol) in DCM (2 mL) were added. The mixture was stirred at 20°C for 14 hours. The detection of the desired spot was confirmed by TLC (ethyl acetate:methanol = 10:1). The mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5g SepaFlash® silica flash column, eluent 20-100% ethyl acetate / petroleum ether gradient @ 50 mL / min), and the title compound (0.3 g, 387.14 μmol, 47.12% yield) was obtained as a white solid. Obtained. MS(M+H) + =775.6.
[0810] Step 4: Synthesis of tert-butyl(1-(2-(2-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide)methyl)-5-(4-methylthiazole-5-yl)phenoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (6)
[0811] To a solution of 2-(2-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide)methyl)-5-(4-methylthiazole-5-yl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (300 mg, 387.14 μmol) and tert-butylpiperidine-4-ylcarbamate (74 mg, 369.49 μmol) in dioxane (6 mL), NaI (5.80 mg, 38.71 μmol) and potassium carbonate (160.51 mg, 1.16 mmol) were added, and the mixture was stirred at 80°C for 14 hours. The desired mass was confirmed by LC-MS. The mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5g SepaFlash® silica flash column, eluent 0-100% methanol / ethyl acetate gradient @ 50 mL / min) to obtain the title compound (280 mg, 348.70 μmol, 90.07% yield) as a yellow solid. MS(M+H) + =803.8.
[0812] Step 5: Synthesis of (2S, 4R)-N-(2-(2-(2-(4-aminopiperidine-1-yl)ethoxy)ethoxy)-4-(4-methylthiazole-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (7)
[0813] To a solution of tert-butyl(1-(2-(2-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide)methyl)-5-(4-methylthiazole-5-yl)phenoxy)ethoxy)ethyl)piperidine-4-yl)carbamate (280 mg, 348.70 μmol) in dioxane (4 mL), HCl / dioxane (4 M, 4 mL) was added, and the mixture was stirred at 20 °C for 1 hour. After treatment, the desired mass was confirmed by LC-MS. The reaction mixture was concentrated under reduced pressure to obtain the title compound (260 mg, crude, HCl salt) as a yellow solid. MS(M+H) + =703.7.
[0814] Step 6: Synthesis of (2S, 4R)-N-(2-(2-(2-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-1-yl)ethoxy)ethoxy)-4-(4-methylthiazole-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (8)
[0815] To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (60 mg, 128.91 μmol) in DMF (1 mL), HATU (74 mg, 194.62 μmol) and DIPEA (37.10 mg, 287.06 μmol, 50 μL) were added, and the mixture was stirred at 20°C for 15 minutes. Then, (2S,4R)-N-(2-(2-(2 A solution of -(4-aminopiperidine-1-yl)ethoxy)ethoxy)-4-(4-methylazole-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropanecarboxamide)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (120 mg, 137.00 μmol, HCl salt) and DIPEA (44.52 mg, 344.47 μmol, 60 μL) was added, and the mixture was stirred at 20°C for 1 hour. The desired mass was confirmed by LC-MS. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with water (10 mL) and brine (10 mL x 2), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10mM ammonium bicarbonate)-ACN]; B%: 49%~79%, 10 min), and the eluent was freeze-dried to obtain the title compound (32.0 mg, 26.43 μmol, 20.50% yield, 95% purity) as a white solid.
[0816] MS(M+H) + =1150.5
[0817] 1H NMR (400MHz, DMSO-d6) δ=8.98(s, 1H), 8.49(br t, J=5.9Hz, 1H), 8.30(s, 1H), 8.24(d, J=13.3Hz, 1H), 8.03(s, 1H), 7.85-7.80(m, 1H), 7.41(d, J=7.7Hz, 1H), 7.31-7.26(m, 1H), 7.19(d, J=6.6Hz, 1H), 7.05(s, 1H), 6.96(br d, J=8.1Hz, 1H), 5.17-5.14(m, 1H), 4.85-4.78(m, 1H), 4.59(br d, J=9.2Hz, 1H), 4.51(br t, J=8.2Hz, 1H), 4.36-4.28(m, 2H), 4.23-4.16(m, 3H), 4.07(br t, J=13.9Hz, 2H), 3.91(s, 3H), 3.77(br d, J=3.3Hz, 2H), 3.73-3.69(m, 1H), 3.63-3.58(m, 4H), 3.33-3.33(m, 3H), 2.89-2.82(m, 2H), 2.53-2.52(m, 2H), 2.46(s, 3H), 2.11-2.02 (m, 4H), 2.00-1.89(m, 4H), 1.76-1.71(m, 2H), 1.64-1.57(m, 4H), 1.55-1.49(m, 2H), 1.40-1.32(m, 2H), 1.24-1.19(m, 2H), 0.95(s, 9H).
[0818] Example 86: Synthesis of (2S, 4R)-N-(2-(2-(2-(2-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine-2-yl)amino)-2-fluoro-5-methoxybenzamide)piperidine-...
Claims
1. Compounds represented by the following formula I, their stereoisomers, or pharmaceutically acceptable salts thereof: [Formula I] 【Chemistry 1】 [Here, in the above formula I, ULM is the CRBN E3 ubiquitin ligase binding site represented by the following formula A-2: [Formula A-2] 【Chemistry 2】 {In the above formula A-2, X 2 ha-CH 2 -, -CO-, or -N=N-} PTM is the PLK1 bond portion represented by the following formula III: [Formula III] 【Transformation 3】 {In the above formula III, R 1 C 1-3 Alkyl or C 3-6 It is a cycloalkyl, R 2 is hydrogen, or -OR 2A And, R 2A is C 1-4 alkyl, C 3-6 cycloalkyl, CF 3 , or -(C 1-3 alkylene)-OH. R 3 is hydrogen or halogen. The above ULM or PTM is represented 【Chemistry 4】 This indicates a covalent bond that connects ULM or PTM to Linker, and Linker is a chemical group that links the ULM and PTM, Select from the following: Table 1-1 Table 1-2 Table 1-3 Table 1-4 Table 1-5 Table 1-6 Table 1-7 Table 1-8 Table 1-9 {Here, Linker 【Transformation 5】 It connects to the ULM site, and Linker 【Transformation 6】 It is connected to the PTM site. However, the compound represented by formula I is not a compound selected from the group consisting of the following compounds 1-5, 8-17, 26-43, 46-48, 50-59, 61-65, 67-79, 90-110, 112-155, 158-168, and 172-175: Table 2-1 Table 2-2 Table 2-3 Table 2-4 Table 2-5 Table 2-6 Table 2-7 Table 2-8 Table 2-9 Table 2-10 Table 2-11 Table 2-12 Table 2-13 Table 2-14 Table 2-15 Table 2-16 Table 2-17 Table 2-18 Table 2-19 Table 2-20 Table 2-21 Table 2-22 Table 2-23 Table 2-24 Table 2-25 Table 2-26 Table 2-27 Table 2-28 Table 2-29 Table 2-30
2. Compounds represented by the following formula I, their stereoisomers, or pharmaceutically acceptable salts thereof: [Formula I] 【Transformation 7】 [Here, in the above formula I, ULM is a VHL E3 ubiquitin ligase binding site represented by the following formula B-2-1 or B-2-2: [Formula B-2-1] 【Transformation 8】 [Formula B-2-2] 【Chemistry 9】 The PTM is the PLK1 coupling portion represented by the following formula III: [Formula III] 【Chemistry 10】 {In the above formula III, R 1 C 1-3 Alkyl or C 3-6 It is a cycloalkyl, R 2 is hydrogen, or -OR 2A And, R 2A C 1-4 Alkyl, C 3-6 Cycloalkyl, CF 3 , or -(C 1-3 It is alkylene)-OH R 3 is hydrogen or halogen. Here, represented in ULM or PTM 【Chemistry 11】 This indicates a covalent bond that connects ULM or PTM to Linker. Linker is a chemical group that links the ULM and PTM, Select from the following: Table 3 {Here, Linker 【Chemistry 12】 It connects to the ULM site, and Linker 【Chemistry 13】 It is connected to the PTM site. However, the compound represented by formula I is not a compound selected from the group consisting of the following 80-89 compounds: Table 4-1 Table 4-2 Table 4-3
3. The compound according to claim 1 or claim 2, which is a bifunctional compound that induces the degradation of PLK1 protein.
4. The compound according to claim 3, which induces the selective degradation of the PLK1 protein.
5. A composition for the prevention or treatment of PLK1-related disease, comprising a compound according to any one of claims 1 to 4, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
6. The composition according to claim 5, wherein the PLK1-related disease is one or more selected from the group consisting of cancer, benign tumors, and neurological diseases.
Citation Information
Patent Citations
Pololo-like kinase inhibitors
JP2010540463A
Pololo-like kinase inhibitors
JP2010540464A
Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases - Patent Application 20070229633
JP2015508414A
JPP7440940B
Protein-protein interaction inducing technology
US20170281784A1
